

Amide compounds and uses thereof

Field of the Invention

5 The present invention relates to novel amide compounds, pharmaceutical compositions comprising same, methods for preparing same, and uses thereof.

Background of the Invention

Members of type III tyrosine kinase receptor family include CSF-1R, PDGFR α ,
10 PDGFR β , FLT3 and c-KIT. The members of this family are all composed of an extracellular immunoglobulin-like domain, a transmembrane domain, a juxtamembrane domain and a protein kinase domain, wherein the kinase domain is highly conserved (Nat Rev Cancer. 2012, 12(11):753-66). The phosphorylation signal mediated thereby participates in numerous cell biological functions and plays an important role in the
15 occurrence of diseases. Specifically, there are reports indicating that mutations in the kinase domain of PDGFR α and c-KIT would lead to gastrointestinal tumors (J Pathol. 2011, 223(2): 251-261). In addition, it is found that FLT-3 tandem duplication (FLT3-ITD) is a key pathogenic factor in approximately 20% of patients with acute lymphoblastic leukemia (Biomark Insights. 2015, 10(Suppl 3):1-14).

20 CSF-1R, i.e. CSF-1 receptor (colony stimulating factor 1 receptor), is encoded by the oncogene c-fms. The human c-fms gene is located at 5q33.3 of chromosome 5, downstream of the β -type platelet-derived growth factor receptor (PDGF-R β) gene, and the two genes are connected end to end. Human CSF-1R is a single-chain, transmembrane receptor tyrosine kinase, a transmembrane glycoprotein composed of 972
25 amino acids, with a molecular weight of 150 Kd. It consists of an extramembrane region with 512 amino acids, a transmembrane region with 25 amino acids, and an intracellular cytoplasmic region with 435 amino acids. The extracellular region has 5 disulfide bonds and 11 possible glycosylation sites, and the intracellular region has a Gly-X-Gly-X-X-Gly motif. Lysine at position 616 is a binding site for ATP, flanked by a kinase insertion
30 region with 72 amino acids. It is speculated that it has the function of recognizing specific substrates (Cold Spring Harb Perspect Biol. 2014, 6(6)).

CSF-1, also called M-CSF (macrophage colony stimulating factor), is encoded by the CSF-1 gene. CSF-1 exerts its biological effects by binding to the only cell surface receptor CSF-1R thereof. After binding to CSF-1, CSF-1R undergoes changes in its conformation and forms a dimer or polymer. After dimerization, the tyrosine kinase activity of the receptor is activated, and the tyrosines at positions 544, 559, 699, 708, 723, 809, 923, etc. are phosphorylated, and subsequently interact with multiple intracellular signaling pathways such as Ras, MAPK, PI3K, JAK, etc. to produce various biological effects in cells (J Cell Biochem. 1988, 38(3):179-87).

The tumor microenvironment is a complex ecosystem, and provides support for the occurrence, growth and metastasis of tumors. Macrophages are particularly abundant in immune cells that migrate to the tumor site, and exist in all stages of tumor development. Studies have shown that tumor-associated macrophages (TAMs) play an important role in the occurrence, growth and metastasis of tumors. For primary tumors, macrophages can stimulate the neovascularization, aid the extravasation, survival and continuous growth of tumor cells, thereby promoting tumor cell metastasis. TAM also exerts an immunosuppressive effect, preventing natural killer cells and T cells from attacking tumor cells (Immunity. 2014, 41(1):49-61). CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. The CSF-1/CSF-1R signaling pathway interferes with tumor progression by regulating TAMs to reduce tumor invasiveness and proliferation, as a consequence, the CSF1/CSF1R signaling pathway is a potential target for cancer treatment.

Overexpression of CSF-1 or CSF-1R is related to tumor malignant invasiveness and poor prognosis. Studies have shown that the application of CSF-1R inhibitors can affect the exchange of inflammatory factors between TAMs and glioma cells, which significantly reduces the volume of glioblastoma, and reduces tumor invasiveness and proliferation (Nat Med. 2013, 19(10):1264-72). In addition, aberrantly high expression of CSF-1 is the main pathogenesis of tenosynovial giant cell tumor (a type of rare non-metastatic tumor with giant cell tumor and pigmented villonodular synovitis in tendon sheath). Patients with tenosynovial giant cell tumor have obvious clinical benefits after using CSF-1R inhibitors (N Engl J Med. 2015, 373(5):428-37).


In addition to tumors, the CSF-1R signaling pathway plays an important role in autoimmune diseases and inflammatory diseases, including systemic lupus erythematosus,

arthritis, atherosclerosis and obesity (Arthritis Res Ther. 2016, 18:75; Nat Rev Immunol. 2008, 8(7):533-44; J Immunother Cancer. 2017, 5(1):53). Therefore, the development of CSF-1R inhibitors may also be used to treat such diseases.

At present, CSF-1R and c-KIT inhibitor Pexidartinib has been approved for marketing by the FDA for the treatment of tenosynovial giant cell tumor in adult patients. There is still a need to develop novel type III tyrosine kinase receptor inhibitors, especially CSF-1R inhibitors, for the treatment of diseases, such as cancer, autoimmune diseases or inflammatory diseases. The present invention addresses these needs.

Summary of the Invention

Provided is a compound of formula (I):



or a pharmaceutically acceptable salt thereof, and/or a deuterate, a solvate, a racemic mixture, an enantiomer, a diastereomer and a tautomer thereof, wherein

X is N or CR₅;

Z₁ and Z₂ are each independently N or CR₆;

Y₁ is N or CR₇; Y₂ is N or CR₈; Y₃ is N or CR₉;

L is NH, O, S or CH₂;

W is absent or NH, O, S or CH₂;

R₁ is phenyl, 5-12 membered heteroaryl, 4-6 membered heterocyclyl or C₃₋₈ cycloalkyl, each of which is optionally substituted with one or more groups chosen from: halogen, -CN, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, -(C₁₋₆ alkylene)_n-NH₂, -(C₁₋₆ alkylene)_n-NH(C₁₋₆ alkyl), -(C₁₋₆ alkylene)_n-N(C₁₋₆ alkyl)₂, -(C₁₋₆ alkylene)_n-OH, -(C₁₋₆ alkylene)_n-O-(C₁₋₆ alkyl) or -(C₁₋₆ alkylene)_n-O-(C₁₋₆ haloalkyl);

R₂ is hydrogen, -CN, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, -(C₁₋₆ alkylene)-NH₂, -(C₁₋₆ alkylene)-NH(C₁₋₆ alkyl), -(C₁₋₆ alkylene)-N(C₁₋₆ alkyl)₂, -(C₁₋₆

alkylene)-O-(C₁₋₆ alkyl), -(C₁₋₆ alkylene)-O-(C₁₋₆ haloalkyl), -(C₁₋₆ alkylene)-OH, C₃₋₈ cycloalkyl or 4-6 membered heterocyclyl;


R₃, R₄, R₅, R₆, R₇ and R₈ are each independently chosen from: hydrogen, halogen, -CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -O(C₁₋₆ alkyl), -O(C₁₋₆ haloalkyl) or -OH;

- 5 R₉ is hydrogen, halogen, -CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -O(C₁₋₆ alkyl), -O(C₁₋₆ haloalkyl), -OH, -(C₁₋₆ alkylene)-OH, -NH₂, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂ or C₃₋₈ cycloalkyl;

n is 0 or 1;

- or when Y₃ is CR₉, R₂ and R₉ together with the N atoms and C atoms to which they
10 are attached form a 5-6 membered heteroaromatic ring or 5-6 membered heterocycle;

or when Y₂ is CR₈ and Y₃ is CR₉, R₈ and R₉ together with the C atoms to which they are attached form a benzene ring;



provided that when X is CH, Z₁ is not N.

- 15 Also provided is a pharmaceutical composition, comprising the compound of formula (I) of the present invention (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof, and optionally comprising at least one pharmaceutically acceptable excipient (e.g., a pharmaceutically acceptable carrier).

- 20 Also provided is a method of *in vivo* or *in vitro* inhibiting the activity of CSF-1R, comprising contacting CSF-1R with an effective amount of at least one compound of formula (I) of the present invention (e.g., a compound of any of the examples as described herein) and/or at least one pharmaceutically acceptable salt thereof.

- Also provided is the use of the compound of formula (I) of the present invention
25 (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof for *in vivo* or *in vitro* inhibiting the activity of CSF-1R.

- Also provided is the use of the compound of formula (I) of the present invention (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for *in vivo* or *in vitro*
30 inhibiting the activity of CSF-1R.

Also provided is a method of treating cancer, an autoimmune disease, an inflammatory disease, a metabolic disease, a neurodegenerative disease, obesity or an obesity-related disease in a subject, comprising administering to the subject in need thereof an effective amount of at least one compound of formula (I) of the present invention (e.g., a compound of any of the examples as described herein) and/or at least one pharmaceutically acceptable salt thereof.

Also provided is the use of the compound of formula (I) of the present invention (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof in the treatment of cancer, an autoimmune disease, an inflammatory disease, a metabolic disease, a neurodegenerative disease, obesity or an obesity-related disease in a subject.

Also provided is a compound of formula (I) of the present invention (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof for the treatment of cancer, an autoimmune disease, an inflammatory disease, a metabolic disease, a neurodegenerative disease, obesity or an obesity-related disease in a subject.

Also provided is the use of the compound of formula (I) of the present invention (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer, an autoimmune disease, an inflammatory disease, a metabolic disease, a neurodegenerative disease, obesity or an obesity-related disease in a subject.

Detailed Description of the Invention

Definitions

As used in the present application, the following words, phrases and symbols are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.

A dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -O(C₁₋₆ alkyl) refers to the attachment of C₁₋₆ alkyl to the rest of the molecule through an oxygen atom. When the point of attachment for a substituent is well known to the person of ordinary skill in the art (“POSITA”), “-” can be omitted, for example, a halogen substituent.

The term “alkyl” as used herein refers to a straight or branched saturated hydrocarbon radical containing 1-18 carbon atoms, preferably 1-10 carbon atoms, particularly preferably 1-6 carbon atoms, further preferably 1-4 carbon atoms. For example, “C₁₋₆ alkyl” refers to an alkyl containing 1-6 carbon atoms. Examples of alkyl
5 include, but are not limited to, methyl (“Me”), ethyl (“Et”), n-propyl (“n-Pr”), i-propyl (“i-Pr”), n-butyl (“n-Bu”), i-butyl (“i-Bu”), s-butyl (“s-Bu”) and t-butyl (“t-Bu”).

The term “alkylene” as used herein refers to a straight or branched saturated divalent hydrocarbon radical containing 1-18 carbon atoms, preferably 1-10 carbon atoms, particularly preferably 1-6 carbon atoms, further preferably 1-4 carbon atoms. For
10 example, “C₁₋₆ alkylene” refers to a straight or branched alkylene containing 1-6 carbon atoms, for example, straight alkylene-(CH₂)_n-, wherein n is an integer from 1 to 6, or a branched alkylene, for example, -CH₂-CH(CH₃)-CH₂-, -CH(CH₃)-CH₂-, and -CH(CH₃)-CH₂-CH₂-, preferably a straight C₁₋₆ alkylene, more preferably -CH₂- and -CH₂-CH₂-.

The term “alkenyl” as used herein refers to a straight or branched unsaturated hydrocarbon radical containing one or more, for example 1, 2, or 3 carbon-carbon double
15 bonds (C=C) and 2-10 carbon atoms, preferably 2-6 carbon atoms, more preferably 2-4 carbon atoms. For example, “C₂₋₆ alkenyl” refers to an alkenyl containing 2-6 carbon atoms. Examples of alkenyl include, but are not limited to, vinyl, 2-propenyl and 2-butenyl. The point of attachment for the alkenyl can be on or not on the double bonds.

The term “alkynyl” as used herein refers to a straight or branched unsaturated hydrocarbon radical containing one or more, for example 1, 2, or 3, carbon-carbon triple
20 bonds (C≡C) and 2-10 carbon atoms, preferably 2-6 carbon atoms, more preferably 2-4 carbon atoms. For example, “C₂₋₆ alkynyl” refers to an alkynyl containing 2-6 carbon atoms. Examples of alkynyl include, but are not limited to, ethynyl, 2-propynyl and 2-butenyl. The point of attachment for the alkynyl can be on or not on the triple bonds.

The term “halogen” or “halo” as used herein refers to fluoro, chloro, bromo, and iodo, preferably fluoro, chloro and bromo, more preferably fluoro and chloro.

The term “haloalkyl” as used herein refers to an alkyl radical, as defined herein, in which one or more, for example 1, 2, 3, 4, or 5, hydrogen atoms are replaced with
30 halogen atoms, and when more than one hydrogen atoms are replaced with halogen atoms, the halogen atoms may be the same or different from each other. In one embodiment, the term “haloalkyl” as used herein refers to an alkyl radical, as defined

herein, in which two or more, such as 2, 3, 4, or 5 hydrogen atoms are replaced with halogen atoms, wherein the halogen atoms are identical to each other. In another embodiment, the term “haloalkyl” as used herein refers to an alkyl radical, as defined herein, in which two or more hydrogen atoms, such as 2, 3, 4, or 5 hydrogen atoms are replaced with halogen atoms, wherein the halogen atoms are different from each other. Examples of haloalkyl include, but are not limited to, -CF₃, -CHF₂, -CH₂CF₃, -CH(CF₃)₂, and the like.

The term “cycloalkyl” as used herein refers to saturated or partially unsaturated cyclic hydrocarbon radical having 3-12 ring carbon atoms (such as 3-8 ring carbon atoms, 5-7 ring carbon atoms, 4-7 ring carbon atoms, 5-6 ring carbon atoms or 3-6 ring carbon atoms); which may have one or more rings, such as 1, 2, or 3 rings, preferably 1 or 2 rings. For example, “C₃₋₈ cycloalkyl” refers to a cycloalkyl containing 3-8 ring carbon atoms. The cycloalkyl may include a fused or bridged ring, or a spirocyclic ring. The rings of the cycloalkyl may be saturated or have one or more, for example, one or two double bonds (i.e. partially unsaturated), but not fully conjugated, and not an aryl as defined herein. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[4.1.0]heptanyl, bicyclo[3.1.1]heptanyl, spiro[3.3]heptanyl, spiro[2.2]pentanyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cycloheptenyl, cyclooctenyl and bicyclo[3.1.1]hept-2-ene. In an embodiment of the present invention, the ring of cycloalkyl is saturated.

The term “heterocyclyl” or “heterocycle” as used herein refers to: saturated or partially unsaturated monocyclic, bicyclic or tricyclic radicals having 3-12 ring atoms (such as 3-8 ring atoms, 4-7 ring atoms, 5-7 ring atoms, 4-6 ring atoms, 3-6 ring atoms or 5-6 ring atoms), and containing one or more (such as 1, 2 or 3, preferably 1 or 2) ring heteroatoms independently chosen from N, O and S in the rings, with the remaining ring atoms being carbon. The heterocycle also includes those wherein the N or S heteroatom are optionally oxidized to various oxidation states. The point of attachment of heterocyclyl can be on the N heteroatom or carbon. For example, “3-12 membered heterocyclyl” or “3-12 membered heterocycle” refers to a heterocyclyl having 3-12 ring atoms, and containing at least one heteroatom chosen from N, O and S; “4-6 membered heterocyclyl” or “4-6 membered heterocycle” refers to a heterocyclyl having 4-6 ring

atoms, and containing at least one heteroatom chosen from N, O and S; “5-6 membered heterocyclyl” or “5-6 membered heterocycle” refers to a heterocyclyl having 5 or 6 ring atoms, and containing at least one heteroatom chosen from N, O and S. The heterocycle or heterocyclyl may include a fused or bridged ring, or a spirocyclic ring, wherein at least one ring contains at least one ring heteroatom independently chosen from N, O and S, and the point of attachment thereof to the rest of the molecule is located on the ring containing ring heteroatom, and the remaining rings are not “aryl” or “heteroaryl” as defined in the present invention. The rings of the heterocycle or heterocyclyl may be saturated or have one or more, for example, one or two double bonds (i.e. partially unsaturated), but not fully conjugated, and not a heteroaryl as defined herein. In an embodiment of the present invention, the rings of heterocycle or heterocyclyl are saturated. Examples of heterocyclyl include, but are not limited to: 4-6 membered heterocyclyl or 5-6 membered heterocyclyl, for example, oxetanyl, azetidiny, pyrrolidyl, tetrahydrofuranyl, dioxolanyl, morpholinyl, thiomorpholinyl, piperidyl, piperazinyl, pyrazolidinyl, dihydrooxadiazolyl, and oxaspiro[3.3]heptanyl.

The term “aryl” or “aromatic ring” as used herein refers to carbocyclic hydrocarbon radical of 6 to 14 carbon atoms consisting of one ring or more fused rings, wherein at least one ring is an aromatic ring. Examples of aryl include, but are not limited to: phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, indenyl, indanyl, azulenyl, preferably phenyl and naphthyl.

The term “heteroaryl” or “heteroaromatic ring” as used herein refers to: aromatic hydrocarbyl (i.e., 5-12 membered heteroaryl, 5-10 membered heteroaryl, 5-6 membered heteroaryl or 6 membered heteroaryl) having 5-12 ring atoms (such as 5-10 ring atoms, 5-6 ring atoms or 6 ring atoms), and containing one or more (such as 1, 2, 3 or 4, preferably 1, 2 or 3, more preferably 1 or 2) ring heteroatoms independently chosen from N, O and S in the rings, with the remaining ring atoms being carbon atoms; which may have one or more rings, such as 1, 2, or 3 rings, preferably 1 or 2 rings. For example, the heteroaryl includes:

monocyclic aromatic hydrocarbyl having 5, 6 or 7 ring atoms (preferably 5 or 6 ring atoms, namely, 5-6 membered heteroaryl), and containing one or more, for example 1, 2, 3 or 4, preferably 1, 2 or 3, more preferably 1 or 2 ring heteroatoms independently chosen

from N, O and S (preferably N and O) in the ring, with the remaining ring atoms being carbon atoms; and

bicyclic aromatic hydrocarbonyl having 8-12 ring atoms (preferably 9 or 10 ring atoms), and at least one of the rings contains one or more, such as 1, 2, 3 or 4, preferably 1, 2 or 3 ring heteroatoms independently chosen from N, O and S (preferably N), with the remaining ring atoms being carbon atoms, wherein at least one ring is aromatic ring and the point of attachment thereof to the rest of the molecule is located on aromatic ring. For example, bicyclic heteroaryl include a 5-6 membered heteroaryl ring fused with a 5-6 membered cycloalkyl ring.

When the total number of S and O atoms in the heteroaryl group exceeds 1, said S and O heteroatoms are not adjacent to one another.

Heteroaryl also include those in which the N ring atom is in the form of N-oxide, for example N-oxide pyridine.

Examples of heteroaryl include, but are not limited to: 5-6 membered heteroaryl, such as pyridyl, N-oxide pyridyl, pyrazinyl, pyrimidyl, triazinyl (such as 1,3,5-triazinyl), pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, oxadiazolyl (such as 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl and 1,3,4-oxadiazolyl), thiazolyl, isothiazolyl, thiadiazolyl, tetrazolyl, triazolyl (such as 1,2,3-triazolyl and 1,2,4-triazolyl), thienyl, furanyl, pyranal, pyrrolyl, and pyridazinyl; and bicyclic heteroaryl, such as benzodioxolyl, benzoxazolyl, benzoisoxazolyl, benzothienyl, benzothiazolyl, benzoisothiazolyl, imidazopyridyl (such as imidazo[1,2-a]pyridyl), imidazopyridazinyl (such as imidazo[1,2-b]pyridazinyl), pyrrolopyridyl (such as 1H-pyrrolo[2,3-b]pyridyl), pyrrolopyrimidyl (such as pyrrolo[3,4-d]pyrimidyl), pyrazolopyridyl (such as 1H-pyrazolo[3,4-b]pyridyl), pyrazolopyrimidyl (such as pyrazolo[1,5-a]pyrimidyl), triazolopyridyl (such as [1,2,4]triazolo[4,3-a]pyridyl and [1,2,4]triazolo[1,5-a]pyridyl), triazolopyridazinyl (such as [1,2,4]triazolo[4,3-b]pyridazinyl), tetrazolopyridyl (such as tetrazolo[1,5-a]pyridyl), benzofuranyl, benzoimidazolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, and quinazolyl.

The term "hydroxyl" as used herein refers to -OH group.

The term "oxo" as used herein refers to =O group.

The term "optional" or "optionally" as used herein means that the subsequently described event or circumstance may or may not occur, and the description includes

instances wherein the event or circumstance occur and instances in which it does not occur. For example, “optionally substituted alkyl” includes “unsubstituted alkyl” and “substituted alkyl” defined herein. It will be understood by the POSITA, with respect to any group containing one or more substituents, that such groups are not intended to
5 introduce any substitution or substitution patterns that are sterically impractical, chemically incorrect, synthetically non-feasible and/or inherently unstable.

The term “substituted” or “substituted with...”, as used herein, means that one or more hydrogen atoms on the designated atom or group are replaced with one or more substituents chosen from the indicated group of substituents, provided that the designated
10 atom's normal valence is not exceeded. When a substituent is oxo (i.e., =O), then two hydrogens on a single atom are replaced by the oxo. Combinations of substituents and/or variables are permitted only when they result in chemically correct and stable compounds. A chemically correct and stable compound is meant to imply a compound that is sufficiently robust to survive sufficient isolation from a reaction mixture, and then can be
15 formulated into a formulation having at least practical utility.

Unless otherwise specified, substituents are named into the core structure. For example, it is to be understood that when (cycloalkyl)alkyl is listed as a possible substituent, the point of attachment of this substituent to the core structure is in the alkyl portion.


20 The term “substituted with one or more substituents” as used herein means that one or more hydrogens on the designated atom or group are independently replaced with one or more substituents chosen from indicated group. In some embodiments, “substituted with one or more substituents” means the designated atom or group is replaced with 1, 2, 3 or 4 substituents independently chosen from designated group.

25 It will be understood by the POSITA that some of the compounds of formula (I) may contain one or more chiral centers and therefore exist in two or more stereoisomeric forms. The racemates of these isomers, the individual isomers and mixtures enriched in one enantiomer, as well as diastereomers when there are two chiral centers, and mixtures partially enriched with specific diastereomers are within the scope of the present
30 invention. It will be further understood by the POSITA that the present invention includes all the individual stereoisomers (e.g. enantiomers), racemic mixtures or partially

resolved mixtures of the compounds of formula (I) and, where appropriate, the individual tautomeric forms thereof.

The racemates can be used as such or can be resolved into their individual isomers. The resolution can afford stereochemically pure compounds or mixtures enriched in one or more isomers. Methods for separation of isomers are well known (cf. Allinger N. L. and Eliel E. L. in *“Topics in Stereochemistry”*, Vol. 6, Wiley Interscience, 1971) and include physical methods such as chromatography using a chiral adsorbent. Individual isomers can be prepared in chiral form from chiral precursors. Alternatively, individual isomers can be separated chemically from a mixture by forming diastereomeric salts with a chiral acid, such as the individual enantiomers of 10-camphorsulfonic acid, camphoric acid, alpha-bromocamphoric acid, tartaric acid, diacetyltartaric acid, malic acid, pyrrolidone-5-carboxylic acid, and the like, fractionally crystallizing the salts, and then freeing one or both of the resolved bases, optionally repeating the process, so as obtain either or both substantially free of the other; i.e., in a form having an optical purity of > 95%. Alternatively, the racemates can be covalently linked to a chiral compound (auxiliary) to produce diastereomers which can be separated by chromatography or by fractional crystallization after which time the chiral auxiliary is chemically removed to afford the pure enantiomers.

The term “tautomer” as used herein refers to constitutional isomers of compounds generated by rapid movement of an atom in two positions in a molecule. Tautomers readily interconvert into each other, e.g., enol form and ketone form are typical tautomers. For another example, some compounds of the present invention, when R₂ is hydrogen, may also exist in the structure of formula (II) as shown in the following figure, namely, the compound of formula (II) may become a tautomer of the compound of formula (I) of the present invention; such tautomer is a compound of the present invention.



A “pharmaceutically acceptable salt” is intended to mean a salt of a free acid or base of a compound of formula (I) that is non-toxic, biologically tolerable, or otherwise

biologically suitable for administration to the subject. For example, the pharmaceutically acceptable salt is an acid addition salt including such as a salt derived from an inorganic acid and an organic acid. Said inorganic acid includes such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and nitric acid; said
5 organic acid includes such as p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, and the like. For examples, see, generally, S. M. Berge, et al., "Pharmaceutical Salts", J. Pharm. Sci., 1977, 66:1-19, and Handbook of Pharmaceutical Salts, Properties, Selection, and Use, Stahl and Wermuth, Eds., Wiley-VCH and VHCA, Zurich, 2002.

10 In addition, if a compound of the present invention herein is obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid addition salt. Conversely, if the product is a free base, an acid addition salt, particularly a pharmaceutically acceptable acid addition salt, may be produced by dissolving the free base in a suitable solvent and treating the solution with an acid, in accordance with
15 conventional procedures for preparing acid addition salts from base compounds. The POSITA will recognize various synthetic methodologies that may be used without undue experimentation to prepare non-toxic pharmaceutically acceptable acid addition salts or base addition salts.

The term "solvates" means solvent addition forms that contain either stoichiometric
20 or non-stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the solid state, thus forming a solvate. If the solvent is water, the solvate formed is a hydrate, when the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more molecules of water, with one molecule of the substances in which the water retains its
25 molecular state as H₂O, such combination being able to form one or more hydrates, for example, hemihydrate, monohydrate, and dihydrate.

As used herein, the terms "group(s)" and "radical(s)" are synonymous and are intended to indicate functional groups or fragments of molecules attachable to other fragments of molecules.

30 The term "active ingredient" is used to indicate a chemical substance which has biological activity. In some embodiments, an "active ingredient" is a chemical substance having pharmaceutical utility. In USA, the practical pharmaceutical activity can be

determined by appropriate pre-clinical trials, whether *in vivo* or *in vitro*. However, the pharmaceutical activity that can sufficiently be accepted by regulatory agencies (such as the US FDA) must have a higher standard than that in pre-clinical trials. Whether such a higher standard of pharmaceutical activity can be successfully obtained is generally not
5 reasonably expected from the results of pre-clinical trials, but it can be established through appropriate and effective randomized, double-blind, and controlled clinical trials in humans.

The terms “treating” or “treatment” of a disease or disorder, in the context of achieving therapeutic benefit, refer to administering one or more pharmaceutical
10 substances, especially the compound of formula (I) or a pharmaceutically acceptable salt thereof described herein to a subject that has the disease or disorder, or has a symptom of a disease or disorder, or has a predisposition toward a disease or disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect the disease or disorder, the symptoms of the disease or disorder, or the predisposition toward
15 the disease or disorder. In some embodiments, the disease or disorder is cancer. In some embodiment, the disease or disorder is an autoimmune disease or inflammatory disease.

The terms “treating”, “contacting” and “reacting”, in the context of a chemical reaction, mean adding or mixing two or more reagents under appropriate conditions to produce the indicated and/or the desired product. It should be appreciated that the
20 reaction which produces the indicated and/or the desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the mixture which ultimately lead to the formation of the indicated and/or the desired product.

The term “effective amount” as used herein refers to an amount or dose of the
25 compound of the present invention sufficient to generally bring about a therapeutic benefit in patients in need of treatment for a disease or disorder mediated by CSF-1R activity or at least in part by CSF-1R. Effective amounts or doses of the active ingredient of the present disclosure may be ascertained by methods such as modeling, dose escalation studies or clinical trials, and by taking into consideration factors, e.g., the
30 mode or route of administration or drug delivery, the pharmacokinetics of the agent, the severity and course of the disease or disorder, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the attending

physician. In USA, the determination of an effective dose is generally difficult to predict from pre-clinical trials. In fact, the dose is completely unpredictable. After the dose was originally used in a randomized, double-blind, and controllable clinical trial, a new unpredictable dose schedule will be developed.

- 5 An exemplary dose is in the range of from about 0.0001 to about 200 mg of active agent per kg of subject's body weight per day, such as from about 0.001 to 100 mg/kg/day, or about 0.01 to 35 mg/kg/day, or about 0.1 to 10 mg/kg daily in single or divided dosage units (e.g., BID, TID, QID). For a 70 kg person, an illustrative range of a suitable dose is from about 0.05 to about 7 g/day, or from about 0.2 to about 5 g/day.
- 10 Once improvement of the patient's disease or disorder has occurred, the dose may be adjusted for maintenance treatment. For example, the dosage or the frequency of administration, or both, may be reduced as a function of the symptoms, to a level at which the desired therapeutic effect is maintained. Of course, if symptoms have been alleviated to an appropriate level, treatment may cease. Patients may, however, require
- 15 intermittent treatment on a long-term basis upon any recurrence of symptoms.

- The term "inhibition" or "inhibiting" refers to a decrease in the baseline activity of a biological activity or process. The term "inhibition of CSF-1R activity" is a practical pharmaceutical activity for purposes of this disclosure and refers to a decrease in the activity of CSF-1R as a direct or indirect response to the presence of the compound of
- 20 formula (I) and/or a pharmaceutically acceptable salt thereof described herein, relative to the activity of CSF-1R in the absence of the compound of formula (I) and/or a pharmaceutically acceptable salt thereof. The decrease in activity may be due to the direct interaction of the compound of formula (I) and/or a pharmaceutically acceptable salt thereof described herein with CSF-1R, or due to the interaction of the compound of
- 25 formula (I) and/or a pharmaceutically acceptable salt thereof described herein, with one or more other factors that in turn affect the CSF-1R activity. For example, the presence of the compound of formula (I) and/or a pharmaceutically acceptable salt thereof described herein may decrease the CSF-1R activity by directly binding to the CSF-1R, by directly or indirectly influencing another factor, or by directly or indirectly decreasing the amount
- 30 of CSF-1R present in the cell or organism.

 The term "subject" as used herein means mammals and non-mammals. Mammals means any member of the mammalia class including, but not limited to, humans; non-


human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, and swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice, and guinea pigs; and the like. Examples of non-mammals include, but are not limited to, birds, and the like.

- 5 The term “subject” does not denote a particular age or sex. In some embodiments, the subject is a human.

In general, the term “about” is used herein to modify a numerical value above or below the stated value by a variance of 20%.

- Technical and scientific terms used herein and not specifically defined have the
10 meaning commonly understood by the POSITA to which the present disclosure pertains.

Provided is a compound of formula (I):



(I)

- or a pharmaceutically acceptable salt thereof, and/or a deuterate, a solvate, a racemic
15 mixture, an enantiomer, a diastereomer and a tautomer thereof, wherein

X is N or CR₅;

Z₁ and Z₂ are each independently N or CR₆;

Y₁ is N or CR₇; Y₂ is N or CR₈; Y₃ is N or CR₉;

L is NH, O, S or CH₂;

- 20 W is absent or NH, O, S or CH₂;

R₁ is phenyl, 5-12 membered heteroaryl, 4-6 membered heterocyclyl or C₃₋₈

cycloalkyl, each of which is optionally substituted with one or more groups chosen from:

halogen, -CN, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, -(C₁₋₆ alkylene)_n-NH₂,
-(C₁₋₆ alkylene)_n-NH(C₁₋₆ alkyl), -(C₁₋₆ alkylene)_n-N(C₁₋₆ alkyl)₂, -(C₁₋₆ alkylene)_n-OH, -

- 25 (C₁₋₆ alkylene)_n-O-(C₁₋₆ alkyl) or -(C₁₋₆ alkylene)_n-O-(C₁₋₆ haloalkyl);

R₂ is hydrogen, -CN, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, -(C₁₋₆
alkylene)-NH₂, -(C₁₋₆ alkylene)-NH(C₁₋₆ alkyl), -(C₁₋₆ alkylene)-N(C₁₋₆ alkyl)₂, -(C₁₋₆

alkylene)-O-(C₁₋₆ alkyl), -(C₁₋₆ alkylene)-O-(C₁₋₆ haloalkyl), -(C₁₋₆ alkylene)-OH, C₃₋₈ cycloalkyl or 4-6 membered heterocyclyl;


R₃, R₄, R₅, R₆, R₇ and R₈ are each independently chosen from: hydrogen, halogen, -CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -O(C₁₋₆ alkyl), -O(C₁₋₆ haloalkyl) or -OH;

- 5 R₉ is hydrogen, halogen, -CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -O(C₁₋₆ alkyl), -O(C₁₋₆ haloalkyl), -OH, -(C₁₋₆ alkylene)-OH, -NH₂, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂ or C₃₋₈ cycloalkyl;

n is 0 or 1;

- or when Y₃ is CR₉, R₂ and R₉ together with the N atoms and C atoms to which they
10 are attached form a 5-6 membered heteroaromatic ring or 5-6 membered heterocycle;

or when Y₂ is CR₈ and Y₃ is CR₉, R₈ and R₉ together with the C atoms to which they are attached form a benzene ring;



provided that when X is CH, Z₁ is not N.

- 15 In some embodiments of the compound of formula (I), X is N.

In some embodiments of the compound of formula (I), X is CR₅.

In some embodiments of the compound of formula (I), R₅ is hydrogen, halogen, C₁₋₆ alkyl or -O(C₁₋₆ alkyl).

In some embodiments of the compound of formula (I), X is CH.

- 20 In some embodiments of the compound of formula (I), Z₁ and Z₂ are each independently CR₆.

In some embodiments of the compound of formula (I), Z₁ is N; Z₂ is CR₆.

In some embodiments of the compound of formula (I), Z₁ is CR₆; Z₂ is N.

In some embodiments of the compound of formula (I), R₆ is hydrogen.

- 25 In some embodiments of the compound of formula (I), both Z₁ and Z₂ are CH.

In some embodiments of the compound of formula (I), Y₁ is CR₇, Y₂ is CR₈, Y₃ is CR₉.

In some embodiments of the compound of formula (I), Y₁ is CR₇, Y₂ is N, Y₃ is CR₉.

In some embodiments of the compound of formula (I), Y₁ is N, Y₂ is CR₈, Y₃ is CR₉.

- 30 In some embodiments of the compound of formula (I), Y₁ is CR₇, Y₂ is CR₈, Y₃ is N.

In some embodiments of the compound of formula (I), L is O or CH₂.

In some embodiments of the compound of formula (I), L is O.

In some embodiments of the compound of formula (I), R₇ is chosen from: hydrogen, C₁₋₆ alkyl or -O(C₁₋₆ alkyl).

In some embodiments of the compound of formula (I), R₇ is hydrogen.

5 In some embodiments of the compound of formula (I), R₈ is chosen from hydrogen, halogen or C₁₋₆ alkyl.

In some embodiments of the compound of formula (I), R₈ is chosen from hydrogen, fluoro or methyl.

In some embodiments of the compound of formula (I), R₉ is hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -O(C₁₋₆ alkyl), -NH₂, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂ or C₃₋₆ cycloalkyl.

In some embodiments of the compound of formula (I), R₉ is hydrogen or methyl.

In some embodiments of the compound of formula (I), Y₁ is CR₇, Y₂ is CR₈, Y₃ is CR₉; R₇ and R₈ are each independently chosen from: hydrogen, halogen, C₁₋₆ alkyl or -O(C₁₋₆ alkyl); R₉ is hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -O(C₁₋₆ alkyl), -NH₂, -NH(C₁₋₆ alkyl) or -N(C₁₋₆ alkyl)₂.

In some embodiments of the compound of formula (I), Y₁ is CR₇, Y₂ is CR₈, Y₃ is CR₉; R₇ is hydrogen or -O(C₁₋₆ alkyl); R₈ is hydrogen, halogen or C₁₋₆ alkyl; R₉ is hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -O(C₁₋₆ alkyl), -NH₂, -NH(C₁₋₆ alkyl) or -N(C₁₋₆ alkyl)₂.

20 In some embodiments of the compound of formula (I), Y₁ is CR₇, Y₂ is CR₈, Y₃ is CR₉; R₇ is hydrogen; R₈ is hydrogen or halogen; R₉ is hydrogen or C₁₋₆ alkyl.

In some embodiments of the compound of formula (I), Y₁ is CR₇, Y₂ is CR₈, Y₃ is CR₉; R₇ is hydrogen; R₈ is hydrogen or fluoro; R₉ is hydrogen or methyl.

In some embodiments of the compound of formula (I), Y₁ is CR₇, Y₂ is CR₈, Y₃ is CR₉; R₇, R₈ and R₉ are hydrogen.

In some embodiments of the compound of formula (I), Y₁ is CR₇, Y₂ is N, Y₃ is CR₉; R₇ is hydrogen, C₁₋₆ alkyl or -O(C₁₋₆ alkyl); R₉ is hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl or C₃₋₆ cycloalkyl.

In some embodiments of the compound of formula (I), Y₁ is CR₇, Y₂ is N, Y₃ is CR₉; R₇ is hydrogen or C₁₋₆ alkyl; R₉ is hydrogen, C₁₋₆ alkyl or C₃₋₆ cycloalkyl.

In some embodiments of the compound of formula (I), Y₁ is CR₇, Y₂ is N, Y₃ is CR₉; R₇ is hydrogen; R₉ is hydrogen, C₁₋₆ alkyl or C₃₋₆ cycloalkyl.

In some embodiments of the compound of formula (I), Y_1 is CR_7 , Y_2 is N, Y_3 is CR_9 ; R_7 is hydrogen; R_9 is C_{1-6} alkyl.

In some embodiments of the compound of formula (I), Y_1 is CR_7 , Y_2 is N, Y_3 is CR_9 ; R_7 is hydrogen; R_9 is methyl.

5 In some embodiments of the compound of formula (I), Y_1 is CR_7 , Y_2 is N, Y_3 is CR_9 ; both R_7 and R_9 are hydrogen.

In some embodiments of the compound of formula (I), Y_1 is N, Y_2 is CR_8 , Y_3 is CR_9 ; both R_8 and R_9 are hydrogen.

10 In some embodiments of the compound of formula (I), Y_1 is CR_7 , Y_2 is CR_8 , Y_3 is N; both R_7 and R_8 are hydrogen.

In some embodiments of the compound of formula (I), W is absent or NH.

In some embodiments of the compound of formula (I), W is absent.

In some embodiments of the compound of formula (I), W is NH.

15 In some embodiments of the compound of formula (I), R_1 is phenyl, 5-12 membered heteroaryl, 4-6 membered heterocyclyl or C_{3-8} cycloalkyl, each of which is optionally substituted with one or more groups chosen from: halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, $-(C_{1-6} \text{ alkylene})_n-NH_2$, $-(C_{1-6} \text{ alkylene})_n-NH(C_{1-6} \text{ alkyl})$, $-(C_{1-6} \text{ alkylene})_n-N(C_{1-6} \text{ alkyl})_2$ or $-(C_{1-6} \text{ alkylene})_n-OH$.

20 In some embodiments of the compound of formula (I), R_1 is phenyl, 5-10 membered heteroaryl, 4-6 membered heterocyclyl or C_{3-8} cycloalkyl, each of which is optionally substituted with one or more groups chosen from: halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, $-(C_{1-6} \text{ alkylene})_n-NH_2$, $-(C_{1-6} \text{ alkylene})_n-NH(C_{1-6} \text{ alkyl})$, $-(C_{1-6} \text{ alkylene})_n-N(C_{1-6} \text{ alkyl})_2$ or $-(C_{1-6} \text{ alkylene})_n-OH$.

25 In some embodiments of the compound of formula (I), R_1 is phenyl, 5-6 membered monocyclic heteroaryl, 9-10 membered bicyclic heteroaryl, 4-6 membered heterocyclyl or C_{3-8} cycloalkyl, each of which is optionally substituted with one or more groups chosen from: halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, $-(C_{1-6} \text{ alkylene})_n-NH_2$, $-(C_{1-6} \text{ alkylene})_n-NH(C_{1-6} \text{ alkyl})$, $-(C_{1-6} \text{ alkylene})_n-N(C_{1-6} \text{ alkyl})_2$ or $-(C_{1-6} \text{ alkylene})_n-OH$.

30 In some embodiments of the compound of formula (I), R_1 is phenyl, pyrazolyl, pyrrolyl, furanyl, thienyl, pyridyl, thiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, imidazolyl, imidazo[1,2-a]pyridyl, piperazinyl or cyclohexenyl, each of which is optionally substituted with one or more groups chosen from: halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, -

(C₁₋₆ alkylene)_n-NH₂, -(C₁₋₆ alkylene)_n-NH(C₁₋₆ alkyl), -(C₁₋₆ alkylene)_n-N(C₁₋₆ alkyl)₂ or -(C₁₋₆ alkylene)_n-OH.


In some embodiments of the compound of formula (I), R₁ is phenyl, pyrazolyl, pyrrolyl, furanyl, thienyl, pyridyl, thiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, imidazolyl, imidazo[1,2-a]pyridyl, piperaziny or cyclohexenyl, each of which is optionally substituted with one or more groups chosen from: halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -(C₁₋₆ alkylene)-NH₂, -(C₁₋₆ alkylene)-NH(C₁₋₆ alkyl), -(C₁₋₆ alkylene)-N(C₁₋₆ alkyl)₂ or -(C₁₋₆ alkylene)-OH.


In some embodiments of the compound of formula (I), R₁ is pyrazolyl or pyrrolyl, each of which is optionally substituted with one or more groups chosen from: C₁₋₆ alkyl, C₁₋₆ haloalkyl, -(C₁₋₆ alkylene)-NH₂, -(C₁₋₆ alkylene)-NH(C₁₋₆ alkyl), -(C₁₋₆ alkylene)-N(C₁₋₆ alkyl)₂ or -(C₁₋₆ alkylene)-OH.

In some embodiments of the compound of formula (I), R₁ is pyrazolyl or pyrrolyl, each of which is optionally substituted with one or more groups chosen from: methyl, ethyl, i-propyl, -CHF₂, -CF₃, -(CH₂CH₂)-NH₂, -(CH₂CH₂)-NH(C₁₋₆ alkyl), -(CH₂CH₂)-N(C₁₋₆ alkyl)₂ or -(CH₂CH₂)-OH.

In some embodiments of the compound of formula (I), R₁ is pyrazolyl or pyrrolyl, each of which is optionally substituted with one or more C₁₋₆ alkyl.

In some embodiments of the compound of formula (I), R₁ is pyrazolyl or pyrrolyl, each of which is optionally substituted with one or more methyl.

In some embodiments of the compound of formula (I), R₁ is ,  or , each of which is substituted with one or more methyl.

In some embodiments of the compound of formula (I), R₁ is  substituted with one or more methyl.

In some embodiments of the compound of formula (I), R₁ is phenyl optionally substituted with one or more halogen.

In some embodiments of the compound of formula (I), R₁ is phenyl optionally substituted with one or more F.

In some embodiments of the compound of formula (I), R₁ is furanyl, thienyl, pyridyl, thiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, imidazolyl, imidazo[1,2-a]pyridyl, piperazinyl or cyclohexenyl, each of which is optionally substituted with one or more C₁₋₆ alkyl.




In some embodiments of the compound of formula (I), R₁ is furanyl, thienyl, pyridyl, 5 thiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, imidazolyl or imidazo[1,2-a]pyridyl, each of which is optionally substituted with one or more methyl.

In some embodiments of the compound of formula (I), R₁ is piperazinyl, which is optionally substituted with one or more ethyl.




In some embodiments of the compound of formula (I), W is NH; R₁ is pyrazolyl, 10 pyridyl or thiazolyl, each of which is optionally substituted with one or more groups chosen from: halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -(C₁₋₆ alkylene)-NH₂, -(C₁₋₆ alkylene)-NH(C₁₋₆ alkyl), -(C₁₋₆ alkylene)-N(C₁₋₆ alkyl)₂ or -(C₁₋₆ alkylene)-OH.


In some embodiments of the compound of formula (I), W is NH; R₁ is pyrazolyl, pyridyl or thiazolyl, each of which is optionally substituted with one or more groups 15 chosen from: C₁₋₆ alkyl or C₁₋₆ haloalkyl.

In some embodiments of the compound of formula (I), W is NH; R₁ is pyrazolyl optionally substituted with one or more methyl.

In some embodiments of the compound of formula (I), W is NH; R₁ is ,  or , each of which is substituted with one or more methyl.

20 In some embodiments of the compound of formula (I), W is absent; R₁ is pyrazolyl or pyrrolyl, each of which is optionally substituted with one or more methyl.

In some embodiments of the compound of formula (I), W is absent; R₁ is ,  or , each of which is substituted with one or more methyl.

In some embodiments of the compound of formula (I), W is absent; R₁ is  25 substituted with one or more methyl.

In some embodiments of the compound of formula (I), R₂ is hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ haloalkyl, -(C₁₋₆ alkylene)-N(C₁₋₆ alkyl)₂, -(C₁₋₆ alkylene)-O-(C₁₋₆ alkyl), -(C₁₋₆ alkylene)-OH, C₃₋₆ cycloalkyl or 4-6 membered heterocyclyl.

In some embodiments of the compound of formula (I), R₂ is hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ haloalkyl, -(CH₂CH₂)-N(C₁₋₆ alkyl)₂, -(CH₂CH₂)-O-(C₁₋₆ alkyl), -(CH₂CH₂)-OH, C₃₋₆ cycloalkyl or 4-6 membered heterocyclyl.

In some embodiments of the compound of formula (I), R₂ is hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ haloalkyl, -(CH₂CH₂)-N(C₁₋₆ alkyl)₂, -(CH₂CH₂)-O-(C₁₋₆ alkyl), -(CH₂CH₂)-OH, C₃₋₆ cycloalkyl or oxetanyl.

10 In some embodiments of the compound of formula (I), R₂ is C₁₋₆ alkyl, C₂₋₆ alkenyl, -(CH₂CH₂)-O-(C₁₋₆ alkyl), -(CH₂CH₂)-OH, cyclopropyl, cyclobutyl or oxetanyl.

In some embodiments of the compound of formula (I), R₂ is C₁₋₆ alkyl.

In some embodiments of the compound of formula (I), R₂ is methyl, ethyl or i-propyl.

15 In some embodiments of the compound of formula (I), R₂ is methyl.

In some embodiments of the compound of formula (I), R₂ is i-propyl.

In some embodiments of the compound of formula (I), R₃ and R₄ are each independently chosen from: hydrogen, halogen, -CN, C₁₋₆ alkyl or -O(C₁₋₆ alkyl).

In some embodiments of the compound of formula (I), R₃ and R₄ are each independently chosen from: hydrogen, halogen, -CN, C₁₋₆ alkyl or -O(C₁₋₆ alkyl); and when X is CH, at least one of R₃ and R₄ is hydrogen.

In some embodiments of the compound of formula (I), R₃ is hydrogen, halogen, -CN, C₁₋₆ alkyl or -O(C₁₋₆ alkyl); R₄ is hydrogen or C₁₋₆ alkyl.

In some embodiments of the compound of formula (I), both R₃ and R₄ are hydrogen.

25 In some embodiments of the compound of formula (I), X is CH; R₃ and R₄ are each independently chosen from: hydrogen, halogen, C₁₋₆ alkyl or -O(C₁₋₆ alkyl), and at least one of R₃ and R₄ is hydrogen.


In some embodiments of the compound of formula (I), X is CH; R₃ is hydrogen, halogen, C₁₋₆ alkyl or -O(C₁₋₆ alkyl); R₄ is hydrogen.


30 In some embodiments of the compound of formula (I), n is 1.

In some embodiments of the compound of formula (I), Y₃ is CR₉; R₂ and R₉ together with the N atoms and C atoms to which they are attached form pyridine or pyrrolidine.

In some embodiments of the compound of formula (I), Y_3 is CR_9 ; R_2 and R_9 together with the N atoms and C atoms to which they are attached form pyridine.

In some embodiments of the compound of formula (I), Y_3 is CR_9 ; R_2 and R_9 together with the N atoms and C atoms to which they are attached form pyrrolidine.

5 In some embodiments of the compound of formula (I),  is , wherein R_{10} is C_{1-6} alkyl.

In some embodiments of the compound of formula (I),  is , wherein R_{10} is methyl.

10 In some embodiments of the compound of formula (I), X is CR_5 ; Z_1 and Z_2 are each independently CR_6 ; Y_1 is CR_7 ; Y_2 is N or CR_8 ; Y_3 is CR_9 ; W is absent; R_1 is 5-6 membered heteroaryl optionally substituted with one or more C_{1-6} alkyl; R_2 is C_{1-6} alkyl; R_3 , R_4 , R_5 , R_6 , R_7 and R_8 are each independently chosen from: hydrogen, halogen, C_{1-6} alkyl or $-O(C_{1-6}$ alkyl), and at least one of R_3 and R_4 is hydrogen; R_9 is hydrogen or C_{1-6} alkyl.

15 In some embodiments of the compound of formula (I), X is CH; both Z_1 and Z_2 are CH; Y_1 is CH; Y_2 is N or CH; Y_3 is CR_9 ; W is absent; R_1 is pyrazolyl optionally substituted with one or more C_{1-6} alkyl; R_2 is C_{1-6} alkyl; R_3 is hydrogen, halogen, C_{1-6} alkyl or $-O(C_{1-6}$ alkyl); R_4 is hydrogen; R_9 is hydrogen or C_{1-6} alkyl.

20 In some embodiments of the compound of formula (I), X is N; both Z_1 and Z_2 are CH; Y_1 is CH; Y_2 is N or CR_8 ; Y_3 is CR_9 ; W is absent; R_1 is pyrazolyl or pyrrolyl, which is optionally substituted with one or more C_{1-6} alkyl; R_2 is C_{1-6} alkyl; R_3 is hydrogen, halogen, C_{1-6} alkyl or $-O(C_{1-6}$ alkyl); R_4 is hydrogen; R_8 is hydrogen or halogen; R_9 is hydrogen or C_{1-6} alkyl.

25 In some embodiments of the compound of formula (I), X is N; both Z_1 and Z_2 are CH; Y_1 is CH; Y_2 is N or CR_8 ; Y_3 is CR_9 ; W is absent; R_1 is pyrazolyl or pyrrolyl, which is substituted with one or more methyl; R_2 is methyl or i-propyl; R_3 is hydrogen; R_4 is hydrogen; R_8 is hydrogen or F; R_9 is hydrogen or methyl.

In some embodiments of the compound of formula (I), X is N; both Z_1 and Z_2 are CH; Y_1 is CH; Y_2 is N or CR_8 ; Y_3 is CR_9 ; W is NH; R_1 is pyrazolyl optionally substituted

















No.	Structural formula	No.	Structural formula
1		69	
2		70	
3		71	
4		72	
5		73	
6		74	

7		75	
8		76	
9		77	
10		78	
11		79	
12		80	
13		81	
14		82	

15		83	
16		84	
17		85	
18		86	
19		87	
20		88	
21		89	
22		90	
23		91	












24		92	
25		93	
26		94	
27		95	
28		96	
29		97	
30		98	

31		99	
32		100	
33		101	
34		102	
35		103	
36		104	
37		105	
38		106	

39		107	
40		108	
41		109	
42		110	
43		111	
44		112	
45		113	
46		114	

47		115	
48		116	
49		117	
50		118	
51		119	
52		120	
53		121	
54		122	

55		123	
56		124	
57		125	
58		126	
59		127	
60		128	
61		129	
62		130	

63		131	
64		132	
65		133	
66		134	
67		135	
68			

In another aspect, also provided is a pharmaceutical composition, comprising the compound of formula (I) (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof, and optionally comprising at least one pharmaceutically acceptable excipient (e.g., a pharmaceutically acceptable carrier).

In another aspect, also provided is a method of *in vivo* or *in vitro* inhibiting the activity of CSF-1R, comprising contacting CSF-1R with an effective amount of a

compound of formula (I) (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof.

In another aspect, also provided is a method of treating a disease mediated by CSF-1R or at least in part by CSF-1R in a subject, comprising administering to the subject in
5 need thereof an effective amount of a compound of formula (I) (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof.

In another aspect, also provided is a method of treating cancer, an autoimmune disease, an inflammatory disease, a metabolic disease, a neurodegenerative disease, obesity or an obesity-related disease in a subject, comprising administering to the subject
10 in need thereof an effective amount of a compound of formula (I) (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof.

In another aspect, also provided is a method of treating cancer, an autoimmune disease or an inflammatory disease in a subject, comprising administering to the subject
15 in need thereof an effective amount of a compound of formula (I) (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof.

In another aspect, also provided is a method of treating a disease mediated by CSF-1R or at least in part by CSF-1R in a subject, comprising administering to the subject in
20 need thereof an effective amount of a pharmaceutical composition comprising a compound of formula (I) (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient (e.g., a pharmaceutically acceptable carrier).

In another aspect, also provided is a method of treating cancer, an autoimmune
25 disease, an inflammatory disease, a metabolic disease, a neurodegenerative disease, obesity or an obesity-related disease in a subject, comprising administering to the subject in need thereof an effective amount of a pharmaceutical composition comprising a compound of formula (I) (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically
30 acceptable excipient (e.g., a pharmaceutically acceptable carrier).

In another aspect, also provided is a method of treating cancer, an autoimmune disease or an inflammatory disease in a subject, comprising administering to the subject

in need thereof an effective amount of a pharmaceutical composition comprising a compound of formula (I) (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient (e.g., a pharmaceutically acceptable carrier).

- 5 In another aspect, also provided is the use of a compound of formula (I) (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof described herein in the treatment of a disease mediated by CSF-1R or at least in part by CSF-1R in a subject.

- 10 In another aspect, also provided is the use of the compound of formula (I) (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof described herein in the treatment of cancer, an autoimmune disease, an inflammatory disease, a metabolic disease, a neurodegenerative disease, obesity or an obesity-related disease in a subject.

- 15 In another aspect, also provided is the use of the compound of formula (I) (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof described herein in the treatment of cancer, an autoimmune disease or an inflammatory disease in a subject.

- 20 In another aspect, also provided is the use of a compound of formula (I) (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof described herein in the manufacture of a medicament for treating a disease mediated by CSF-1R or at least in part by CSF-1R in a subject.

- 25 In another aspect, also provided is the use of the compound of formula (I) (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof described herein in the manufacture of a medicament for treating cancer, an autoimmune disease, an inflammatory disease, a metabolic disease, a neurodegenerative disease, obesity or an obesity-related disease in a subject.

- 30 In another aspect, also provided is the use of a compound of formula (I) (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof described herein in the manufacture of a medicament for treating cancer, an autoimmune disease or an inflammatory disease in a subject.

In another aspect, also provided is a combination, comprising a compound of formula (I) (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof, and at least one additional therapeutic agent.

In another aspect, also provided is a method of treating a disease mediated by CSF-1R or at least in part by CSF-1R in a subject, comprising administering to the subject in need thereof an effective amount of a compound of formula (I) (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof, and additional therapeutic agents.

In another aspect, also provided is a method of treating cancer, an autoimmune disease or an inflammatory disease in a subject, comprising administering to the subject in need thereof an effective amount of a compound of formula (I) (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof, and additional therapeutic agents.

In another aspect, also provided is the use of a compound of formula (I) (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof described herein together with additional therapeutic agents in the manufacture of a combined drug for treating a disease mediated by CSF-1R or at least in part by CSF-1R in a subject.

In another aspect, also provided is the use of a compound of formula (I) (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof described herein together with additional therapeutic agents in the manufacture of a combined drug for treating cancer, an autoimmune disease or an inflammatory disease.

In some embodiments, the additional therapeutic agent is an anti-neoplastic agent.

In some embodiments, the anti-neoplastic agent is chosen from a chemotherapeutic agent, an immune checkpoint inhibitor or agonist, and a targeted therapeutic agent.

In some embodiments, the disease mediated by CSF-1R or at least in part by CSF-1R is cancer, an autoimmune disease, an inflammatory disease, a metabolic disease, a neurodegenerative disease, obesity or an obesity-related disease.

In some embodiments, the disease mediated by CSF-1R or at least in part by CSF-1R is cancer, an autoimmune disease or an inflammatory disease.

In some embodiments, the cancer is solid tumor or hematologic malignancy (such as leukemia, lymphoma or myeloma).

In some embodiments, the cancer is chosen from ovarian cancer, lung cancer (including non-small cell lung cancer), brain tumor (including glioblastoma (GBM)),
5 tenosynovial giant cell tumor, gastrointestinal stromal tumor (GIST), gastric cancer, esophageal cancer, colon cancer, colorectal cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, melanoma, mesothelioma, mesothelial carcinoma, renal cancer, liver cancer, thyroid carcinoma, head and neck cancer, urothelial carcinoma, bladder cancer, endometrial cancer, choriocarcinoma, adrenal carcinoma, sarcoma,
10 leukemia, lymphoma or myeloma.

In some embodiments, the cancer is chosen from ovarian cancer, lung cancer (including non-small cell lung cancer), glioblastoma (GBM), tenosynovial giant cell tumor, gastrointestinal stromal tumor (GIST), gastric cancer, esophageal cancer, colon cancer, colorectal cancer, pancreatic cancer, prostate cancer, breast cancer, cervical
15 cancer, melanoma, mesothelioma, mesothelial carcinoma, renal cancer, liver cancer, thyroid carcinoma, head and neck cancer, urothelial carcinoma, bladder cancer, endometrial cancer, choriocarcinoma, adrenal carcinoma, sarcoma, acute myelogenous leukemia (AML) (including recurrent or refractory AML), acute lymphocytic leukemia (ALL), B-cell lymphoma, T-cell lymphoma, diffuse large B-cell lymphoma (DLBCL) or
20 multiple myeloma (MM).

In some embodiments, the autoimmune disease or inflammatory disease is chosen from arthritis (including rheumatoid arthritis and collagen-induced arthritis), osteoarthritis, pigmented villonodular synovitis (PVNS), systemic lupus erythematosus, multiple sclerosis, autoimmune nephritis, Crohn's disease, asthma or chronic obstructive
25 pulmonary disease.

In some embodiments, the metabolic disease is chosen from osteoporosis, diabetes, diabetic ketoacidosis, hyperglycemia and hyperosmolar syndrome, hypoglycemia, gout, protein-energy malnutrition, vitamin A deficiency disease, scurvy, vitamin D deficiency disease, etc.

30 In some embodiments, the neurodegenerative disease is chosen from Parkinson's disease (PD), multiple system atrophy, Alzheimer's disease (AD), frontotemporal dementia, Huntington's disease (HD), corticobasal degeneration, spinocerebellar ataxia,


motor neuron disease (including amyotrophic lateral sclerosis (ALS)), hereditary motor and sensory neuropathy (CMT), etc.

In some embodiments, the obesity-related disease is chosen from diabetes, hypertension, insulin resistance syndrome, dyslipidemia, heart disease, cardiovascular disease (including atherosclerosis, abnormal heart rhythms, arrhythmias, myocardial infarction, congestive heart failure, coronary heart disease, and angina pectoris), cerebral infarction, cerebral hemorrhage, osteoarthritis, metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and the like.

10 General synthetic methods of the disclosed embodiments

The compound of formula (I) and/or a pharmaceutically acceptable salt thereof described herein can be synthesized using commercially available materials, by methods known in the art, or methods disclosed in the patent application. The synthetic routes shown in routes 1-3 illustrate the general synthetic methods of the compounds of the present invention.

Method 1:




Route 1

As shown in route 1, under alkaline conditions (such as, but not limited to potassium carbonate), a compound represented by molecular formula (1-1) is subjected to a substitution reaction with a compound represented by molecular formula (1-2), or the compound represented by molecular formula (1-1') is subjected to a substitution reaction


with the compound represented by molecular formula (1-2') to obtain a compound represented by molecular formula (1-3). The compound represented by molecular formula (1-3) is subjected to a coupling reaction with a compound represented by molecular formula (1-4) under the catalysis of a palladium reagent (such as, but not limited to Pd(dppf)Cl₂), or is subjected to a substitution reaction with a compound represented by molecular formula (1-4') under the catalysis of a palladium reagent (such as, but not limited to Pd₂(dba)₃) and ligand (such as, but not limited to BINAP) to obtain a compound represented by molecular formula (1-5); which is continuously subjected to a reduction reaction to obtain a compound represented by molecular formula (1-6). The compound represented by molecular formula (1-6) is subjected to a condensation reaction with a compound represented by molecular formula (1-7) in the presence of a condensing agent (such as, but not limited to HATU, and the like) to obtain a compound of formula (I), wherein R₁, R₂, R₃, R₄, W, X, Y₁, Y₂, Y₃, Z₁ and Z₂ are as defined herein; M is borate, boronic acid or alkyl tin; X₁ is halogen, chosen from Cl and Br; X₂ is halogen, chosen from F and Cl.

Method 2:



As shown in route 2, the compound represented by molecular formula (1-3) is subjected to a reduction reaction to obtain a compound represented by molecular formula (1-8), and then which is continuously subjected to a condensation reaction with the compound represented by molecular formula (1-7) in the presence of a condensing agent (such as, but not limited to HATU, and the like) to obtain a compound represented by molecular formula (1-9). The compound represented by molecular formula (1-9) is subjected to a coupling reaction with the compound represented by molecular formula (1-

- 4) under the catalysis of a palladium reagent (such as, but not limited to $\text{Pd}(\text{dppf})\text{Cl}_2$), or is subjected to a substitution reaction with the compound represented by molecular formula (1-4') under the catalysis of a palladium reagent (such as, but not limited to $\text{Pd}_2(\text{dba})_3$) and ligand (such as, but not limited to BINAP) to obtain a compound of formula (I), wherein R_1 , R_2 , R_3 , R_4 , W , X , Y_1 , Y_2 , Y_3 , Z_1 and Z_2 are as defined herein; M is borate, boronic acid or alkyl tin; X_1 is halogen, chosen from Cl and Br .

Method 3:

Route 3

10

- As shown in route 3, the compound represented by molecular formula (1-1') is subjected to a substitution reaction with a compound represented by molecular formula (1-10) under alkaline conditions (such as, but not limited to cesium carbonate) to obtain a compound represented by molecular formula (1-8). The compound represented by molecular formula (1-8) is subjected to a coupling reaction with the compound represented by molecular formula (1-4) under the catalysis of a palladium reagent (such as, but not limited to $\text{Pd}(\text{dppf})\text{Cl}_2$), or is subjected to a substitution reaction with the compound represented by molecular formula (1-4') under the catalysis of a palladium reagent (such as, but not limited to $\text{Pd}_2(\text{dba})_3$) and ligand (such as, but not limited to BINAP) to obtain a compound represented by molecular formula (1-6). The compound represented by molecular formula (1-6) is subjected to a condensation reaction with the compound represented by molecular formula (1-7) in the presence of a condensing agent (such as, but not limited to HATU, and the like) to obtain a compound of formula (I),

15

20

wherein R₁, R₂, R₃, R₄, W, X, Y₁, Y₂, Y₃, Z₁ and Z₂ are as defined herein; M is borate, boronic acid or alkyl tin; X₁ is halogen, chosen from Cl and Br; X₂ is halogen, chosen from F and Cl.

The substituents of the compounds thus obtained can be further modified to provide other desired compounds. Synthetic chemistry transformations are described, for example, in R. Larock, *Comprehensive Organic Transformations*, VCH Publishers (1989); L. Fieser and M. Fieser, *Fieser and Fieser's Reagents for Organic Synthesis*, John Wiley and Sons (1994); and L. Paquette, ed., *Encyclopedia of Reagents for Organic Synthesis*, John Wiley and Sons (1995) and subsequent editions thereof.

Before use, the compound of formula (I) and/or a pharmaceutically acceptable salt thereof described herein can be purified by column chromatography, high performance liquid chromatography, crystallization or other suitable methods.

Pharmaceutical Compositions and Practical Utility

The compound of formula (I) (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof described herein is used, alone or in combination with one or more additional active ingredients, to formulate pharmaceutical compositions. A pharmaceutical composition comprises: (a) an effective amount of a compound of formula (I) and/or a pharmaceutically acceptable salt thereof described herein and optional additional active ingredients; and (b) a pharmaceutically acceptable excipient (e.g., a pharmaceutically acceptable carrier).

A pharmaceutically acceptable carrier refers to a carrier that is compatible with active ingredients of the composition (and in some embodiments, capable of stabilizing the active ingredients) and not deleterious to the subject to be treated. For example, solubilizing agents, such as cyclodextrins (which form specific, more soluble complexes with the compound of formula (I) and/or a pharmaceutically acceptable salt thereof described herein), can be utilized as pharmaceutical excipients for delivery of the active ingredients. Examples of other carriers include colloidal silicon dioxide, magnesium stearate, cellulose, sodium lauryl sulfate, and pigments such as D&C Yellow # 10.

Suitable pharmaceutically acceptable carriers are disclosed in Remington's Pharmaceutical Sciences, A. Osol, a standard reference text in the art.

A pharmaceutical composition comprising the compound of formula (I) (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof described herein can be administered in various known manners, such as orally, topically, rectally, parenterally, by inhalation spray, or via an implanted
5 reservoir. The term "parenteral" as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.

A pharmaceutical composition described herein can be prepared in the form of tablet, capsule, sachet, dragee, powder, granule, lozenge, powder for reconstitution, liquid
10 preparation, or suppository. In some embodiments, a pharmaceutical composition comprising the compound of formula (I) and/or a pharmaceutically acceptable salt thereof is formulated for intravenous infusion, topical administration, or oral administration.

An oral composition can be any orally acceptable dosage form including, but not
15 limited to, tablets, capsules, emulsions, and aqueous suspensions, dispersions and solutions. Commonly used carriers for tablets include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added to tablets. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions or emulsions are administered orally, the active ingredient
20 can be suspended or dissolved in an oily phase combined with emulsifying or suspending agents. If desired, certain sweetening, flavoring, or coloring agents can be added.

In some embodiments, the compound of formula (I) and/or a pharmaceutically acceptable salt thereof can be present in an amount of 1, 5, 10, 15, 20, 25, 50, 75, 80, 85, 90, 95, 100, 125, 150, 200, 250, 300, 400 and 500 mg in a tablet. In some embodiments,
25 the compound of formula (I) and/or a pharmaceutically acceptable salt thereof can be present in an amount of 1, 5, 10, 15, 20, 25, 50, 75, 80, 85, 90, 95, 100, 125, 150, 200, 250, 300, 400 and 500 mg in a capsule.

A sterile injectable composition (e.g., aqueous or oleaginous suspension) can be formulated according to techniques known in the art using suitable dispersing or wetting
30 agents (for example, Tween 80) and suspending agents. The sterile injectable intermediate medium can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.

Among the pharmaceutically acceptable vehicles and solvents that can be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium (e.g., synthetic mono- or di-glycerides). Fatty acids, such as oleic acid and its glyceride
5 derivatives, and natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions, can be used as injectable intermediate medium. These oil solutions or suspensions can also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents.

An inhalation composition can be prepared according to techniques well known in
10 the art of pharmaceutical formulation and can be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.

A topical composition can be formulated in form of oil, cream, lotion, ointment, and
15 the like. Suitable carriers for the composition include vegetable or mineral oils, white petrolatum (white soft paraffin), branched chain fats or oils, animal fats and high molecular weight alcohols (greater than C12). In some embodiments, the pharmaceutically acceptable carrier is one in which the active ingredient is soluble. Emulsifiers, stabilizers, humectants and antioxidants may also be included as well as
20 agents imparting color or fragrance, if desired. Additionally, transdermal penetration enhancers may be employed in those topical formulations. Examples of such enhancers can be found in U.S. Patent Nos. 3,989,816 and 4,444,762.

Creams may be formulated from a mixture of mineral oil, self-emulsifying beeswax and water in which mixture the active ingredient, dissolved in a small amount of an oil,
25 such as almond oil, is admixed. An example of such a cream is one which includes, by weight, about 40 parts water, about 20 parts beeswax, about 40 parts mineral oil and about 1 part almond oil. Ointments may be formulated by mixing a solution of the active ingredient in a vegetable oil, such as almond oil, with warm soft paraffin and allowing the mixture to cool. An example of such an ointment is one which includes about 30% by
30 weight almond oil and about 70% by weight white soft paraffin.

Suitable in vitro assays can be used to evaluate the practical utility of the compound of formula (I) and/or a pharmaceutically acceptable salt thereof described herein in

inhibiting the activity of CSF-1R. The compound of formula (I) and/or a pharmaceutically acceptable salt thereof described herein can further be examined for additional practical utility in treating cancer, an autoimmune disease or an inflammatory disease, and the like by *in vivo* assays. For example, the compound of formula (I) and/or
5 a pharmaceutically acceptable salt thereof described herein can be administered to an animal (e.g., a mouse model) having cancer and its therapeutic effects can be accessed. If the pre-clinical results are successful, the dosage range and administration route for animals, such as humans, can be projected.

The compound of formula (I) and/or a pharmaceutically acceptable salt thereof
10 described herein can be shown to have sufficient pre-clinical practical utility to merit clinical trials hoped to demonstrate a beneficial therapeutic or prophylactic effect, for example, in subjects with cancer.

As used herein, the term “cancer” refers to a cellular disorder characterized by uncontrolled or dysregulated cell proliferation, decreased cellular differentiation,
15 inappropriate ability to invade surrounding tissue, and/or ability to establish new growth at ectopic sites. The term “cancer” includes, but is not limited to, solid tumors and hematologic malignancies. The term “cancer” encompasses diseases of skin, tissues, organs, bone, cartilage, blood, and vessels. The term “cancer” encompasses primary cancer, and further metastatic cancer.

20 Non-limiting examples of solid tumors include pancreatic cancer; bladder cancer; colorectal cancer; colon cancer; breast cancer, including metastatic breast cancer; prostate cancer, including androgen-dependent and androgen-independent prostate cancer; testicular cancer; renal cancer, including, e.g., metastatic renal cell carcinoma; urothelial carcinoma; liver cancer; hepatocellular cancer; lung cancer, including, e.g., non-small
25 cell lung cancer (NSCLC), bronchioloalveolar carcinoma (BAC), and adenocarcinoma of the lung; ovarian cancer, including, e.g., progressive epithelial or primary peritoneal cancer; cervical cancer; endometrial cancer; gastrointestinal stromal tumor (GIST); gastric cancer; esophageal cancer; head and neck cancer, including, e.g., squamous cell carcinoma of the head and neck; skin cancer, including, e.g., melanoma and basal
30 carcinoma; neuroendocrine cancer, including metastatic neuroendocrine tumors; brain tumors, including, e.g., glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma; bone cancer; sarcoma, including, e.g.,

Kaposi's sarcoma; adrenal carcinoma; mesothelioma; mesothelial carcinoma; choriocarcinoma; muscle carcinoma; connective tissue carcinoma; tenosynovial giant cell tumor; and thyroid carcinoma.

Non-limiting examples of hematologic malignancies include acute myelogenous leukemia (AML); chronic myelogenous leukemia (CML), including accelerated phase CML and CML blastic phase (CML-BP); acute lymphocytic leukemia (ALL); chronic lymphocytic leukemia (CLL); Hodgkin's lymphoma; non-Hodgkin's lymphoma (NHL); follicular lymphoma; mantle cell lymphoma (MCL); B-cell lymphoma; T cell lymphoma; diffuse large B-cell lymphoma (DLBCL); multiple myeloma (MM); Waldenstrom
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995
1000
1005
1010
1015
1020
1025
1030
1035
1040
1045
1050
1055
1060
1065
1070
1075
1080
1085
1090
1095
1100
1105
1110
1115
1120
1125
1130
1135
1140
1145
1150
1155
1160
1165
1170
1175
1180
1185
1190
1195
1200
1205
1210
1215
1220
1225
1230
1235
1240
1245
1250
1255
1260
1265
1270
1275
1280
1285
1290
1295
1300
1305
1310
1315
1320
1325
1330
1335
1340
1345
1350
1355
1360
1365
1370
1375
1380
1385
1390
1395
1400
1405
1410
1415
1420
1425
1430
1435
1440
1445
1450
1455
1460
1465
1470
1475
1480
1485
1490
1495
1500
1505
1510
1515
1520
1525
1530
1535
1540
1545
1550
1555
1560
1565
1570
1575
1580
1585
1590
1595
1600
1605
1610
1615
1620
1625
1630
1635
1640
1645
1650
1655
1660
1665
1670
1675
1680
1685
1690
1695
1700
1705
1710
1715
1720
1725
1730
1735
1740
1745
1750
1755
1760
1765
1770
1775
1780
1785
1790
1795
1800
1805
1810
1815
1820
1825
1830
1835
1840
1845
1850
1855
1860
1865
1870
1875
1880
1885
1890
1895
1900
1905
1910
1915
1920
1925
1930
1935
1940
1945
1950
1955
1960
1965
1970
1975
1980
1985
1990
1995
2000
2005
2010
2015
2020
2025
2030
2035
2040
2045
2050
2055
2060
2065
2070
2075
2080
2085
2090
2095
2100
2105
2110
2115
2120
2125
2130
2135
2140
2145
2150
2155
2160
2165
2170
2175
2180
2185
2190
2195
2200
2205
2210
2215
2220
2225
2230
2235
2240
2245
2250
2255
2260
2265
2270
2275
2280
2285
2290
2295
2300
2305
2310
2315
2320
2325
2330
2335
2340
2345
2350
2355
2360
2365
2370
2375
2380
2385
2390
2395
2400
2405
2410
2415
2420
2425
2430
2435
2440
2445
2450
2455
2460
2465
2470
2475
2480
2485
2490
2495
2500
2505
2510
2515
2520
2525
2530
2535
2540
2545
2550
2555
2560
2565
2570
2575
2580
2585
2590
2595
2600
2605
2610
2615
2620
2625
2630
2635
2640
2645
2650
2655
2660
2665
2670
2675
2680
2685
2690
2695
2700
2705
2710
2715
2720
2725
2730
2735
2740
2745
2750
2755
2760
2765
2770
2775
2780
2785
2790
2795
2800
2805
2810
2815
2820
2825
2830
2835
2840
2845
2850
2855
2860
2865
2870
2875
2880
2885
2890
2895
2900
2905
2910
2915
2920
2925
2930
2935
2940
2945
2950
2955
2960
2965
2970
2975
2980
2985
2990
2995
3000
3005
3010
3015
3020
3025
3030
3035
3040
3045
3050
3055
3060
3065
3070
3075
3080
3085
3090
3095
3100
3105
3110
3115
3120
3125
3130
3135
3140
3145
3150
3155
3160
3165
3170
3175
3180
3185
3190
3195
3200
3205
3210
3215
3220
3225
3230
3235
3240
3245
3250
3255
3260
3265
3270
3275
3280
3285
3290
3295
3300
3305
3310
3315
3320
3325
3330
3335
3340
3345
3350
3355
3360
3365
3370
3375
3380
3385
3390
3395
3400
3405
3410
3415
3420
3425
3430
3435
3440
3445
3450
3455
3460
3465
3470
3475
3480
3485
3490
3495
3500
3505
3510
3515
3520
3525
3530
3535
3540
3545
3550
3555
3560
3565
3570
3575
3580
3585
3590
3595
3600
3605
3610
3615
3620
3625
3630
3635
3640
3645
3650
3655
3660
3665
3670
3675
3680
3685
3690
3695
3700
3705
3710
3715
3720
3725
3730
3735
3740
3745
3750
3755
3760
3765
3770
3775
3780
3785
3790
3795
3800
3805
3810
3815
3820
3825
3830
3835
3840
3845
3850
3855
3860
3865
3870
3875
3880
3885
3890
3895
3900
3905
3910
3915
3920
3925
3930
3935
3940
3945
3950
3955
3960
3965
3970
3975
3980
3985
3990
3995
4000
4005
4010
4015
4020
4025
4030
4035
4040
4045
4050
4055
4060
4065
4070
4075
4080
4085
4090
4095
4100
4105
4110
4115
4120
4125
4130
4135
4140
4145
4150
4155
4160
4165
4170
4175
4180
4185
4190
4195
4200
4205
4210
4215
4220
4225
4230
4235
4240
4245
4250
4255
4260
4265
4270
4275
4280
4285
4290
4295
4300
4305
4310
4315
4320
4325
4330
4335
4340
4345
4350
4355
4360
4365
4370
4375
4380
4385
4390
4395
4400
4405
4410
4415
4420
4425
4430
4435
4440
4445
4450
4455
4460
4465
4470
4475
4480
4485
4490
4495
4500
4505
4510
4515
4520
4525
4530
4535
4540
4545
4550
4555
4560
4565
4570
4575
4580
4585
4590
4595
4600
4605
4610
4615
4620
4625
4630
4635
4640
4645
4650
4655
4660
4665
4670
4675
4680
4685
4690
4695
4700
4705
4710
4715
4720
4725
4730
4735
4740
4745
4750
4755
4760
4765
4770
4775
4780
4785
4790
4795
4800
4805
4810
4815
4820
4825
4830
4835
4840
4845
4850
4855
4860
4865
4870
4875
4880
4885
4890
4895
4900
4905
4910
4915
4920
4925
4930
4935
4940
4945
4950
4955
4960
4965
4970
4975
4980
4985
4990
4995
5000
5005
5010
5015
5020
5025
5030
5035
5040
5045
5050
5055
5060
5065
5070
5075
5080
5085
5090
5095
5100
5105
5110
5115
5120
5125
5130
5135
5140
5145
5150
5155
5160
5165
5170
5175
5180
5185
5190
5195
5200
5205
5210
5215
5220
5225
5230
5235
5240
5245
5250
5255
5260
5265
5270
5275
5280
5285
5290
5295
5300
5305
5310
5315
5320
5325
5330
5335
5340
5345
5350
5355
5360
5365
5370
5375
5380
5385
5390
5395
5400
5405
5410
5415
5420
5425
5430
5435
5440
5445
5450
5455
5460
5465
5470
5475
5480
5485
5490
5495
5500
5505
5510
5515
5520
5525
5530
5535
5540
5545
5550
5555
5560
5565
5570
5575
5580
5585
5590
5595
5600
5605
5610
5615
5620
5625
5630
5635
5640
5645
5650
5655
5660
5665
5670
5675
5680
5685
5690
5695
5700
5705
5710
5715
5720
5725
5730
5735
5740
5745
5750
5755
5760
5765
5770
5775
5780
5785
5790
5795
5800
5805
5810
5815
5820
5825
5830
5835
5840
5845
5850
5855
5860
5865
5870
5875
5880
5885
5890
5895
5900
5905
5910
5915
5920
5925
5930
5935
5940
5945
5950
5955
5960
5965
5970
5975
5980
5985
5990
5995
6000
6005
6010
6015
6020
6025
6030
6035
6040
6045
6050
6055
6060
6065
6070
6075
6080
6085
6090
6095
6100
6105
6110
6115
6120
6125
6130
6135
6140
6145
6150
6155
6160
6165
6170
6175
6180
6185
6190
6195
6200
6205
6210
6215
6220
6225
6230
6235
6240
6245
6250
6255
6260
6265
6270
6275
6280
6285
6290
6295
6300
6305
6310
6315
6320
6325
6330
6335
6340
6345
6350
6355
6360
6365
6370
6375
6380
6385
6390
6395
6400
6405
6410
6415
6420
6425
6430
6435
6440
6445
6450
6455
6460
6465
6470
6475
6480
6485
6490
6495
6500
6505
6510
6515
6520
6525
6530
6535
6540
6545
6550
6555
6560
6565
6570
6575
6580
6585
6590
6595
6600
6605
6610
6615
6620
6625
6630
6635
6640
6645
6650
6655
6660
6665
6670
6675
6680
6685
6690
6695
6700
6705
6710
6715
6720
6725
6730
6735
6740
6745
6750
6755
6760
6765
6770
6775
6780
6785
6790
6795
6800
6805
6810
6815
6820
6825
6830
6835
6840
6845
6850
6855
6860
6865
6870
6875
6880
6885
6890
6895
6900
6905
6910
6915
6920
6925
6930
6935
6940
6945
6950
6955
6960
6965
6970
6975
6980
6985
6990
6995
7000
7005
7010
7015
7020
7025
7030
7035
7040
7045
7050
7055
7060
7065
7070
7075
7080
7085
7090
7095
7100
7105
7110
7115
7120
7125
7130
7135
7140
7145
7150
7155
7160
7165
7170
7175
7180
7185
7190
7195
7200
7205
7210
7215
7220
7225
7230
7235
7240
7245
7250
7255
7260
7265
7270
7275
7280
7285
7290
7295
7300
7305
7310
7315
7320
7325
7330
7335
7340
7345
7350
7355
7360
7365
7370
7375
7380
7385
7390
7395
7400
7405
7410
7415
7420
7425
7430
7435
7440
7445
7450
7455
7460
7465
7470
7475
7480
7485
7490
7495
7500
7505
7510
7515
7520
7525
7530
7535
7540
7545
7550
7555
7560
7565
7570
7575
7580
7585
7590
7595
7600
7605
7610
7615
7620
7625
7630
7635
7640
7645
7650
7655
7660
7665
7670
7675
7680
7685
7690
7695
7700
7705
7710
7715
7720
7725
7730
7735
7740
7745
7750
7755
7760
7765
7770
7775
7780
7785
7790
7795
7800
7805
7810
7815
7820
7825
7830
7835
7840
7845
7850
7855
7860
7865
7870
7875
7880
7885
7890
7895
7900
7905
7910
7915
7920
7925
7930
7935
7940
7945
7950
7955
7960
7965
7970
7975
7980
7985
7990
7995
8000
8005
8010
8015
8020
8025
8030
8035
8040
8045
8050
8055
8060
8065
8070
8075
8080
8085
8090
8095
8100
8105
8110
8115
8120
8125
8130
8135
8140
8145
8150
8155
8160
8165
8170
8175
8180
8185
8190
8195
8200
8205
8210
8215
8220
8225
8230
8235
8240
8245
8250
8255
8260
8265
8270
8275
8280
8285
8290
8295
8300
8305
8310
8315
8320
8325
8330
8335
8340
8345
8350
8355
8360
8365
8370
8375
8380
8385
8390
8395
8400
8405
8410
8415
8420
8425
8430
8435
8440
8445
8450
8455
8460
8465
8470
8475
8480
8485
8490
8495
8500
8505
8510
8515
8520
8525
8530
8535
8540
8545
8550
8555
8560
8565
8570
8575
8580
8585
8590
8595
8600
8605
8610
8615
8620
8625
8630
8635
8640
8645
8650
8655
8660
8665
8670
8675
8680
8685
8690
8695
8700
8705
8710
8715
8720
8725
8730
8735
8740
8745
8750
8755
8760
8765
8770
8775
8780
8785
8790
8795
8800
8805
8810
8815
8820
8825
8830
8835
8840
8845
8850
8855
8860
8865
8870
8875
8880
8885
8890
8895
8900
8905
8910
8915
8920
8925
8930
8935
8940
8945
8950
8955
8960
8965
8970
8975
8980
8985
8990
8995
9000
9005
9010
9015
9020
9025
9030
9035
9040
9045
9050
9055
9060
9065
9070
9075
9080
9085
9090
9095
9100
9105
9110
9115
9120
9125
9130
9135
9140
9145
9150
9155
9160
9165
9170
9175
9180
9185
9190
9195
9200
9205
9210
9215
9220
9225
9230
9235
9240
9245
9250
9255
9260
9265
9270
9275
9280
9285
9290
9295
9300
9305
9310
9315
9320
9325
9330
9335
9340
9345
9350
9355
9360
9365
9370
9375
9380
9385
9390
9395
9400
9405
9410
9415
9420
9425
9430
9435
9440
9445
9450
9455
9460
9465
9470
9475
9480
9485
9490
9495
9500
9505
9510
9515
9520
9525
9530
9535
9540
9545
9550
9555
9560
9565
9570
9575
9580
9585
9590
9595
9600
9605
9610
9615
9620
9625
9630
9635
9640
9645
9650
9655
9660
9665
9670
9675
9680
9685
9690
9695
9700
9705
9710
9715
9720
9725
9730
9735
9740
9745
9750
9755
9760
9765
9770
9775
9780
9785
9790
9795
9800
9805
9810
9815
9820
9825
9830
9835
9840
9845
9850
9855
9860
9865
9870
9875
9880
9885
9890
9895
9900
9905
9910
9915
9920
9925
9930
9935
9940
9945
9950
9955
9960
9965
9970
9975
9980
9985
9990
9995
10000
10005
10010
10015
10020
10025
10030
10035
10040
10045
10050
10055
10060
10065
10070
10075
10080
10085
10090
10095
10100
10105
10110
10115
10120
10125
10130
10135
10140
10145
10150
10155
10160
10165
10170
10175
10180

The term “autoimmune disease” refers to a disease or disorder arising from and/or directed against an individual's own tissues or organs, or a co-segregate or manifestation thereof, or resulting condition therefrom. Examples of autoimmune diseases include, but are not limited to: chronic obstructive pulmonary disease (COPD), allergic rhinitis, lupus erythematosus, myasthenia gravis, multiple sclerosis (MS), rheumatoid arthritis (RA), collagen-induced arthritis, psoriasis, inflammatory bowel disease (including Crohn's disease), asthma, autoimmune nephritis, idiopathic thrombocytopenic purpura (ITP) and myeloproliferative disease, such as myelofibrosis, and post-polycythemia vera/essential thrombocytosis myelofibrosis (post-PV/ET myelofibrosis).

The term “inflammatory disease” or “inflammatory disorder” refers to a pathological state that leads to inflammation, especially due to neutrophil chemotaxis. Non-limiting examples of inflammatory diseases include systemic inflammation and local inflammation, inflammation associated with immunosuppression, organ-graft rejection, allergic disease, inflammatory skin disease (including psoriasis and atopic dermatitis); systemic scleroderma and sclerosis; reactions associated with inflammatory bowel diseases (IBD, such as Crohn's disease and ulcerative colitis); ischemia reperfusion injury, including reperfusion injury of tissue caused by surgery, myocardial ischemia, such as myocardial infarction, cardiac arrest, reperfusion after heart operation and abnormal contractile response of coronary vessel after percutaneous transluminal coronary angioplasty, surgical tissue reperfusion injury of stroke and abdominal aortic aneurysm; cerebral edema secondary to stroke; cranial trauma, and hemorrhagic shock; asphyxia; adult respiratory distress syndrome; acute lung injury; Behcet's disease; dermatomyositis; polymyositis; multiple sclerosis (MS); dermatitis; meningitis; encephalitis; uveitis; osteoarthritis; lupus nephritis; autoimmune disease such as rheumatoid arthritis (RA), Sjorgen's syndrome, and vasculitis; diseases involving leukopenia; central nervous system (CNS) inflammatory disease and multiple organ injury syndrome secondary to septicemia or trauma; alcoholic hepatitis; bacterial pneumonia; antigen-antibody complex mediated disease, including glomerulonephritis; pyaemia; sarcoidosis; immunopathologic responses to tissue/organ transplantation; lung inflammation, including pleurisy, alveolitis, vasculitis, pneumonia, chronic bronchitis, bronchiectasia, diffuse panbronchiolitis, hypersensitivity pneumonitis, idiopathic pulmonary fibrosis (IPF), cystic fibrosis, etc. Preferably indications include, but are not

limited to, chronic inflammation, autoimmune diabetes, rheumatoid arthritis (RA),
rheumatoid spondylitis, gouty arthritis and other arthrosis conditions, multiple sclerosis
(MS), asthma, systemic lupus erythematosus, adult respiratory distress syndrome,
Behcet's disease, psoriasis, chronic pulmonary inflammatory disease, graft versus host
5 reaction, Crohn's disease, ulcerative colitis, inflammatory bowel disease (IBD),
Alzheimer's disease and pyresis, and any diseases associated with inflammation and
related conditions.

The term "metabolic diseases" refers to diseases or disorders caused by metabolic
problems, including metabolic disorders and hypermetabolism. Examples of metabolic
10 diseases include, but are not limited to: osteoporosis, diabetes, diabetic ketoacidosis,
hyperglycemia and hyperosmolar syndrome, hypoglycemia, gout, protein-energy
malnutrition, vitamin A deficiency disease, scurvy, vitamin D deficiency disease, etc.

The term "neurodegenerative diseases" refers to degenerative diseases or disorders
of the nervous system caused by neuronal degeneration and apoptosis. Examples of
15 neurodegenerative diseases include, but are not limited to: Parkinson's disease (PD),
multiple system atrophy, Alzheimer's disease (AD), frontotemporal dementia,
Huntington's disease (HD), corticobasal degeneration, spinocerebellar ataxia, motor
neuron disease (including amyotrophic lateral sclerosis (ALS)), hereditary motor and
sensory neuropathy (CMT), etc.

20 The term "obesity-related diseases" refers to diseases or disorders related to,
resulted from, or caused by obesity. Examples of obesity-related disease include, but are
not limited to: diabetes, hypertension, insulin resistance syndrome, dyslipidemia, heart
disease, cardiovascular disease (including atherosclerosis, abnormal heart rhythms,
arrhythmias, myocardial infarction, congestive heart failure, coronary heart disease, and
25 angina pectoris), cerebral infarction, cerebral hemorrhage, osteoarthritis, metabolic
syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and the like.

In addition, the compound of formula (I) (e.g., a compound of any of the examples
as described herein) and/or a pharmaceutically acceptable salt thereof described herein
can be administered in combination with additional therapeutic agents, for treating cancer,
30 an autoimmune disease or an inflammatory disease. The additional therapeutic agents
may be administered separately with the compound of formula (I) and/or a
pharmaceutically acceptable salt thereof described herein or included with such an

ingredient in a pharmaceutical composition according to the disclosure, such as a fixed-dose combination drug product. In some embodiments, additional therapeutic agents are those that are known or discovered to be effective in the treatment of diseases mediated by CSF-1R or at least in part by CSF-1R, such as another CSF-1R inhibitor or a
5 compound active against another target associated with the particular disease. The combination may serve to increase efficacy (e.g., by including in the combination a compound potentiating the potency or effectiveness of the compound of formula (I) and/or a pharmaceutically acceptable salt thereof described herein), decrease one or more side effects, or decrease the required dose of the compound of formula (I) and/or a
10 pharmaceutically acceptable salt thereof described herein.

In some embodiments, the compound of formula (I) (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof described herein can be administered in combination with anti-neoplastic agents. The term “anti-neoplastic agent” as used herein refers to any agent that is administered to a subject
15 suffering from cancer for the purposes of treating the cancer, includes, but is not limited to a radiotherapeutic agent, a chemotherapeutic agent, an immune checkpoint inhibitor or agonist, a targeted therapeutic agent, and the like.

In some embodiments, the compound of formula (I) (e.g., a compound of any of the examples as described herein) and/or a pharmaceutically acceptable salt thereof described
20 herein can be administered in combination with immune checkpoint inhibitors or agonists, targeted therapeutic agents or chemotherapeutic agents.

Non-limiting examples of immune checkpoint inhibitors or agonists include PD-1 inhibitors, for example, anti-PD-1 antibodies, such as pembrolizumab, nivolumab and PDR001 (spartalizumab); PD-L1 inhibitors, for example, anti-PD-L1 antibodies, such as
25 atezolizumab, durvalumab, and avelumab; CTLA-4 inhibitors, for example, anti-CTLA-4 antibodies, such as ipilimumab; and BTLA inhibitors, LAG-3 inhibitors, TIM3 inhibitors, TIGIT inhibitors, VISTA inhibitors, OX-40 agonists, and the like.

Non-limiting examples of chemotherapeutic agents include topoisomerase I inhibitors (e.g., irinotecan, topotecan, camptothecin and analogs or metabolites thereof,
30 and doxorubicin); topoisomerase II inhibitors (e.g., etoposide, teniposide, mitoxantrone, idarubicin, and daunorubicin); alkylating agents (e.g., melphalan, chlorambucil, busulfan, thiotepa, ifosfamide, carmustine, lomustine, semustine, streptozocin, decarbazine,

methotrexate, mitomycin C, and cyclophosphamide); DNA intercalators (e.g., cisplatin, oxaliplatin, and carboplatin); DNA intercalators and free radical generators such as bleomycin; nucleoside mimetics (e.g., 5-fluorouracil, capecitabine, gemcitabine, fludarabine, cytarabine, azacitidine, mercaptopurine, thioguanine, pentostatin, and hydroxyurea); paclitaxel, docetaxel, and related analogs; vincristine, vinblastin, and related analogs; thalidomide and related analogs (e.g., CC-5013 and CC-4047).

Non-limiting examples of targeted therapeutic agents include: protein tyrosine kinase inhibitors (such as imatinib mesylate and gefitinib); proteasome inhibitors (such as bortezomib); NF- κ B inhibitors, including I κ B kinase inhibitors; IDO inhibitors; A2AR inhibitors; BRAF inhibitors (such as dabrafenib); MEK inhibitors (such as trametinib); mTOR inhibitors (such as rapamycin); anti-CD40 antibodies (such as APX005M, RO7009789); antibodies that bind to proteins overexpressed in cancer to down-regulate cell replication, such as anti-CD20 antibodies (such as rituximab, ibritumomab tiuxetan, and tositumomab), anti-Her2 monoclonal antibodies (such as trastuzumab), anti-EGFR antibodies (such as cetuximab) and anti-VEGF antibodies (such as bevacizumab); anti-angiogenic drugs, such as lenalidomide; and other protein or enzyme inhibitors, these proteins or enzymes are known to be upregulated, overexpressed or activated in cancers, and the inhibition of which can down-regulate cell replication.

20

EXAMPLES

The examples below are intended to be purely exemplary and should not be considered to be limiting in any way. Efforts have been made to ensure the accuracy with respect to numbers used (for example, amounts, temperature, etc.), but the POSITA should understand that some experimental errors and deviations should be accounted for.

Unless indicated otherwise, parts are parts by weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric. All MS data were determined by Agilent 6120 or Agilent 1100. All NMR data were generated using a Varian 400 MHz NMR machine. All reagents, except intermediates, used in this invention are commercially available. All compound names except the reagents are generated by Chemdraw 18.0.

If there is any atom with empty valence(s) in any one of the structures disclosed herein, the empty balance(s) is (are) the hydrogen atom(s) which is (are) omitted for convenience purpose.

In the present application, in the case of inconsistency of the name and structure of a compound, when the two of which are both given for the compound, it is subject to the structure of the compound, unless the context shows that the structure of the compound is incorrect and the name is correct.

In the following examples, the abbreviations are used:

AcOH	Acetic acid
Ac ₂ O	Acetic anhydride
AcOK	Potassium acetate
BINAP	(±)-2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl
DMF	<i>N,N</i> -dimethylformamide
DMSO	Dimethyl sulfoxide
DCM	Dichloromethane
DMA	<i>N,N</i> -dimethylacetamide
DCE	Dichloroethane
DMAP	4-dimethylaminopyridine
EtOH	Ethanol
Et ₃ N	Triethylamine
HATU	Hexafluorophosphate <i>O</i> -(7-azobenzotriazole-1-yl)- <i>N,N,N',N'</i> -tetramethyluronium
i-PrOH	Isopropyl alcohol
MeOH	Methanol
MeI	Iodomethane
Me ₄ tBuXPhos	2-di-tert-butyl phosphino-3,4,5,6-tetramethyl-2',4',6'-triisopropyl biphenyl
MsCl	Methanesulfonyl chloride
NaOMe	Sodium methoxide
NBS	<i>N</i> -bromosuccinimide
NMP	<i>N</i> -methyl-2-pyrrolidone


n-BuLi	N-butyl lithium
Pd(dppf)Cl ₂	[1,1'-bis(diphenylphosphino) ferrocene]palladium dichloride
Pd(dppf)Cl ₂ ·CH ₂ Cl ₂	[1,1'-bis(diphenylphosphino) ferrocene]palladium dichloride dichloromethane complex
Pd ₂ (dba) ₃	Tris(dibenzylidene acetone)dipalladium
Pd(PPh ₃) ₄	Tetra(triphenylphosphine)palladium
p-TsOH	p-toluenesulfonic acid
t-BuOK	Potassium t-butoxide
t-BuONa	Tert-butoxysodium
TBAF	Tetrabutylammonium fluoride
TBSCl	Tert-butyldimethylchlorosilane
THF	Tetrahydrofuran
TEA	Triethylamine
XantPhos	4,5-bis(diphenylphosphino)-9,9-dimethylxanthene
p-TLC	Preparative thin layer chromatography

Example 1

Preparation of intermediates

Intermediate 1

5-chloro-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid



(A) Isopropyl 5-chloro-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxylate

Under nitrogen, 5-chloro-2-oxo-1,2-dihydropyridin-3-carboxylic acid (200 mg, 1.15 mmol), 2-iodopropane (784 mg, 4.61 mmol), potassium carbonate (637 mg, 4.61 mmol) and DMF (5 ml) were successively added to a reaction flask, and the mixture was reacted at 80°C for 5 hours. The reaction solution was concentrated, and the residue was dissolved by adding water (10 ml) and adjusted to pH 2 with 1N HCl solution, and then extracted with dichloromethane (50 ml × 3), the organic layers were combined and concentrated, and the residue was purified with flash column chromatography (petroleum


ether/ethyl acetate = 100 : 0 - 0 : 100, gradient elution), to obtain 110 mg of the title product as a white solid. MS (m/z): 258.1 [M+H]⁺.

(B) 5-chloro-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid

Isopropyl 5-chloro-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxylate (110 mg, 0.43 mmol), lithium hydroxide monohydrate (36 mg, 0.86 mmol), methanol (3 ml) and water (1 ml) were added to a reaction flask, and the mixture was reacted at room temperature for 2 hours. The reaction solution was concentrated, and the residue was dissolved by adding water (2 ml) (adjusting pH to 4 with 1N HCl solution), the precipitated solid was filtered, washed and dried to obtain 74 mg of the title product as a white solid. MS (m/z): 216.0 [M+H]⁺.

Intermediate 2

4-methyl-3-oxo-3,4-dihydropyrazine-2-carboxylic acid




(A) Methyl 4-methyl-3-oxo-3,4-dihydropyrazine-2-carboxylate

Under nitrogen, methyl 3-oxo-3,4-dihydropyrazine-2-carboxylate (250 mg, 1.6 mmol), iodomethane (461 mg, 2.4 mmol), potassium carbonate (448 mg, 3.2 mmol) and DMF (5 ml) were successively added to a reaction flask, and the mixture was reacted at 50°C for 4 hours. The reaction solution was concentrated, and the residue was dissolved by adding water (10 ml) (adjusting pH to 4 with 1N HCl solution), and then extracted with dichloromethane (50 ml × 3), the organic layers were combined and concentrated, the resulting crude product can be directly used in the next step.

(B) 4-methyl-3-oxo-3,4-dihydropyrazine-2-carboxylic acid


Methyl 4-methyl-3-oxo-3,4-dihydropyrazine-2-carboxylate (155 mg, 0.92 mmol), lithium hydroxide monohydrate (77 mg, 1.84 mmol), methanol (4 ml) and water (1 ml) were added to a reaction flask, and the mixture was reacted at room temperature for 2 hours. The reaction solution (adjusting pH to 4 with 1N HCl solution) was concentrated, and the residue was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 83 mg of the title product as a white solid. MS (m/z): 155.1 [M+H]⁺.

Intermediate 3**4-isopropyl-3-oxo-3,4-dihydropyrazine-2-carboxylic acid****5 (A) Methyl 4-isopropyl-3-oxo-3,4-dihydropyrazine-2-carboxylate**

Under nitrogen, methyl 3-oxo-3,4-dihydropyrazine-2-carboxylate (500 mg, 3.25 mmol), 2-iodopropane (827 mg, 4.87 mmol), potassium carbonate (1.4 g, 9.75 mmol) and DMF (10 ml) were successively added to a reaction flask, and the mixture was reacted at 50°C for 4 hours. The reaction solution was concentrated, and the residue was dissolved by adding water (50 ml) (adjusting pH to 3 with 1N HCl solution), and then extracted with dichloromethane (50 ml × 3), the organic layers were combined and concentrated, and the residue was purified with flash column chromatography (dichloromethane/methanol = 100 : 0-10:1, gradient elution), to obtain 263 mg of the title product as a colorless liquid. MS (m/z): 197.1 [M+H]⁺.

15 (B) 4-isopropyl-3-oxo-3,4-dihydropyrazine-2-carboxylic acid

Methyl 4-isopropyl-3-oxo-3,4-dihydropyrazine-2-carboxylate (263 mg, 1.34 mmol), lithium hydroxide monohydrate (113 mg, 2.68 mmol), methanol (3 ml) and water (1 ml) were added to a reaction flask, and the mixture was reacted at room temperature for 2 hours. The reaction solution was concentrated, and the residue was dissolved by adding water (5 ml) (adjusting pH to 4 with 1N HCl solution), the precipitated solid was filtered, washed and dried to obtain 200 mg of the title product as a white solid. MS (m/z): 183.1[M+H]⁺.

Intermediate 4**2-isopropyl-3-oxo-2,3-dihydropyridazine-4-carboxylic acid****(A) Isopropyl 2-isopropyl-3-oxo-2,3-dihydropyridazine-4-carboxylate**


Under nitrogen, 3-oxo-2,3-dihydropyridazin-4-carboxylic acid (500 mg, 3.57 mmol), 2-iodopropane (1.5 g, 8.92 mmol), potassium carbonate (1.5 g, 10.71 mmol) and DMF (10 ml) were successively added to a reaction flask, and the mixture was reacted at 40°C for 2 hours. The reaction solution was concentrated, and the residue was dissolved by adding water (50 ml) (adjusting pH to 3 with 1N HCl solution), and then extracted with dichloromethane (50 ml × 3), the organic layers were combined and concentrated, and the residue was purified with flash column chromatography (petroleum ether/ethyl acetate = 100 : 0 - 0 : 100, gradient elution), to obtain 90 mg of the title product as a yellow oil. MS (m/z): 225.1 [M+H]⁺.

(B) 2-isopropyl-3-oxo-2,3-dihydropyridazine-4-carboxylic acid

Isopropyl 2-isopropyl-3-oxo-2,3-dihydropyridazine-4-carboxylate (90 mg, 0.4 mmol), lithium hydroxide monohydrate (34 mg, 0.8 mmol), methanol (3 ml) and water (1 ml) were added to a reaction flask, and the mixture was reacted at room temperature for 1 hour. The reaction solution (adjusting pH to 4 with 1N HCl solution) was concentrated, and the resulting crude product can be directly used in the next step.

Intermediate 5

1-(difluoromethyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid



(A) methyl 1-(difluoromethyl)-2-oxo-1,2-dihydropyridine-3-carboxylate

Under nitrogen, methyl 2-oxo-1,2-dihydropyridine-3-carboxylate (153 mg, 1 mmol), 2,2-difluoro-2-(fluorosulfonyl)acetic acid (267 mg, 1.5 mmol), sodium bicarbonate (168 mg, 2 mmol) and acetonitrile (10 ml) were successively added to a reaction flask, and the mixture was refluxed and reacted for 6 hours. The reaction solution was filtered, and the filtrate was concentrated, the residue was purified with flash column chromatography (petroleum ether/ethyl acetate = 100 : 0 - 0 : 100, gradient elution), to obtain 146 mg of the title product as a white solid. MS (m/z): 204.1 [M+H]⁺.


(B) 1-(difluoromethyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid

Methyl 1-(difluoromethyl)-2-oxo-1,2-dihydropyridine-3-carboxylate (146 mg, 0.72 mmol), lithium hydroxide monohydrate (60 mg, 1.44 mmol), methanol (2 ml) and water

(0.5 ml) were added to a reaction flask, and the mixture was reacted at room temperature for 30 minutes. The reaction solution (adjusting pH to 4 with 1N HCl solution) was concentrated, and the residue was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 84 mg of the title product as a white solid. MS (m/z): 190.1 [M+H]⁺.

Intermediate 6

4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid



10 (A) Ethyl 4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylate


2-aminopyridine (500 mg, 5.31 mmol) and 2-(ethoxymethylene)diethyl malonate (1.206 g, 5.58 mmol) were added to a reaction flask, and the mixture was heated to 130°C and reacted for 40 minutes, and then acetic acid (25 ml) was added, the reaction solution was further heated, refluxed and reacted for 4 hours, and the reaction solution was concentrated to obtain a oil, which was directly used in the next step without purification. MS (m/z): 219.0 [M+H]⁺.

(B) 4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid

Ethyl 4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylate (1.16 g, 5.32 mmol), lithium hydroxide monohydrate (894 mg, 21.28 mmol), THF (20 ml), MeOH (8 ml) and water (8 ml) were added to a reaction flask, and the mixture was stirred at room temperature overnight (adjusting pH to 3.0 with 1N hydrochloric acid), the white solid was precipitated, filtered, and the solid was dried to obtain 828 mg of the title product. MS (m/z): 191.0 [M+H]⁺.

25 Intermediate 7

5-oxo-1,2,3,5-tetrahydroindolizine-6-carboxylic acid



(A) (3-bromopropoxy)(tert-butyl)dimethylsilane

3-bromopropan-1-ol (4.0g, 28.78 mmol), 1*H*-imidazole (3.92 g, 57.56 mmol), DCM (150 ml) and TBSCl (4.55 g, 30.22 mmol) were successively added to a reaction flask, and the mixture was stirred at room temperature overnight. The reaction solution was washed with water, the organic phase was dried and concentrated, and the residue was purified with flash column chromatography (petroleum ether/ethyl acetate = 100 : 0-90 : 10, gradient elution), to obtain 6.5 g of the title product as a colorless liquid.

(B) 2-((3-((tert-butyldimethylsilyl)oxy)propyl)-6-methoxypyridine

2-bromo-6-methoxypyridine (4.83 g, 25.67 mmol) and dried THF (100 ml) were added to a reaction flask, and the reaction solution was cooled to -78°C, under nitrogen, added dropwise 2.4*N* n-BuLi (11.77 ml, 28.24 mmol), reacted for 30 minutes, and then slowly added dropwise (3-bromopropoxy)(tert-butyl)dimethylsilane (6.5 g, 25.67 mmol), continuously reacted at -78°C for 1 hour, and then warmed to room temperature, reacted overnight, quenched by adding water, and extracted with ethyl acetate, the organic phase was dried and concentrated to obtain a yellow oil. MS (*m/z*): 282.2 [*M*+*H*]⁺.

(C) 3-(6-methoxypyridin-2-yl)propan-1-ol

The oil obtained from the above-mentioned step (B) was dissolved in THF (80 ml), the solution was added TBAF trihydrate (16.1 g, 51.34 mmol), stirred at room temperature overnight, and the reaction solution was added ethyl acetate, washed with water, the organic phase was dried and concentrated, and the residue was purified with flash column chromatography (petroleum ether/ethyl acetate = 100 : 0 - 0 : 100, gradient elution), to obtain 1.2 g of the title product as a colorless liquid.

(D) 3-(6-methoxypyridin-2-yl)propyl methanesulfonate

3-(6-methoxypyridin-2-yl)propan-1-ol (1.0 g, 5.98 mmol), TEA (1.66 ml, 11.96 mmol) and DCM (50 ml) were added to a reaction flask, and the reaction solution was

cooled in an ice bath, and then added dropwise MsCl (822 mg, 7.18 mmol), reacted for half an hour, washed with water, and the organic phase was dried and concentrated, to obtain a colourless liquid. MS (m/z): 246.1 $[\text{M}+\text{H}]^+$.

(E) 2,3-dihydroindolizin-5(1H)-one

- 5 3-(6-methoxypyridin-2-yl)propyl methanesulfonate crude product obtained from the above-mentioned step (D) and acetonitrile (25 ml) were added to a reaction flask, and the reactant was reacted under the microwave at 125°C for 15 minutes, and then concentrated, the residue was purified with flash column chromatography ($\text{H}_2\text{O}/\text{MeOH} = 100 : 0 - 0 : 100$, gradient elution), to obtain 400 mg of the title product as a light yellow oil. MS (m/z): 136.1 $[\text{M}+\text{H}]^+$.

(F) 6-bromo-2,3-dihydroindolizin-5(1H)-one

- 2,3-dihydroindolizin-5(1H)-one (300 mg, 2.22 mmol), DMF (5.0 ml) and NBS (435 mg, 2.44 mmol) were added to a reaction flask, and the mixture was stirred at room temperature overnight, the reaction solution was purified with flash column chromatography ($\text{H}_2\text{O}/\text{MeOH} = 100 : 0 - 0 : 100$, gradient elution), to obtain 120 mg of a light yellow title product. MS (m/z): 214.0, 216.0 $[\text{M}+\text{H}]^+$.
- ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 7.79 (d, $J = 7.4$ Hz, 1H), 6.12 (dt, $J = 7.4, 1.2$ Hz, 1H), 4.06 - 3.93 (m, 3H), 3.09 - 2.97 (m, 3H), 2.18 - 2.01 (m, 3H).

(G) 5-oxo-1,2,3,5-tetrahydroindolizine-6-carbonitrile


- 20 6-bromo-2,3-dihydroindolizin-5(1H)-one (120 mg, 0.56 mmol), zinc cyanide (43 mg, 0.365 mmol), $\text{Pd}(\text{PPh}_3)_4$ (65 mg, 0.0561 mmol) and DMF (5.0 ml) were added to a reaction flask, and the mixture was heated to 100°C under nitrogen and stirred overnight, the reaction solution was purified with flash column chromatography ($\text{H}_2\text{O}/\text{MeOH} = 100 : 0 - 0 : 100$, gradient elution), to obtain 60 mg of a white title product. MS (m/z): 161.1 $[\text{M}+\text{H}]^+$.

(H) 5-oxo-1,2,3,5-tetrahydroindolizine-6-carboxylic acid

- 5-oxo-1,2,3,5-tetrahydroindolizine-6-carbonitrile (60 mg, 0.375 mmol) and 2N concentration of sodium hydroxide aqueous solution (1.0 ml, 2.0 mmol) were added to a reaction flask, the mixture was heated to 100°C and stirred overnight, and then cooled to room temperature (adjusting pH to 3 with 1N concentration of hydrochloric acid), and filtered, to obtain 60 mg of a white title product. MS (m/z): 180.1 $[\text{M}+\text{H}]^+$.

Intermediate 8

1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid



(A) methyl 1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate

5 In a reaction flask, uracil-5-carboxylic acid (1 g, 6.4 mmol) was dissolved in DMF (15 ml), and Cs_2CO_3 (12.5 g, 38.4 mmol) and CH_3I (4.6 g, 32 mmol) were successively added, the reaction solution was reacted at 60°C for 16 hours. Water was added to the reaction solution, and the reaction solution was extracted with ethyl acetate, washed with saturated brine, and dried with anhydrous sodium sulfate. The reactant was concentrated

10 to obtain 0.8 g of a khaki solid. MS (m/z): 199 $[\text{M}+\text{H}]^+$.


(B) 1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid

In a reaction flask, methyl 1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (500 mg, 2.5 mmol) was dissolved in methanol (6 ml) and water (1.5 ml), and NaOH (200 mg, 5 mmol) was added, the reaction solution was reacted at room

15 temperature for 3 hours. The reaction solution was revolved to remove methanol, and neutralized with 1N hydrochloric acid to pH = 3, the solid was precipitated, filtered, dried, to obtain 300 mg of a white solid. MS (m/z): 185 $[\text{M}+\text{H}]^+$.

Intermediate 9

1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid



(A) diethyl 2-(2-nitrobenzylidene)malonate

Under nitrogen, 2-nitrobenzene formaldehyde (2.0 g, 13.2 mmol), diethyl malonate (2.0 ml, 13.2 mmol), potassium carbonate (2.74 g, 19.8 mmol) and acetic anhydride (5 ml) were successively added to a reaction flask, and the mixture was heated to 80°C and stirred for 4 hours. The reaction solution was cooled to room temperature, and then
5 poured into ice water (100 ml), and extracted with ethyl acetate (100 ml). The organic phase was washed with saturated sodium bicarbonate (100 ml) and saturated brine (100 ml), dried with anhydrous sodium sulfate, and then filtered. The filtrate was concentrated, and the residue was purified with flash column chromatography (petroleum ether: ethyl acetate = 100 : 0 - 0 : 100, gradient elution), to obtain 3.2 g of the title product as a light
10 yellow solid. MS (m/z): 294.1 [M+H]⁺.

(B) Ethyl 2-oxo-1,2-dihydroquinoline-3-carboxylate


Diethyl 2-(2-nitrobenzylidene)malonate (3.2 g, 10.9 mmol), ethanol (50 ml) and Raney-Ni (1.0 g) were successively added to a reaction flask, after replacing hydrogen with hydrogen balloon, the reaction solution was stirred under normal pressure at room
15 temperature overnight. Dichloromethane (30 ml) and methanol (30 ml) were added, and then the reaction solution was filtered, the filtrate was concentrated to obtain 2.87 g of the title product as a brown solid. MS (m/z): 218.1 [M+H]⁺.

(C) 1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid

Ethyl 2-oxo-1,2-dihydroquinoline-3-carboxylate (500 mg, 2.3 mmol), iodomethane
20 (430 µl, 6.9 mmol), potassium carbonate (636 mg, 4.6 mmol) and DMF (5 ml) were successively added to a reaction flask, and the mixture was stirred at room temperature overnight. Sodium hydroxide aqueous solution (2N, 4 ml) was added dropwise, and the reaction solution was stirred at room temperature for 4 hours. Water (100 ml) was added, and the pH was adjusted to 4 with concentrated hydrochloric acid. The reaction solution
25 was filtered, and the solid was washed with water and dried, to obtain 350 mg of the title product as a white solid. MS (m/z): 204.1 [M+H]⁺.

Intermediate 10

5-fluoro-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid



(A) Methyl 5-fluoro-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate


Under nitrogen, 5-fluoro-2-hydroxynicotinic acid (720 mg, 4.6 mmol), iodomethane (860 μ l, 13.8 mmol), potassium carbonate (2.74 g, 19.8 mmol) and DMF (10 ml) were successively added to a reaction flask, and the mixture was heated to 50°C and stirred overnight. The reaction solution was cooled to room temperature, and purified with flash column chromatography (water (0.5% formic acid): methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 750 mg of the title product as a light yellow solid. MS (m/z): 186.1 [M+H]⁺.

(B) 5-fluoro-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid

Methyl 5-fluoro-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate (750 mg, 4.05 mmol), lithium hydroxide monohydrate (340 mg, 9.1 mmol) and methanol/water (15 ml / 5 ml) were successively added to a reaction flask, and the mixture was stirred at room temperature for 2 hours. The reaction solution was concentrated, and then added water (40 ml) (adjusting pH to 4 with hydrochloric acid aqueous solution (2N)) and filtered. The solid was dried to obtain 600 mg of a white title product. MS (m/z): 172.0 [M+H]⁺.

Intermediate 11

2-isopropyl-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid



(A) Methyl 2-isopropyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate

Under nitrogen, isopropylamine hydrochloride (1.23 g, 10 mmol), anhydrous methanol (20 ml) and sodium methoxide (504 mg, 10 mmol) were successively added to a reaction flask, and the mixture was stirred for half an hour, and then 2-(methoxymethylene)dimethyl malonate (1.74 g, 10 mmol) and sodium methoxide (504 mg, 10 mmol) were successively added in an ice bath, the reaction solution was warmed

slowly to room temperature and then stirred overnight. The reaction solution was concentrated, after stirring the sample with silica gel, which was purified with flash column chromatography (dichloromethane : methanol = 100 : 0-90 : 10, gradient elution), to obtain 700 mg of the title product as a light yellow solid. MS (m/z): 197.1 [M+H]⁺.

5 **(B) Methyl 2-isopropyl-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate**

Under nitrogen, methyl 2-isopropyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate (700 mg, 3.6 mmol), iodomethane (436 μ l, 7 mmol), cesium carbonate (2.28 g, 7 mmol) and DMF (10 ml) were successively added to a reaction flask, and the mixture was heated to 80°C and stirred overnight. The reaction solution was cooled to room

10 temperature, and purified with flash column chromatography (water (0.5% formic acid): methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 250 mg of the title product as a white solid. MS (m/z): 211.1 [M+H]⁺.


(C) 2-isopropyl-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid

Methyl 2-isopropyl-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate (250 mg, 1.2 mmol), sodium hydroxide (96 mg, 2 mmol) and methanol/water (10 ml/2 ml) were successively added to a reaction flask, and the mixture was stirred at room temperature for 2 hours. Adjusting pH to 4 with 2N hydrochloric acid aqueous solution, and the reaction solution was concentrated. The residue was purified with flash column chromatography (water (0.5% formic acid): methanol = 100 : 0 - 0 : 100, gradient

20 elution), to obtain 180 mg of a white title product. MS (m/z): 197.1 [M+H]⁺.

Intermediate 12

2-cyclopropyl-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid



(A) methyl 2-cyclopropyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate

25 The title compound was prepared with cyclopropylamine hydrochloride and corresponding reagents with reference to the preparation processes of intermediate 11(A). MS (m/z): 195.1 [M+H]⁺.

(B) Methyl 2-cyclopropyl-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate


The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 11(B). MS (m/z): 209.1 [M+H]⁺.

(C) 2-cyclopropyl-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid

- 5 Methyl 2-cyclopropyl-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate (750 mg, 3.6 mmol), sodium hydroxide (288 mg, 7.2 mmol) and methanol/water (20 ml/4 ml) were successively added to a reaction flask, and the mixture was stirred at room temperature for 2 hours. The reaction solution was concentrated, and then added water (40 ml) (adjusting pH to 4 with hydrochloric acid aqueous solution (2N)) and filtered.
- 10 The solid was dried to obtain 450 mg of a yellow title product. MS (m/z): 195.1 [M+H]⁺.

Intermediate 13

5-fluoro-1,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid




- 15 **(A) 5-fluoro-1,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonitrile**

- 1,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (500 mg, 3.38 mmol), fluorine reagent Selectfluor (1.19 g, 3.38 mmol) and acetonitrile (10 ml) were successively added to a reaction flask, and the mixture was reacted under nitrogen at room temperature for 15 hours. The reaction solution was concentrated and purified with flash column chromatography (petroleum ether/ethyl acetate = 100 : 0 - 0 : 100, gradient elution), to obtain 133 mg of the title product as a white solid. MS (m/z): 166.7[M+H]⁺.
- 20

(B) 5-fluoro-1,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid

- 5-fluoro-1,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (133 g, 0.80 mmol) and concentrated hydrochloric acid (2 ml) were successively added to a reaction flask, and the mixture was refluxed and reacted for 3 hours. The reaction solution was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 60 mg of the title product as a white solid. MS (m/z): 186.0[M+H]⁺.
- 25

Intermediate 14**1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid****(A) methyl 6-oxo-1,6-dihydropyrimidine-5-carboxylate**

2-(methoxymethylene) dimethyl malonate (0.87 g, 5.0 mmol), formamidine (0.22 g, 5.0 mmol), sodium methoxide (0.27 g, 5.0 mmol) and anhydrous methanol (10 ml) were successively added to a reaction flask, and the mixture was refluxed and reacted under nitrogen for 7 hours. The reaction solution was concentrated and purified with flash column chromatography (petroleum ether/ethyl acetate = 100 : 0 - 0 : 100, gradient elution), to obtain 0.51 g of the title product as a white solid. MS (m/z): 155.1[M+H]⁺.



(B) methyl 1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate


Methyl 6-oxo-1,6-dihydropyrimidine-5-carboxylate (0.51 g, 3.31 mmol), iodomethane (0.94 g, 6.62 mmol), potassium carbonate (0.69 g, 4.97 mmol) and DMSO (10 ml) were successively added to a reaction flask, and the mixture was reacted at 50°C for 1 hour. The reaction solution was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 0.44 g of the title product as a yellow solid. MS (m/z): 169.1[M+H]⁺.

(C) 1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid

Methyl 1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate (0.44 g, 2.61 mmol), lithium hydroxide monohydrate (0.22 g, 5.22 mmol), methanol (10 ml) and water (2 ml) were successively added to a reaction flask, and the mixture was reacted at 50°C for 1 hour. The reaction solution (adjusting pH to 3-4) was extracted with ethyl acetate, concentrated to obtain crude product, which was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 0.37 g of the title product as a white solid. MS (m/z): 155.1 [M+H]⁺.

The following intermediates were prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 14 under suitable conditions recognized by the POSITA.

Intermediate	Structural formula	MS (M+H) ⁺	Intermediate	Structural formula	MS (M+H) ⁺
15		169.1	16		169.1

Intermediate 17**(2-methyl-2H-1,2,3-triazol-4-yl)boronic acid****5 (A) 4,5-dibromo-1H-1,2,3-triazole**

1H-1,2,3-triazole (10.0 g, 145 mmol) and water (150 ml) were added to a reaction flask, and the reaction solution was cooled in an ice bath, and then slowly added dropwise liquid bromine (10 ml), after the dropwise addition was completed, the reaction solution was warmed to room temperature and stirred overnight, the reaction mixture was filtered, the solid obtained was washed with water, and dried, to obtain 18.9 g of the title product.

(B) 4,5-dibromo-2-methyl-2H-1,2,3-triazole

4,5-dibromo-1H-1,2,3-triazole (18.9 g, 83.3 mmol), K₂CO₃ (23.04 g, 166.7 mmol) and DMF (150 ml) were added to a reaction flask, and the mixture was cooled to minus 10°C, and then slowly added dropwise iodomethane (23.67 g, 166.7 mmol), after the dropwise addition was completed, the reaction solution was slowly warmed to room temperature and stirred overnight, added 500 ml of water, extracted with ethyl acetate three times, the organic phase was washed with saturated brine, dried, and concentrated, the residue was purified with flash column chromatography (petroleum ether/ethyl acetate = 100 : 0 - 0 : 100, gradient elution), to obtain 9.2 g of a product 4,5-dibromo-2-methyl-2H-1,2,3-triazole as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 4.16 (s, 3H). And isomer 4,5-dibromo-1-methyl-1H-1,2,3-triazole 4.66 g. MS (m/z): 239.9, 241.9, 243.9 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 4.06 (s, 3H).

(C) 4-bromo-2-methyl-2H-1,2,3-triazole


4,5-dibromo-2-methyl-2*H*-1,2,3-triazole (9.2 g, 38.19 mmol) and THF(150 ml) were added to a reaction flask, the reaction solution was cooled to minus 78°C, and then slowly added dropwise 2.5*N* *N*-butyl lithium (19.0 ml, 45.83 mmol), after the dropwise addition was completed, the reaction solution was continuously stirred for one hour, quenched by adding 50 ml of water, and extracted with ethyl acetate three times, the organic phase was washed with saturated brine, dried, and concentrated, the residue was purified with flash column chromatography (petroleum ether/ethyl acetate = 100 : 0 - 0 : 100, gradient elution), to obtain 2.5 g of a liquid title product. MS (*m/z*): 162.0 ,164.0 [*M*+*H*]⁺.

(D) (2-methyl-2*H*-1,2,3-triazol-4-yl)boronic acid

4-bromo-2-methyl-2*H*-1,2,3-triazole (2.5 g, 15.43 mmol) and THF (50 ml) were added to a reaction flask, under nitrogen, 1.3*N* isopropyl magnesium chloride lithium chloride (14.2 ml, 18.52 mmol) was added dropwise, after the dropwise addition was completed, the reaction solution was continuously stirred for 2 hours, and then the reaction solution was cooled to minus 20°C, added trimethyl borate, continuously stirred for 1.5 hours, warmed to room temperature, quenched with water, and extracted with ethyl acetate, the organic phase was washed with saturated brine, dried, and concentrated, to obtain 1.02 g of the title product as a white solid. MS (*m/z*): 128.1 [*M*+*H*]⁺.

Intermediate 18

5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine



(A) 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine

2-chloro-4-hydroxyl pyridine (12.9 g, 0.1 mol), 5-fluoro-2-nitropyridine (14.2 g, 0.1 mol) and potassium carbonate (27.6 g, 0.2 mol) were dissolved in DMSO (130 ml), and the mixture was heated at 80°C for 2 days. The reaction was cooled to room temperature, and the mixture was diluted with water (100 ml) and ethyl acetate (200 ml). The organic phase was separated, and the aqueous phase was extracted with ethyl acetate. The organic

phases were combined, concentrated to obtain crude product, which was purified with flash column chromatography (petroleum ether/ethyl acetate = 1 : 1, elution), to obtain 10.8 g of the title product. MS (m/z):251.9 [M+H]⁺.



(B) 2-(1-methyl-1H-pyrazol-4-yl)-4-((6-nitropyridin-3-yl)oxy)pyridine




- 5 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (10.8 g, 42.9 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (10.7 g, 52.0 mmol), Pd(dppf)Cl₂(3.14 g, 4.3 mmol) and K₂CO₃(11.9 g, 86.0 mmol) were dissolved in the mixed solution of 1,4-dioxane (110 ml) and water (11 ml), under nitrogen, the mixture was heated to 80°C and stirred for 5 hours. The reaction was cooled to room temperature, quenched with water, and concentrated to obtain crude product, which was purified with flash column chromatography (petroleum ether/ethyl acetate = 100 : 0 - 0 : 100 and dichloromethane/methanol = 100 : 0 - 90 : 10, gradient elution), to obtain 8.2 g of the title product. MS (m/z):298.0 [M+H]⁺.

(C) 5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine

- 15 2-(1-methyl-1H-pyrazol-4-yl)-4-((6-nitropyridin-3-yl)oxy)pyridine (4.8 g, 16.1 mmol) and palladium carbon (1.0 g) were dissolved in methanol (50 ml), under hydrogen, the reaction solution was stirred at room temperature for 15 hours. The reactant was filtered to remove palladium carbon, and the liquid was concentrated to obtain crude product, which was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 3.6 g of the title product. MS (m/z):268.0 [M+H]⁺.


The following intermediates were prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 18 under suitable conditions recognized by the POSITA.

Intermediate	Structural formula	MS (M+H) ⁺	Intermediate	Structural formula	MS (M+H) ⁺
19		267.1	20		281.1

Intermediate	Structural formula	MS (M+H) ⁺	Intermediate	Structural formula	MS (M+H) ⁺
21		297.1	22		285.0
23		282.1			

Intermediate 24

5-((2-(2-Methylthiazol-5-yl)pyridin-4-yl)oxy)pyridin-2-amine



5 (A) 2-methyl-5-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)thiazole

Under nitrogen, 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (200 mg, 0.79 mmol), 2-methyl-5-(tributylstannyl) thiazole (339 mg, 0.87 mmol), Pd(PPh₃)₄ (46 mg, 0.04 mmol) and DMF(5 ml) were successively added to a reaction flask, and the mixture was reacted at 100°C overnight. The reaction solution was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 120 mg of a solid title product. MS (m/z): 315.1 [M+H]⁺.

(B) 5-((2-(2-methylthiazol-5-yl)pyridin-4-yl)oxy)pyridin-2-amine

Under nitrogen, 2-methyl-5-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)thiazole (120 mg, 0.38 mmol), ammonium chloride (102 mg, 1.91 mmol), iron powder (85 mg, 1.52 mmol), ethanol (20 ml) and water (5 ml) were successively added to a reaction flask, and the mixture was reacted at 90°C for 3 hours. The reaction solution was filtered, and the filtrate was concentrated, the residue was purified with flash column chromatography


(water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 88 mg of a solid title product. MS (m/z): 285.1 [M+H]⁺.

The following intermediates were prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 24 under suitable
5 conditions recognized by the POSITA.

Intermediate	Structural formula	Intermediate	Structural formula	MS (M+H) ⁺
25		54		271.0

Intermediate 26

4-((6-aminopyridin-3-yl)oxy)-N-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine




10 (A) N-(1-methyl-1H-pyrazol-4-yl)-4-((6-nitropyridin-3-yl)oxy)pyridin-2-amine

Under nitrogen, 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (150 mg, 0.6 mmol), 1-methyl-1H-pyrazol-4-amine hydrochloride salt (96 mg, 0.72 mmol), p-toluenesulfonic acid monohydrate (103 mg, 0.6 mmol) and isopropyl alcohol (5 ml) were successively added to a reaction flask, and the mixture was reacted at 150°C for 16 hours. The reaction
15 solution was concentrated, and the residue was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 90 mg of the title product as a brown solid. MS (m/z): 313.1 [M+H]⁺.

(B) 4-((6-aminopyridin-3-yl)oxy)-N-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine


The title compound was prepared with corresponding intermediates and reagents
20 with reference to the preparation processes of intermediate 24(B). MS (m/z): 283.1 [M+H]⁺.

Intermediate 27**4-((6-aminopyridin-3-yl)oxy)-N-(pyridin-2-yl)pyridin-2-amine****(A) 4-((6-nitropyridin-3-yl)oxy)-N-(pyridin-2-yl)pyridin-2-amine**

5 Under nitrogen, 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (300 mg, 1.2 mmol), 2-aminopyridine (123 mg, 1.3 mmol), BINAP (150 mg, 0.24 mmol), Pd₂(dba)₃ (69 mg, 0.12 mmol), cesium carbonate (782 mg, 2.4 mmol) and DMA (5 ml) were successively added to a reaction flask, and the mixture was reacted at 145°C microwave for 10 minutes. The reaction solution was filtered, and the filtrate was concentrated, the residue was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 210 mg of the title product as a brown solid. MS (m/z): 310.1 [M+H]⁺.

(B) 4-((6-aminopyridin-3-yl)oxy)-N-(pyridin-2-yl)pyridin-2-amine

The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 24(B). MS (m/z): 280.1 [M+H]⁺.

Intermediate 28**5-((2-(imidazo[1,2-a]pyridin-7-yl)pyridin-4-yl)oxy)pyridin-2-amine****(A) 4-((6-nitropyridin-3-yl)oxy)-[2,4'-bipyridin]-2'-amine**

20 Under nitrogen, 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (300 mg, 1.2 mmol), (2-aminopyridin-4-yl)boronic acid (197 mg, 1.4 mmol), Pd(dppf)Cl₂ (98 mg, 0.12 mmol), 2M potassium carbonate solution (1.5 ml) and 1,4-dioxane (6 ml) were successively added to a reaction flask, and the mixture was reacted at 90°C overnight. The reaction solution was concentrated, and the residue was purified with flash column

chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 187 mg of the title product as a yellow solid. MS (m/z): 310.1 [M+H]⁺.

(B) 7-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)imidazo[1,2-a]pyridine


Under nitrogen, 4-((6-nitropyridin-3-yl)oxy)-[2,4'-bipyridin]-2'-amine (187 mg, 0.61 mmol), 40% chloroacetaldehyde aqueous solution (1 ml), potassium carbonate (84 mg, 0.61 mmol) and ethanol (5 ml) were successively added to a reaction flask, and the mixture was refluxed and reacted overnight. The reaction solution was concentrated, and the residue was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 130 mg of the title product as a yellow solid. MS (m/z): 334.0 [M+H]⁺.

(C) 5-((2-(imidazo[1,2-a]pyridin-7-yl)pyridin-4-yl)oxy)pyridin-2-amine

The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 24(B). MS (m/z): 304.1 [M+H]⁺.

Intermediate 29

4-((6-aminopyridin-3-yl)oxy)-N-(1-(difluoromethyl)-1H-pyrazol-3-yl)pyridin-2-amine



(A) 1-(difluoromethyl)-3-nitro-1H-pyrazole

Under nitrogen, 3-nitro-1H-pyrazole (5 g, 44.2 mmol), 2-chloro-2,2-sodium difluoroacetate (8.1 g, 53.0 mmol), potassium carbonate (9.2 g, 66.3 mmol), 18-crown-6 (2.3 g, 8.8 mmol) and acetonitrile (20 ml) were successively added to a reaction flask, and the mixture was refluxed and reacted overnight. The reaction solution was filtered,

and the filtrate was concentrated, the residue was dissolved by adding water (200 ml), and extracted with ethyl acetate (100 ml $\times$ 3), the organic layers were combined and concentrated, the residue was purified with flash column chromatography (petroleum ether/ethyl acetate = 100 : 0 - 0 : 100, gradient elution), to obtain 5 g of the title product
 5 as a yellow oil. MS (m/z): 164.1 $[M+H]^+$.

(B) 1-(difluoromethyl)-1*H*-pyrazol-3-amine

1-(difluoromethyl)-3-nitro-1*H*-pyrazole (5 g, 30.7 mmol), Pd/C(500 mg) and methanol (15 ml) were successively added to a reaction flask, and the mixture was reacted under hydrogen at room temperature overnight. The reaction solution was filtered,
 10 and the filtrate was concentrated to obtain 4 g of a crude product as a yellow oil. MS (m/z): 134.0 $[M+H]^+$.

(C) *N*-(1-(difluoromethyl)-1*H*-pyrazol-3-yl)-4-((6-nitropyridin-3-yl)oxy)pyridin-2-amine


Under nitrogen, 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (500 mg, 2.59 mmol),
 15 1-(difluoromethyl)-1*H*-pyrazol-3-amine (345 mg, 1.3 mmol), XantPhos(231 mg, 0.40 mmol), Pd₂(dba)₃(183 mg, 0.20 mmol), cesium carbonate (1.3 g, 3.88 mmol) and 1,4-dioxane (10 ml) were successively added to a reaction flask, and the mixture was reacted at 100°C overnight. The reaction solution was concentrated, and the residue was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution),
 20 to obtain 600 mg of a solid title product. MS (m/z): 349.0 $[M+H]^+$.

(D) 4-((6-aminopyridin-3-yl)oxy)-*N*-(1-(difluoromethyl)-1*H*-pyrazol-3-yl)pyridin-2-amine

The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 24(B). MS (m/z): 319.0
 25 $[M+H]^+$.

Intermediate 30

5-((2-(1-methyl-1*H*-imidazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine




(A) 2-(1-methyl-1*H*-imidazol-4-yl)-4-((6-nitropyridin-3-yl)oxy)pyridine

2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (300 mg, 1.19 mmol), 1-methyl-4-(tributylstannyl)-1*H*-imidazole (663 mg, 1.79 mmol), Pd(PPh₃)₄ (137 mg, 0.119 mmol) and DMF (5.0 ml) were added to a reaction flask, under nitrogen, the mixture was heated to 100°C and stirred for 3 hours, after cooling, the reaction solution was purified with
 5 flash column chromatography (H₂O/MeOH= 100 : 0 - 0 : 100, gradient elution), to obtain 220 mg of the title product as a white solid. MS (m/z): 298.1 [M+H]⁺.

(B) 5-((2-(1-methyl-1*H*-imidazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine


2-(1-methyl-1*H*-imidazol-4-yl)-4-((6-nitropyridin-3-yl)oxy)pyridine (220 mg, 0.74 mmol), Pd/C (30 mg) and methanol (15.0 ml) were added to a reaction flask, and the
 10 mixture was stirred under hydrogen pressure overnight, and filtered, the filtrate was concentrated to obtain 152 mg of the title product as a yellow oil. MS (m/z): 268.1 [M+H]⁺.

The following intermediates were prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 30 under suitable
 15 conditions recognized by the POSITA.

Intermediate	Structural formula	MS (M+H) ⁺
31		268.1

Intermediate 32

5-((2-(1*H*-1,2,4-triazol-1-yl)pyridin-4-yl)oxy)pyridin-2-amine



20 (A) 4-((6-nitropyridin-3-yl)oxy)-2-(1*H*-1,2,4-triazol-1-yl)pyridine

2-chloropyridin-4-ol (500 mg, 3.86 mmol), 1*H*-1,2,4-triazole (400 mg, 5.79 mmol), Cs₂CO₃ (4.71 mg, 14.48 mmol), CuI (73 mg, 0.386 mmol) and DMF (20.0 ml) were added to a sealed tube, and under nitrogen, the mixture was heated to 130°C and stirred

for 2 days, after cooling, 5-fluoro-2-nitropyridine (1.1 g, 7.72 mmol) was added, the reaction solution was heated to 100°C and stirred overnight, and filtered, the filtrate was purified with flash column chromatography (H₂O/MeOH= 100 : 0-0 : 100, gradient elution), to obtain 396 mg of the title product as a light yellow solid. MS (m/z): 285.1

5 [M+H]⁺.


(B) 5-((2-(1*H*-1,2,4-triazol-1-yl)pyridin-4-yl)oxy)pyridin-2-amine

The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 24(B). MS (m/z): 255.1 [M+H]⁺.

10

Intermediate 33

5-((2-(4-methyl-1*H*-imidazol-1-yl)pyridin-4-yl)oxy)pyridin-2-amine



(A) 2-(4-methyl-1*H*-imidazol-1-yl)-4-((6-nitropyridin-3-yl)oxy)pyridine

15 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (500 mg, 2.0 mmol), 4-methyl-1*H*-imidazole (490 mg, 5.97 mmol), Pd₂(dba)₃ (36.5 mg, 0.04 mmol), Me₄tBuXPhos (38 mg, 0.08 mmol), K₃PO₄ (845 mg, 3.98 mmol), dioxane (4.0 ml) and toluene (20.0 ml) were added to a sealed tube, and under nitrogen, the mixture was heated to 120°C and stirred overnight, the reaction solution was concentrated, and the residue was purified with flash
20 column chromatography (H₂O/MeOH = 100 : 0 - 0 : 100, gradient elution), to obtain 280 mg of the title product as a light yellow solid. MS (m/z): 298.1 [M+H]⁺.

(B) 5-((2-(4-methyl-1*H*-imidazol-1-yl)pyridin-4-yl)oxy)pyridin-2-amine


The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 24(B). MS (m/z):

25 268.1[M+H]⁺.

Intermediate 34

5-([2,3'-bipyridin]-4-yloxy)pyridin-2-amine

-72-

**(A) 4-((6-nitropyridin-3-yl)oxy)-2,3'-bipyridine**


2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (500 mg, 0.2 mmol), pyridin-3-yl boronic acid (367 mg, 0.3 mmol), Na₂CO₃ (640 mg, 6.0 mmol), Pd(dppf)Cl₂·CH₂Cl₂ (163 mg, 0.02 mmol), dioxane (25.0 ml) and water (3.0 ml) were added to a reaction flask, and the mixture was heated to 100°C and stirred overnight, after cooling, the reaction solution was concentrated, and the residue was purified with flash column chromatography (H₂O/MeOH= 100 : 0 - 0 : 100, gradient elution), to obtain 441 mg of the title product as a yellow solid. MS (m/z): 295.0 [M+H]⁺.

(B) 5-([2,3'-bipyridin]-4-yloxy)pyridin-2-amine

The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 24(B). MS (m/z): 265.1 [M+H]⁺.

The following intermediates were prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 34 under suitable conditions recognized by the POSITA.


Intermediate	Structural formula	MS (M+H) ⁺	Intermediate	Structural formula	MS (M+H) ⁺
55		270.0	56		268.1
57		268.1			

Intermediate 35**4-((6-aminopyridin-3-yl)oxy)-N-(6-methylpyridin-2-yl)pyridin-2-amine****(A) 6-methyl-N-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)pyridin-2-amine**

- 5 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (500 mg, 2.0 mmol), 6-methylpyridin-2-amine (432 mg, 4.0 mmol), $\text{Pd}_2(\text{dba})_3$ (183 mg, 0.2 mmol), Xantphos (231 mg, 0.4 mmol), Cs_2CO_3 (1.63 g, 5.0 mmol) and dioxane (50.0 ml) were added to a sealed tube, and under nitrogen, the mixture was heated to 100°C and stirred for 4 hours, the reaction solution was concentrated, and the residue was purified with flash column chromatography ($\text{H}_2\text{O}/\text{MeOH} = 100 : 0 - 0 : 100$, gradient elution), to obtain 550 mg of a product as a light yellow solid. MS (m/z): 324.1 $[\text{M}+\text{H}]^+$.

(B) 4-((6-aminopyridin-3-yl)oxy)-N-(6-methylpyridin-2-yl)pyridin-2-amine

- The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 24(B). MS (m/z): 294.1 $[\text{M}+\text{H}]^+$.

Intermediate 36**5-((2-(1H-pyrazol-1-yl)pyridin-4-yl)oxy)pyridin-2-amine****(A) 2-(1H-pyrazol-1-yl)pyridin-4-ol**

- 20 2-chloro-4-hydroxypyridine (500 mg, 3.9 mmol), pyrazole (527 mg, 7.8 mmol), Cs_2CO_3 (2.5 g, 7.8 mmol), CuI (76 mg, 0.4 mmol) and DMF (10 ml) were successively added to a sealed tube, and the mixture was reacted at 130°C for 12 hours. The reaction solution was concentrated, and the residue was purified with flash column chromatography (petroleum ether/ethyl acetate = 100 : 0-50 : 50, gradient elution), to obtain 300 mg of the title product as a yellow solid. MS (m/z): 162 $[\text{M}+\text{H}]^+$.

(B) 4-((6-nitropyridin-3-yl)oxy)-2-(1H-pyrazol-1-yl)pyridine


2-(1*H*-pyrazol-1-yl)pyridin-4-ol (250 mg, 1.6 mmol), 5-fluoro-2-nitropyridine (220 mg, 1.6 mmol), K₂CO₃ (321 mg, 2.4 mmol) and DMF (10 ml) were successively added to a reaction flask, and the mixture was reacted at 100°C for 12 hours. Water was added to the reaction solution, and the reaction solution was extracted with ethyl acetate, washed with saturated brine, and dried with anhydrous sodium sulfate. The reactant was concentrated to obtain 250 mg of a light yellow solid. MS (m/z): 284 [M+H]⁺.

(C) 5-((2-(1*H*-pyrazol-1-yl)pyridin-4-yl)oxy)pyridin-2-amine

The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 24(B). MS (m/z): 254 [M+H]⁺.

Intermediate 37

5-((2-(1-ethyl-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine



(A) 2-(1-ethyl-1*H*-pyrazol-4-yl)-4-((6-nitropyridin-3-yl)oxy)pyridine


Under nitrogen, 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (300 mg, 1.2 mmol), 1-ethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-pyrazole (398 mg, 1.8 mmol), Pd(PPh₃)₄ (138 mg, 0.12 mmol), Cs₂CO₃ (779 mg, 2.4 mmol), dioxane (8 ml) and water (2 ml) were successively added to a reaction flask, and the mixture was reacted at 100°C for 3 hours. The reaction solution was concentrated, and the residue was purified with flash column chromatography (petroleum ether/ethyl acetate = 100 : 0 - 50 : 50, gradient elution), to obtain 300 mg of the title product as a yellow solid. MS (m/z): 312 [M+H]⁺.

(B) 5-((2-(1-ethyl-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine

The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 24(B). MS (m/z): 282 [M+H]⁺.

The following intermediates were prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 37 under suitable conditions recognized by the POSITA.

Intermediate	Structural formula	MS (M+H) ⁺
38		296



Intermediate 39**5-([2,4'-bipyridin]-4-yloxy)pyridin-2-amine****5 (A) 4-((6-nitropyridin-3-yl)oxy)-2,4'-bipyridine**

Under nitrogen, 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (300 mg, 1.2 mmol), 4-pyridine boronic acid (220 mg, 1.8 mmol), Pd(PPh₃)₄ (138 mg, 0.12 mmol), Cs₂CO₃ (779 mg, 2.4 mmol), dioxane (8 ml) and water (2 ml) were successively added to a reaction flask, and the mixture was reacted at 100°C for 3 hours. The reaction solution was concentrated, and the residue was purified with flash column chromatography (petroleum ether/ethyl acetate = 100 : 0 - 0 : 100, gradient elution), to obtain 300 mg of the title product as a yellow solid. MS (m/z): 295 [M+H]⁺.

(B) 5-([2,4'-bipyridin]-4-yloxy)pyridin-2-amine


The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 24(B). MS (m/z): 265 [M+H]⁺.

The following intermediates were prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 39 under suitable conditions recognized by the POSITA.

Intermediate	Structural formula	MS (M+H) ⁺	Intermediate	Structural formula	MS (M+H) ⁺
40		282	41		264

Intermediate 42

4-(((6-aminopyridin-3-yl)oxy)-N-(1-methyl-1H-pyrazol-3-yl)pyridin-2-amine



5 (A) N-(1-methyl-1H-pyrazol-3-yl)-4-(((6-nitropyridin-3-yl)oxy)pyridin-2-amine

Under nitrogen, 2-chloro-4-(((6-nitropyridin-3-yl)oxy)pyridine (400 mg, 1.6 mmol), 1-methyl-1H-pyrazol-3-amine (309 mg, 3.2 mmol), Pd₂(dba)₃ (145 mg, 0.16 mmol), Xantphos (184 mg, 0.32 mmol), Cs₂CO₃ (779 mg, 2.4 mmol) and dioxane (10 ml) were successively added to a reaction flask, and the mixture was reacted at 100°C for 16 hours.

- 10 The reaction solution was concentrated, and the residue was purified with flash column chromatography (petroleum ether/ethyl acetate = 100 : 0 - 0 : 100, gradient elution), to obtain 200 mg of the title product as a yellow solid. MS (m/z): 313 [M+H]⁺.

(B) 4-(((6-aminopyridin-3-yl)oxy)-N-(1-methyl-1H-pyrazol-3-yl)pyridin-2-amine


- The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 24(B). MS (m/z): 283 [M+H]⁺.
- 15

The following intermediates were prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 42 under suitable conditions recognized by the POSITA.

Intermediate	Structural formula	MS (M+H) ⁺	Intermediate	Structural formula	MS (M+H) ⁺
43		283	44		283

Intermediate 45

5-((2-(1-(difluoromethyl)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine



5 (A) 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1 g, 5.1 mmol), 2-chloro-2,2-sodium difluoroacetate (0.94 g, 6.2 mmol), 18-crown-6 (0.27 g, 1.02 mmol) and acetonitrile (20 ml) were successively added to a reaction flask, and the mixture was reacted at 85°C for 20 hours. Water was added to the reaction solution, and the reaction solution was extracted with ethyl acetate, washed with saturated brine, and dried with anhydrous sodium sulfate. The reactant was concentrated to obtain 900 mg of a crude product, which was directly used in the next step. MS (m/z): 245 [M+H]⁺.

(B) 2-(1-(difluoromethyl)-1H-pyrazol-4-yl)-4-((6-nitropyridin-3-yl)oxy)pyridine


The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 37(A). MS (m/z): 334 [M+H]⁺.

(C) 5-((2-(1-(difluoromethyl)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine

The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 24(B). MS (m/z): 304 [M+H]⁺.

Intermediate 46

2-chloro-4-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)aniline



(A) 2-chloro-4-(3-chloro-4-nitrophenoxy)pyridine

2-chloro-4-hydroxyl pyridine (294 mg, 2.28 mmol), 2-chloro-4-fluoro-1-nitrobenzene (400 mg, 2.28 mmol), K_2CO_3 (473 mg, 3.42 mmol) and DMF (8 ml) were successively added to a reaction flask, and the mixture was reacted at $80^\circ C$ for 4 hours. Water was added to the reaction solution, and the reaction solution was extracted with ethyl acetate, washed with saturated brine, and dried with anhydrous sodium sulfate. The reactant was concentrated to obtain 500 mg of the title product as a yellow solid. MS (m/z): 285 $[M+H]^+$.

(B) 4-(3-chloro-4-nitrophenoxy)-2-(1-methyl-1H-pyrazol-4-yl)pyridine


The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 37(A). MS (m/z): 331 $[M+H]^+$.

(C) 2-chloro-4-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)aniline

The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 24(B). MS (m/z): 301 $[M+H]^+$.

Intermediate 47

5-((2-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine



(A) 4-((6-nitropyridin-3-yl)oxy)-2-(1H-pyrazol-4-yl)pyridine

2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (1.0 g, 4.0 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.55 g, 8.0 mmol), $Pd(dppf)Cl_2$ (0.29 g, 0.4 mmol) and K_2CO_3 (0.83 g, 6.0 mmol) were dissolved in the mixed solution of 1,4-dioxane (16 ml) and water (4 ml), and under nitrogen, the mixture was heated to $80^\circ C$ and reacted overnight. The reaction solution was concentrated to obtain a crude product, which was purified with flash column chromatography (dichloromethane/methanol = 100 : 0-90:10, gradient elution), to obtain 0.57 g of the title product. MS (m/z): 284.1 $[M+H]^+$.

(B) *N,N*-dimethyl-2-(4-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)-1*H*-pyrazol-1-yl)ethan-1-amine


4-((6-nitropyridin-3-yl)oxy)-2-(1*H*-pyrazol-4-yl)pyridine (100 mg, 0.35 mmol), 2-chloro-*N,N*-dimethylethyl-1-amine (72 mg, 0.70 mmol) and cesium carbonate (170 mg, 0.52 mmol) were dissolved in acetonitrile (10 ml), and the mixture was stirred at 80°C for 5 hours. The reactant was concentrated to obtain a crude product, which was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 88 mg of the title product. MS (m/z): 355.1 [M+H]⁺.

(C) 5-((2-(1-(2-(dimethylamino)ethyl)-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine

N,N-dimethyl-2-(4-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)-1*H*-pyrazol-1-yl)ethan-1-amine (88 mg, 0.25 mmol) and palladium carbon (10 mg) were dissolved in methanol (10 ml), and the mixture was stirred under hydrogen at room temperature for 5 hours. The reaction solution was filtered to remove palladium carbon, and the liquid was concentrated to obtain 67 mg of a crude product of title compound. MS (m/z): 325.2 [M+H]⁺.

Intermediate 48

5-((2-(1-methyl-1*H*-1,2,4-triazol-3-yl)pyridin-4-yl)oxy)pyridin-2-amine



(A) 4-((6-aminopyridin-3-yl)oxy)picolinonitrile

4-chloropyridine carbonitrile (1.38 g, 10.0 mmol), 6-aminopyridin-3-ol (1.1 g, 10.0 mmol), potassium *t*-butoxide (1.12 g, 10.0 mmol) and potassium carbonate (1.38 g, 10.0 mmol) were dissolved in DMSO (20 ml), and the mixture was stirred at 80°C for 15 hours. The reaction solution was quenched with saturated ammonium chloride solution, extracted with ethyl acetate, and concentrated, to obtain a crude product, which was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 1.12 g of the title product. MS (m/z): 213.0 [M+H]⁺.

(B) 4-((6-aminopyridin-3-yl)oxy)-*N'*-methylpicolinimidohydrazide

4-((6-aminopyridin-3-yl)oxy)picolinonitrile (1.12 g, 5.28 mmol) and methylhydrazine (1.21 g, 26.4 mmol) were dissolved in ethanol (20 ml), and the mixture was reacted at room temperature for 15 hours. The reaction solution was concentrated to obtain a crude product, which was purified with flash column chromatography

- 5 (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 430 mg of the title product. MS (m/z): 259.1 [M+H]⁺.


(C) 5-((2-(1-methyl-1*H*-1,2,4-triazol-3-yl)pyridin-4-yl)oxy)pyridin-2-amine

4-((6-aminopyridin-3-yl)oxy)-N'-methylpicolinimidohydrazide (258 mg, 1.0 mmol) was dissolved in formic acid (5 ml), and the mixture was refluxed and reacted for 4 hours.

- 10 The reaction solution was concentrated to obtain a crude product, which was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 88 mg of the title product. MS (m/z): 269.1 [M+H]⁺.

Intermediate 49

- 15 **N-(4-((6-aminopyridin-3-yl)oxy)pyridin-2-yl)-5-methylthiazol-2-amine**




(A) 5-methyl-N-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)thiazol-2-amine

2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (300 mg, 1.20 mmol), 5-methylthiazol-2-amine (200 mg, 1.80 mmol), Pd₂(dba)₃ (100 mg, 0.12 mmol),

- 20 Xantphos (60 mg, 0.12 mmol) and potassium carbonate (331 mg, 2.40 mmol) were dissolved in dioxane (15 ml), and the mixture was stirred and reacted at 90°C for 6 hours. The reaction solution was concentrated to obtain a crude product, which was purified with flash column chromatography (dichloromethane/methanol = 100 : 0-90 : 10, gradient elution), to obtain 370 mg of the title product. MS (m/z): 330.1 [M+H]⁺.

- 25 **(B) N-(4-((6-aminopyridin-3-yl)oxy)pyridin-2-yl)-5-methylthiazol-2-amine**

The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 24(B). MS (m/z): 300.0 [M+H]⁺.


Intermediate 50**3-fluoro-5-((2-(1-methyl-1H-imidazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine****(A) 5-((2-chloropyridin-4-yl)oxy)-3-fluoropyridin-2-amine**

5 6-amino-5-fluoropyridin-3-ol (1.70 g, 13.3 mmol), 2-chloro-4-fluoropyridine (1.74 g, 13.3 mmol) and cesium carbonate (6.50 g, 20.0 mmol) were dissolved in DMSO (50 ml), and the mixture was stirred and reacted at 90°C for 2 hours. The reactant was concentrated to obtain a crude product, which was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 1.41 g of the title product. MS (m/z): 240.1[M+H]⁺.

(B) 3-fluoro-5-((2-(1-methyl-1H-imidazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine


The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 30(A). MS (m/z): 286.0[M+H]⁺.

15

Intermediate 51**3-fluoro-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine**

The title compound was prepared with 5-((2-chloropyridin-4-yl)oxy)-3-fluoropyridin-2-amine and corresponding reagents with reference to the preparation processes of intermediate 18(B). MS (m/z): 286.0[M+H]⁺.

Intermediate 52**2-amino-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)nicotinonitrile**



(A) 2-amino-5-((2-chloropyridin-4-yl)oxy)nicotinonitrile

The title compound was prepared with 6-amino-5-cyanopyridin-3-ol and corresponding reagents with reference to the preparation processes of intermediate 50(A).

5 MS (m/z):247.1[M+H]⁺.


(B) 2-amino-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)nicotinonitrile

2-amino-5-((2-chloropyridin-4-yl)oxy)nicotinonitrile (150 mg, 0.61 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (253 mg, 1.22 mmol), Pd(dppf)Cl₂(43 mg, 0.06 mmol) and sodium carbonate (95 mg, 0.92 mmol) were dissolved in dioxane (5 ml) and water (1 ml), and the mixture was reacted under nitrogen at 80°C for 5 hours. The reactant was concentrated to obtain a crude product, which was purified with flash column chromatography (water/methanol =100 : 0 - 0 : 100, gradient elution), to obtain 93 mg of the title product. MS (m/z):293.0[M+H]⁺.

15

Intermediate 53

5-((2-(2-methylthiazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine



(A) 2-(1-ethoxyvinyl)-4-((6-nitropyridin-3-yl)oxy)pyridine

Under nitrogen, 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (252 mg, 1.0 mmol), tributyl(1-ethoxyvinyl)stannane (722 mg, 2.0 mmol) and Pd(PPh₃)₄(58 mg, 0.05 mmol) were dissolved in 10 ml DMF, and the reaction solution was heated at 100°C for 15 hours. The reaction solution was cooled to room temperature, and 20 ml of water and 50 ml of ethyl acetate were added. The reaction solution was extracted, and concentrated, a crude product was purified with flash column chromatography (petroleum ether/ethyl acetate

=100 : 0 - 0 : 100, gradient elution), to obtain the title product (162 mg) as a yellow solid.

MS (m/z): 288.0[M+H]⁺.

(B) 2-bromo-1-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)ethan-1-one

In a reaction flask, 2-(1-ethoxyvinyl)-4-((6-nitropyridin-3-yl)oxy)pyridine (162 mg, 0.564 mmol) and NBS (100 mg, 0.564 mmol) were dissolved in the mixed solvent of tetrahydrofuran (10 ml) and water (1 ml), and the reaction solution was stirred at room temperature for 1 hour. The reaction solution was concentrated, and then a crude product was purified with flash column chromatography (water/methanol =100 : 0 - 0 : 100, gradient elution), to obtain the title product (136 mg) as a yellow solid. MS (m/z):

338.0[M+H]⁺.

(C) 2-methyl-4-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)thiazole

In a reaction flask, 2-bromo-1-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)ethan-1-one (136 mg, 0.402 mmol) and thioacetamide (151 mg, 2.01 mmol) were dissolved in 5 ml of ethanol, and the reaction solution was heated and refluxed for 1 hour. The reaction solution was concentrated, and then a crude product was purified with flash column chromatography (water/methanol =100 : 0 - 0 : 100, gradient elution), to obtain the title product (98 mg) as a yellow solid. MS (m/z): 315.0[M+H]⁺.

(D) 5-((2-(2-methylthiazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine


The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of intermediate 24(B). MS (m/z): 285.0[M+H]⁺.

Example 2

Preparation of compound 1-135

Compound 1

6-(dimethylamino)-1-isopropyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide



(A) 6-chloro-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide



Under nitrogen, 5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine (500 mg, 1.87 mmol), 6-chloro-2-oxo-1,2-dihydropyridin-3-carboxylic acid (487 mg, 2.81 mmol), HATU(1.07 g, 2.81 mmol) and DMF(5 ml) were successively added to a reaction flask, and then TEA(0.76 ml, 5.61 mmol) was added, the mixture was reacted at room temperature overnight. The reaction solution was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 320 mg of the title product as a brown solid. MS (m/z): 423.1 [M+H]⁺.

(B) 6-(dimethylamino)-1-isopropyl-N-(5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide

Under nitrogen, 6-chloro-*N*-(5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide (70 mg, 0.17 mmol), 2-bromopropane (41 mg, 0.33 mmol), potassium carbonate (69 mg, 0.50 mmol) and DMF(3 ml) were added to a reaction flask, and the mixture was reacted at 80°C overnight. The reaction solution was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution) and p-TLC plate (dichloromethane/methanol = 15:1), to obtain 12 mg of the title product as a yellow solid. MS (m/z): 474.2 [M+H]⁺.


¹H NMR (400 MHz, DMSO-d₆) δ 10.48 (s, 1H), 8.36 (d, J = 3.1 Hz, 1H), 8.35 (s, 1H), 8.27 (d, J = 2.9 Hz, 1H), 8.25 (s, 1H), 8.12 (d, J = 8.7 Hz, 1H), 7.95 (s, 1H), 7.72 (dd, J = 9.0, 2.9 Hz, 1H), 7.22 (d, J = 2.4 Hz, 1H), 6.70 (dd, J = 5.7, 2.3 Hz, 1H), 6.36 (d, J = 8.8 Hz, 1H), 5.53-5.41 (m, 1H), 3.82 (s, 3H), 3.09 (s, 6H), 1.44 (d, J = 6.2 Hz, 6H).

The following compounds were prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 1 under suitable conditions recognized by the POSITA.

Compound	Structural formula	MS (M+H) ⁺	¹ HNMR
118		417.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.76 (s, 1H), 8.37 (d, J = 3.3 Hz, 1H), 8.36 (s, 1H), 8.34 (d, J = 2.6 Hz, 1H), 8.28 (d, J = 2.9 Hz, 1H), 8.26 (s, 1H), 8.12 (s, 1H), 8.01 (d, J = 1.9 Hz, 1H), 7.96 (s, 1H), 7.74 (dd, J = 9.0, 2.9 Hz, 1H), 7.24 (d, J = 2.4 Hz, 1H), 6.71 (dd, J = 5.7, 2.4 Hz, 1H), 3.83 (s, 3H), 3.57 (s, 3H), 2.14 (s, 3H).
124		416.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.75 (s, 1H), 8.37 (s, 1H), 8.35-8.33 (m, 1H), 8.30 (d, J = 5.7 Hz, 1H), 8.27 (d, J = 2.9 Hz, 1H), 8.01 (d, J = 2.3 Hz, 1H), 7.72 (dd, J = 9.0, 2.9 Hz, 1H), 7.35-7.34 (m, 1H), 7.08 (d, J = 2.4 Hz, 1H), 6.71-6.69 (m, 1H), 6.61 (dd, J = 5.6, 2.2 Hz, 1H), 6.52-6.47 (m, 1H), 3.60 (s, 3H), 3.58 (s, 3H), 2.14 (s, 3H).

Compound 2

6-(dimethylamino)-1-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide



Under nitrogen, 6-chloro-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide (100 mg, 0.24 mmol), iodomethane (30 μl, 0.47 mmol), potassium carbonate (100 mg, 0.72 mmol) and DMF (4 ml) were added to a reaction flask, and the mixture was reacted at 80°C overnight. And then dimethylamine hydrochloride (38 mg, 0.47 mmol) was added, and the mixture was reacted at room temperature overnight, the reaction solution was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution) and p-TLC


10

plate (dichloromethane/methanol = 15:1), to obtain 16 mg of the title product as a light yellow solid. MS (m/z): 446.2 [M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ 12.48 (s, 1H), 8.36 (dd, J = 7.4, 4.3 Hz, 2H), 8.29 (d, J = 8.5 Hz, 1H), 8.25 (m, 2H), 7.95 (d, J = 0.6 Hz, 1H), 7.71 (dd, J = 9.0, 2.9 Hz, 1H),
 5 7.22 (d, J = 2.4 Hz, 1H), 6.70 (dd, J = 5.7, 2.4 Hz, 1H), 6.16 (d, J = 8.6 Hz, 1H), 3.82 (s, 3H), 3.49 (s, 3H), 2.87 (s, 6H).

Compound 3

6-methoxy-1-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide



(A) 6-chloro-1-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide

Under nitrogen, 6-chloro-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide (320 mg, 0.76 mmol),
 15 iodomethane (71 μl, 1.14 mmol), potassium carbonate (540 mg, 1.42 mmol) and DMF (5 ml) were added to a reaction flask, and the mixture was reacted at 80°C overnight. The reaction solution was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 130 mg of the title product as a brown solid. MS
 20 (m/z): 437.1 [M+H]⁺.

(B) 6-methoxy-1-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide


Under nitrogen, 6-chloro-1-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide (30 mg, 0.07 mmol) and
 25 7M ammonia methanol solution (3 ml) were added to a reaction flask, the tube was sealed and the mixture was reacted at 80°C for 2 h. And then the reaction solution was concentrated, the residue was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution) and p-TLC plate (dichloromethane/methanol = 15 : 1), to obtain 3 mg of the title product as a yellow solid.
 30 MS (m/z): 433.2 [M+H]⁺.

^1H NMR (400 MHz, DMSO- d_6) δ 12.39 (s, 1H), 8.46 (d, J = 8.6 Hz, 1H), 8.38-8.33 (m, 2H), 8.29-8.20 (m, 2H), 7.95 (d, J = 0.5 Hz, 1H), 7.72 (dd, J = 9.0, 2.9 Hz, 1H), 7.23 (d, J = 2.3 Hz, 1H), 6.70 (dd, J = 5.7, 2.4 Hz, 1H), 6.25 (d, J = 8.7 Hz, 1H), 4.04 (s, 3H), 3.82 (s, 3H), 3.45 (s, 3H).

5

Compound 4

***N*-(3-fluoro-5-((2-((1-methyl-1*H*-pyrazol-4-yl)amino)pyridin-4-yl)oxy)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide**



10 (A) 5-((2-bromopyridin-4-yl)oxy)-3-fluoropyridin-2-amine

Under nitrogen, 6-amino-5-fluoropyridin-3-ol (1.28 g, 10 mmol), 2-bromo-4-fluoropyridine (1.76 g, 10 mmol), cesium carbonate (4.9 g, 15 mmol) and DMSO (10 ml) were successively added to a reaction flask, and the mixture was reacted at 80°C for 2 hours. The reaction solution was cooled to room temperature, added to water (100 ml)

15 under stirring, and extracted with ethyl acetate (100 ml $\times$ 3), the organic layers were combined and concentrated, and the residue was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 2.7 g of the title product as a yellow solid. MS (m/z): 285.9 [$M+H$] $^+$.

20 (B) *N*-(5-((2-bromopyridin-4-yl)oxy)-3-fluoropyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide

5-((2-bromopyridin-4-yl)oxy)-3-fluoropyridin-2-amine (200 mg, 0.70 mmol), 1-methyl-2-oxo-1,2-dihydropyridin-3-carboxylic acid (118 mg, 0.77 mmol), HATU (322 mg, 0.85 mmol), TEA (148 μ l, 1.05 mmol) and DMF (6 ml) were successively added to a reaction flask, and the mixture was reacted at 45°C overnight. The reaction solution was

25 purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 133 mg of the title product as a brown solid. MS (m/z): 419.0 [$M+H$] $^+$.

(C) *N*-(3-fluoro-5-((2-((1-methyl-1*H*-pyrazol-4-yl)amino)pyridin-4-yl)oxy)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide

Under nitrogen, *N*-(5-((2-bromopyridin-4-yl)oxy)-3-fluoropyridin-2-yl)-1-methyl-2-

30 oxo-1,2-dihydropyridine-3-carboxamide (133 mg, 0.32 mmol), 1-methyl-1*H*-pyrazol-4-


amine (37 mg, 0.38 mmol), XantPhos(37 mg, 0.064 mmol), Pd₂(dba)₃(29 mg, 0.032 mmol), cesium carbonate (261 mg, 0.8 mmol) and 1,4-dioxane (10 ml) were successively added to a reaction flask, and the mixture was reacted at 100°C overnight. The reaction solution was concentrated, and the residue was purified with flash column

- 5 chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution) and p-TLC plate (dichloromethane/methanol/formic acid = 10:1:0.1), to obtain 15 mg of the title product as a yellow solid. MS (m/z): 436.1[M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ 12.22 (s, 1H), 8.83 (s, 1H), 8.46 (dd, J = 7.3, 2.1 Hz, 1H), 8.25 (d, J = 2.3 Hz, 1H), 8.21 (dd, J = 6.5, 2.1 Hz, 1H), 8.16 (s, 2H), 8.05 (d, J =
10 5.8 Hz, 1H), 7.94 (dd, J = 10.5, 2.4 Hz, 1H), 7.90 (s, 1H), 7.35 (s, 1H), 6.66-6.58 (m, 1H), 6.39 (dd, J = 5.8, 2.2 Hz, 1H), 6.12 (d, J = 2.1 Hz, 1H), 3.78 (s, 3H), 3.65 (s, 3H).

Compound 5

- 1,2-dimethyl-N-((6-((1-methyl-1H-pyrazol-4-yl)pyrimidin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide**
15



(A) 5-((6-chloropyrimidin-4-yl)oxy)pyridin-2-amine

- Under nitrogen, 4,6-dichloropyrimidine (530 mg, 3.56 mmol), 6-aminopyridin-3-ol (390 mg, 3.56 mmol), potassium t-butoxide (800 mg, 7.12 mmol) and DMSO (18 ml)
20 were successively added to a reaction flask, and the mixture was reacted at 100°C overnight. The reaction solution was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain a solid title product 494 mg. MS (m/z): 233.0 [M+H]⁺.

(B) 5-((6-((1-methyl-1H-pyrazol-4-yl)pyrimidin-4-yl)oxy)pyridin-2-amine

- 25 Under nitrogen, 5-((6-chloropyrimidin-4-yl)oxy)pyridin-2-amine (300 mg, 1.35 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (336 mg, 1.62 mmol), Pd(dppf)Cl₂(110 mg, 0.135 mmol), cesium carbonate (660 mg, 2.03 mmol), water (2 ml) and 1,4-dioxane (8 ml) were successively added to a reaction flask, and the mixture was reacted at 50°C overnight. The reaction solution was concentrated, and the

residue was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 160 mg of a solid title product. MS (m/z): 269.1 [M+H]⁺.

(C) 1,2-dimethyl-N-(5-((6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide


5 The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 1(A). MS (m/z): 419.1 [M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ 11.85 (s, 1H), 8.76 (s, 1H), 8.65 (d, J = 0.7 Hz, 1H), 8.49 (s, 1H), 8.38-8.27 (m, 2H), 8.18 (s, 1H), 7.82 (dd, J = 8.9, 2.8 Hz, 1H), 7.46 (d, J = 0.7 Hz, 1H), 3.91 (s, 3H), 3.60 (s, 3H), 2.65 (s, 3H).

10

Compound 6

1-isopropyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide



15 **(A) 5-((2-chloropyrimidin-4-yl)oxy)pyridin-2-amine**

2,4-dichloropyrimidine (1.49 g, 10.0 mmol), 6-aminopyridin-3-ol (1.1 g, 10.0 mmol), K₂CO₃ (3.45 g, 25.0 mmol) and DMF (15.0 ml) were added to a reaction flask, and the mixture was heated to 100°C and stirred for 4 hours, after cooling, the reaction solution was filtered, and the filtrate was purified with flash column chromatography (H₂O/MeOH = 100 : 0-0 : 100, gradient elution), to obtain 1.3 g of the title product as a light yellow solid. MS (m/z): 223.0, 225.0 [M+H]⁺.

(B) N-(5-((2-chloropyrimidin-4-yl)oxy)pyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide

25 The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 1(A). MS (m/z): 386.0, 388.0 [M+H]⁺.

(C) 1-isopropyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide

N-(5-((2-chloropyrimidin-4-yl)oxy)pyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide (100 mg, 0.26 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-

30


1,3,2-dioxaborolan-2-yl)-1*H*-pyrazole (65 mg, 0.311 mmol), Na₂CO₃ (83 mg, 0.78 mmol), Pd(dppf)Cl₂·CH₂Cl₂ (22 mg, 0.026 mmol), dioxane (25.0 ml) and water (3.0 ml) were added to a reaction flask, and the mixture was heated to 100°C and stirred overnight, after cooling, the reaction solution was purified with flash column chromatography (H₂O/MeOH= 100 : 0-0 : 100, gradient elution), to obtain 40 mg of the title product as a white solid. MS (m/z): 432.2 [M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ 12.70 (s, 1H), 8.70-8.56 (m, 1H), 8.55-8.44 (m, 1H), 8.44 - 8.31 (m, 2H), 8.24 (s, 1H), 8.11 (s, 1H), 7.93-7.72 (m, 2H), 7.00-6.82 (m, 1H), 6.79-6.56 (m, 1H), 5.35-5.11 (m, 1H), 3.83 (s, 3H), 1.37 (d, J = 5.3 Hz, 6H).

10

Compound 7

1,2-dimethyl-*N*-(5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyrimidin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide



15 (A) 5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyrimidin-4-yl)oxy)pyridin-2-amine

5-((2-chloropyrimidin-4-yl)oxy)pyridin-2-amine (1.9 g, 8.56 mmol), (1-methyl-1*H*-pyrazol-4-yl)boronic acid (1.18 g, 9.41 mmol), Na₂CO₃ (2.72 g, 25.68 mmol), Pd(dppf)Cl₂·CH₂Cl₂ (1.05 g, 1.284 mmol), dioxane (25.0 ml) and water (3.0 ml) were added to a reaction flask, and the mixture was heated to 100°C and stirred for 4 hours, after cooling, the reaction solution was concentrated, and purified with flash column chromatography (H₂O/MeOH= 100 : 0 - 0 : 100, gradient elution), to obtain 1.72 g of the title product as a yellow solid. MS (m/z): 269.1 [M+H]⁺.

20


(B) 1,2-dimethyl-*N*-(5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyrimidin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide

The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 1(A). MS (m/z): 419.1 [M+H]⁺.

25

¹H NMR (400 MHz, DMSO-d₆) δ 11.85 (s, 1H), 8.75 (s, 1H), 8.62 (d, J = 6.2 Hz, 1H), 8.40-8.31 (m, 2H), 8.11 (s, 1H), 7.89-7.76 (m, 1H), 7.81 (s, 1H), 6.90 (d, J = 5.3 Hz, 1H), 3.83 (s, 3H), 3.58 (s, 3H), 2.64 (s, 3H).

Compound 8


1,2-dimethyl-*N*-(5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide

5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine (158 mg, 0.59 mmol), 1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (100 mg, 0.59 mmol), HATU (224 mg, 0.59 mmol), triethylamine (178 mg, 1.77 mmol) and DMF (5 ml) were successively added to a reaction flask, and the mixture was heated to 40°C and
 10 reacted for 15 hours. The reaction solution was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 22 mg of a product as a light yellow solid. MS (*m/z*): 418.1 [*M*+*H*]⁺.

¹H NMR (400 MHz, DMSO-*d*₆) δ 11.85 (s, 1H), 8.73 (s, 1H), 8.36 (d, *J* = 5.7 Hz, 1H), 8.33 (d, *J* = 9.0 Hz, 1H), 8.29 (d, *J* = 2.6 Hz, 1H), 8.25 (s, 1H), 7.95 (s, 1H), 7.76 (dd, *J* = 9.0, 2.6 Hz, 1H), 7.23 (d, *J* = 1.9 Hz, 1H), 6.71 (dd, *J* = 5.5, 2.2 Hz, 1H), 3.83 (s, 3H), 3.57 (s, 3H), 2.62 (s, 3H).


The following compounds were prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 8 under suitable conditions recognized by the POSITA.

Compound	Structural formula	MS (<i>M</i> + <i>H</i>) ⁺	¹ H NMR
116		420.1	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.86 (s, 1H), 8.73 (s, 1H), 8.39 (d, <i>J</i> = 5.7 Hz, 1H), 8.34 (d, <i>J</i> = 9.3 Hz, 1H), 8.32 (d, <i>J</i> = 2.8 Hz, 1H), 7.83-7.79 (m, 2H), 7.65 - 7.59 (m, 1H), 7.55 (d, <i>J</i> = 2.2 Hz, 1H), 7.4-7.071 (m, 1H), 6.81 (dd, <i>J</i> = 5.7, 2.4 Hz, 1H), 3.57 (s, 3H), 2.63 (s, 3H).

Compound	Structural formula	MS (M+H) ⁺	¹ H NMR
119		421.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.88 (s, 1H), 8.73 (s, 1H), 8.52 (d, J = 5.7 Hz, 1H), 8.43 - 8.29 (m, 2H), 7.91 (d, J = 3.1 Hz, 1H), 7.89-7.81 (m, 2H), 7.51 (d, J = 2.3 Hz, 1H), 7.12 (dd, J = 5.6, 2.4 Hz, 1H), 3.57 (s, 3H), 2.63 (s, 3H).

Compound 9






N-(5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide










Under nitrogen, 5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine (100 mg, 0.37 mmol), 2-hydroxynicotinic acid (78 mg, 0.56 mmol), HATU (213 mg, 0.56 mmol), dichloromethane (20 ml) and TEA (155 μl, 1.1 mmol) were successively added to a reaction flask, and the mixture was stirred at room temperature overnight, added water (5 ml), and then concentrated. The residue was purified with flash column chromatography (water (0.5% formic acid): methanol = 100 : 0 - 0 : 100, gradient elution) and p-TLC plate, to obtain 45 mg of the title product as a white solid. MS (m/z): 389.2 [M+H]⁺.





¹H NMR (400 MHz, DMSO-d₆) δ 12.86 (s, 1H), 12.69 (s, 1H), 8.52 (dd, J = 7.2, 2.2 Hz, 1H), 8.40 (d, J = 2.6 Hz, 1H), 8.38 (s, 1H), 8.31 (d, J = 2.9 Hz, 1H), 8.28 (s, 1H), 7.98 (s, 1H), 7.86 (dd, J = 6.2, 2.2 Hz, 1H), 7.77 (dd, J = 9.0, 2.9 Hz, 1H), 7.26 (d, J = 2.4 Hz, 1H), 6.74 (dd, J = 5.7, 2.4 Hz, 1H), 6.60 (dd, J = 7.1, 6.3 Hz, 1H), 3.85 (s, 3H).





The following compounds were prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 9 under suitable conditions recognized by the POSITA.






Compound	Structural formula	MS (M+H) ⁺	¹ H NMR
10		404.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.81 (s, 1H), 8.82 (s, 2H), 8.42 - 8.18 (m, 4H), 7.96 (s, 1H), 7.79 - 7.75 (m, 1H), 7.24 (s, 1H), 6.73 - 6.71 (m, 1H), 3.83 (s, 3H), 3.56 (s, 3H).
11		430.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.76 (s, 1H), 8.81 (s, 1H), 8.43 - 8.17 (m, 4H), 7.96 (s, 1H), 7.76 (d, J = 8.4 Hz, 1H), 7.24 (s, 1H), 6.73 (s, 1H), 4.16 (t, J = 6.9 Hz, 2H), 3.83 (s, 3H), 3.18 (t, J = 7.6 Hz, 2H), 2.33 - 2.11 (m, 2H).
12		435.1	¹ H NMR (400 MHz, CD ₃ OD) δ 8.45 (dd, J = 9.0, 4.0 Hz, 2H), 8.37 (d, J = 5.8 Hz, 1H), 8.24 (d, J = 2.8 Hz, 1H), 7.99 (s, 1H), 7.91 (s, 1H), 7.61 (dd, J = 9.0, 2.8 Hz, 1H), 7.54 (s, 1H), 7.10 (d, J = 2.3 Hz, 1H), 6.76 (dd, J = 5.8, 2.4 Hz, 1H), 3.96 (s, 3H), 3.72 (s, 3H), 2.54 (d, J = 2.9 Hz, 3H).
13		418.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.47 (s, 1H), 8.55 (s, 1H), 8.39 (d, J = 5.7 Hz, 1H), 8.36 - 8.21 (m, 3H), 7.99 (s, 1H), 7.76 (dd, J = 9.0, 2.7 Hz, 1H), 7.27 (d, J = 1.9 Hz, 1H), 6.75 (dd, J = 5.6, 2.1 Hz, 1H), 3.86 (s, 3H), 3.48 (s, 3H), 2.44 (s, 3H).
14		475.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.85 (s, 1H), 8.74 (s, 1H), 8.43 - 8.26 (m, 4H), 7.97 (s, 1H), 7.78 - 7.74 (m, 1H), 7.25 (s, 1H), 6.73 - 6.70 (m, 1H), 4.19 - 4.16 (m, 2H), 3.57 (s, 3H), 2.65 - 2.61 (m, 5H), 2.13 (s, 6H).




Compound	Structural formula	MS (M+H) ⁺	¹ H NMR
15		432.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.71 (s, 1H), 8.61 - 8.43 (m, 3H), 8.38 - 8.34 (m, 2H), 8.24 - 8.21 (m, 1H), 7.86 - 7.74 (m, 1H), 7.44 (s, 1H), 7.05 (s, 1H), 6.68 - 6.64 (m, 1H), 5.26 - 5.10 (m, 1H), 3.89 (s, 3H), 1.36 (d, J = 6.7 Hz, 6H).
16		450.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.88 (s, 1H), 10.83 (s, 1H), 8.76 (s, 1H), 8.37 (d, J = 9.0 Hz, 1H), 8.32 (d, J = 2.6 Hz, 1H), 8.17 (d, J = 5.8 Hz, 1H), 7.81 (dd, J = 9.0, 2.7 Hz, 1H), 6.99 (s, 1H), 6.63 - 6.56 (m, 1H), 6.53 (s, 1H), 3.60 (s, 3H), 2.66 (s, 3H), 2.31 (s, 3H).
17		430.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.27 (s, 1H), 8.42 (d, J = 7.1 Hz, 1H), 8.33 (d, J = 5.7 Hz, 1H), 8.26 - 8.15 (m, 2H), 7.92 (s, 1H), 7.78 (d, J = 8.8 Hz, 2H), 7.19 - 7.15 (m, 3H), 6.75 - 6.56 (m, 2H), 5.24 - 5.19 (m, 1H), 3.82 (s, 3H), 1.35 (d, J = 6.8 Hz, 6H).
18		460.0	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.38 (s, 1H), 8.54 (d, J = 8.8 Hz, 1H), 8.42 (dd, J = 7.2, 1.5 Hz, 1H), 8.33 (d, J = 5.7 Hz, 1H), 8.22 (s, 1H), 8.16 (dd, J = 6.7, 1.6 Hz, 1H), 7.93 (s, 1H), 7.19 (d, J = 2.2 Hz, 1H), 6.96 (d, J = 2.3 Hz, 1H), 6.74 (dd, J = 8.8, 2.3 Hz, 1H), 6.67 - 6.55 (m, 2H), 5.30 - 5.20 (m, 1H), 3.84 (d, J = 16.8 Hz, 6H), 1.33 (d, J = 6.8 Hz, 6H).





Compound	Structural formula	MS (M+H) ⁺	¹ HNMR
19		444.0	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.18 (s, 1H), 8.45 (d, J = 6.8 Hz, 1H), 8.38 (d, J = 8.8 Hz, 1H), 8.33 (d, J = 5.7 Hz, 1H), 8.22 (s, 1H), 8.20 (d, J = 6.5 Hz, 1H), 7.94 (s, 1H), 7.20 (s, 1H), 7.10 (s, 1H), 7.02 (dd, J = 8.8, 2.0 Hz, 1H), 6.66 (m, 1H), 6.61 (dd, J = 5.3, 1.7 Hz, 1H), 5.26 (m, 1H), 3.83 (s, 3H), 2.34 (s, 3H), 1.35 (d, J = 6.8 Hz, 6H).
20		448.2	¹ H NMR (400MHz, a mixture of CD ₃ OD and CDCl ₃) δ 8.56 - 8.45 (m, 2H), 8.31 (d, J = 5.6 Hz, 1H), 8.02 (s, 1H), 7.97 (dd, J = 6.7, 2.0 Hz, 1H), 7.90 (s, 1H), 7.13 (d, J = 2.2 Hz, 1H), 7.03 (dd, J = 11.2, 2.6 Hz, 1H), 6.96 (d, J = 8.8 Hz, 1H), 6.74 (dd, J = 5.8, 2.3 Hz, 1H), 6.64 (m, 1H), 5.34 (m, 1H), 3.90 (s, 3H), 1.43 (d, J = 6.8 Hz, 6H).
21		421.0	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.24 (s, 1H), 8.43 (dd, J = 7.3, 2.1 Hz, 1H), 8.39 (d, J = 5.6 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.19 (dd, J = 6.5, 2.1 Hz, 1H), 7.99 (dd, J = 10.4, 2.4 Hz, 1H), 7.70 (s, 1H), 7.62 (s, 1H), 7.31 (s, 1H), 6.87 (dd, J = 5.5, 2.3 Hz, 1H), 6.63 - 6.56 (m, 1H), 3.67 (s, 3H), 3.62 (s, 3H).





Compound	Structural formula	MS (M+H) ⁺	¹ HNMR
22		421.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.25 (s, 1H), 8.43 (dd, J = 7.3, 2.1 Hz, 1H), 8.40 (d, J = 5.7 Hz, 1H), 8.27 (s, 1H), 8.24 (d, J = 2.3 Hz, 1H), 8.18 (dd, J = 6.5, 2.0 Hz, 1H), 7.98 (s, 1H), 7.93 (dd, J = 10.5, 2.3 Hz, 1H), 7.32 (d, J = 2.2 Hz, 1H), 6.80 (dd, J = 5.7, 2.3 Hz, 1H), 6.60 (m, 1H), 3.83 (s, 3H), 3.62 (s, 3H).
23		436.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.40 (s, 1H), 8.69 (s, 1H), 8.41 (d, J = 5.7 Hz, 1H), 8.28 (s, 1H), 8.26 (d, J = 2.3 Hz, 1H), 7.98 (s, 1H), 7.94 (dd, J = 10.4, 2.3 Hz, 1H), 7.32 (d, J = 2.1 Hz, 1H), 6.81 (dd, J = 5.7, 2.3 Hz, 1H), 3.85 (s, 3H), 3.58 (s, 3H), 2.63 (s, 3H).
24		445.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.08 (s, 1H), 8.42 (d, J = 7.1 Hz, 1H), 8.38 (d, J = 5.6 Hz, 1H), 8.26 (s, 1H), 8.22 - 8.17 (m, 2H), 7.97 (s, 1H), 7.64 (s, 1H), 7.29 (d, J = 1.6 Hz, 1H), 6.70 (d, J = 3.5 Hz, 1H), 6.64 (m, 1H), 5.23 (m, 1H), 3.84 (s, 3H), 2.25 (s, 3H), 1.36 (d, J = 6.7 Hz, 6H).
25		456.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.66 (s, 1H), 8.67 (s, 1H), 8.49 - 8.45 (m, 1H), 8.42 - 8.39 (m, 2H), 8.28 (s, 2H), 7.99 (s, 1H), 7.33 (s, 1H), 6.84 - 6.81 (m, 1H), 6.70 - 6.66 (m, 1H), 5.31 - 5.16 (m, 1H), 3.84 (s, 3H), 1.37 (d, J = 6.6 Hz, 6H).




Compound	Structural formula	MS (M+H) ⁺	¹ H NMR
26		440.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.66 (s, 1H), 9.25 (d, J = 6.9 Hz, 1H), 9.13 (s, 1H), 8.44-8.34 (m, 2H), 8.30 - 8.21 (m, 3H), 7.98-7.89 (m, 2H), 7.76 (dd, J = 8.9, 2.7 Hz, 1H), 7.65 (m, 1H), 7.23 (d, J = 2.1 Hz, 1H), 6.71 (dd, J = 5.6, 2.3 Hz, 1H), 3.82 (s, 3H).
27		429.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.56 (s, 1H), 8.43 (d, J = 7.5 Hz, 1H), 8.38 (d, J = 3.5 Hz, 1H), 8.36 (s, 1H), 8.28 (d, J = 2.9 Hz, 1H), 8.25 (s, 1H), 7.96 (s, 1H), 7.73 (dd, J = 9.0, 2.8 Hz, 1H), 7.23 (d, J = 2.4 Hz, 1H), 6.71 (dd, J = 5.7, 2.4 Hz, 1H), 6.58 (d, J = 7.5 Hz, 1H), 4.16 (t, J = 7.3 Hz, 2H), 3.83 (s, 3H), 3.21 (t, J = 7.8 Hz, 2H), 2.26 - 2.11 (m, 2H).
28		440.0	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.69 (s, 1H), 9.27 (d, J = 7.0 Hz, 1H), 9.15 (s, 1H), 8.40 (d, J = 9.0 Hz, 1H), 8.37 (d, J = 5.7 Hz, 1H), 8.33 (d, J = 2.8 Hz, 1H), 8.29 - 8.22 (m, 1H), 7.95 (d, J = 8.8 Hz, 1H), 7.81 (dd, J = 9.0, 2.9 Hz, 1H), 7.71 - 7.63 (m, 2H), 7.58 (s, 1H), 7.26 (d, J = 2.5 Hz, 1H), 6.82 (dd, J = 5.6, 2.6 Hz, 1H), 3.66 (s, 3H).
29		390.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.67 (s, 1H), 9.35 (s, 1H), 8.48 (dd, J = 7.4, 2.2 Hz, 1H), 8.42 (d, J = 5.8 Hz, 1H), 8.39 (d, J = 9.0 Hz, 1H), 8.36 (d, J = 2.9 Hz, 1H), 8.23 (s, 1H), 8.18 (dd, J = 6.5, 2.2 Hz, 1H), 7.84 (dd, J = 9.0, 2.9 Hz, 1H), 7.27 (d, J = 2.4 Hz, 1H), 7.09 (dd, J = 5.8, 2.4 Hz, 1H), 6.68 - 6.54 (m, 1H), 3.62 (s, 3H).





Compound	Structural formula	MS (M+H) ⁺	¹ H NMR
30		418.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.87 (s, 1H), 8.74 (s, 1H), 8.44 - 8.26 (m, 3H), 7.86-7.76 (m, 1H), 7.68 (s, 1H), 7.59 (s, 1H), 7.26 (s, 1H), 6.90-6.75 (m, 1H), 3.67 (s, 3H), 3.58 (s, 3H), 2.63 (s, 3H).
31		418.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.85 (s, 1H), 8.73 (s, 1H), 8.47 (d, J = 5.6 Hz, 1H), 8.40-8.26 (m, 2H), 7.78 (dd, J = 8.9, 2.5 Hz, 1H), 7.72 (s, 1H), 7.48 (s, 1H), 7.35 (d, J = 1.8 Hz, 1H), 6.86-6.75 (m, 1H), 3.91 (s, 3H), 3.57 (s, 3H), 2.63 (s, 3H).
32		418.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.86 (s, 1H), 8.74 (s, 1H), 8.46 - 8.26 (m, 4H), 7.80 (d, J = 7.2 Hz, 1H), 7.64 (s, 1H), 7.40 (s, 1H), 6.86 (d, J = 4.1 Hz, 1H), 3.58 (s, 3H), 2.63 (s, 3H), 2.13 (s, 3H).
33		415.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.86 (s, 1H), 9.23 (dd, J = 2.3, 0.7 Hz, 1H), 8.74 (s, 1H), 8.62 (dd, J = 4.8, 1.6 Hz, 1H), 8.58 (d, J = 5.7 Hz, 1H), 8.42 - 8.37 (m, 1H), 8.35 (m, 2H), 7.81 (dd, J = 9.0, 3.0 Hz, 1H), 7.70 (d, J = 2.4 Hz, 1H), 7.48 (m, 1H), 6.95 (dd, J = 5.7, 2.4 Hz, 1H), 3.58 (s, 3H), 2.63 (s, 3H).
34		415.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.04-11.95 (br, 1H), 8.92 - 8.81 (m, 1H), 8.76-8.64 (m, 2H), 8.77-8.62 (m, 3H), 8.10-7.99 (m, 1H), 7.99-7.86 (m, 2H), 7.61-7.46 (m, 1H), 7.32 - 7.15 (m, 1H), 3.76 - 3.63 (m, 3H), 2.79-2.68 (m, 3H).





Compound	Structural formula	MS (M+H) ⁺	¹ H NMR
35		444.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.89 (s, 1H), 9.43 (s, 1H), 8.77 (s, 1H), 8.38 (d, J = 9.0 Hz, 1H), 8.34 (d, J = 2.7 Hz, 1H), 8.19 (d, J = 5.8 Hz, 1H), 8.15 (d, J = 5.7 Hz, 1H), 7.83 (dd, J = 9.0, 2.9 Hz, 1H), 7.49 (s, 1H), 7.43 (dd, J = 5.7, 1.8 Hz, 1H), 6.63 (dd, J = 5.8, 2.2 Hz, 1H), 6.33 (d, J = 2.1 Hz, 1H), 3.61 (s, 3H), 2.66 (s, 3H), 2.36 (s, 3H).
36		444.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.88 (s, 1H), 9.64 (s, 1H), 8.77 (s, 1H), 8.38 (d, J = 9.0 Hz, 1H), 8.33 (d, J = 2.8 Hz, 1H), 8.12 (d, J = 5.7 Hz, 1H), 7.82 (dd, J = 9.0, 2.8 Hz, 1H), 7.64 (d, J = 2.2 Hz, 1H), 7.49 (m, 1H), 7.28 (d, J = 8.3 Hz, 1H), 6.66 (d, J = 7.3 Hz, 1H), 6.58 (dd, J = 5.7, 2.3 Hz, 1H), 3.60 (s, 3H), 2.66 (s, 3H), 2.16 (s, 3H).
37		389.0	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.67 (s, 1H), 8.58 (d, J = 2.6 Hz, 1H), 8.48 (dd, J = 7.3, 2.1 Hz, 1H), 8.40 (d, J = 9.0 Hz, 1H), 8.37 - 8.35 (m, 2H), 8.18 (dd, J = 6.5, 2.2 Hz, 1H), 7.84 (dd, J = 9.0, 2.9 Hz, 1H), 7.74 (d, J = 1.5 Hz, 1H), 7.30 (d, J = 2.4 Hz, 1H), 6.99 (dd, J = 5.8, 2.4 Hz, 1H), 6.62 - 6.59 (m, 1H), 6.55 - 6.53 (m, 1H), 3.62 (s, 3H).

Compound	Structural formula	MS (M+H) ⁺	¹ H NMR
38		432.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.85 (s, 1H), 8.74 (s, 1H), 8.38 (d, J = 5.7 Hz, 1H), 8.34 (d, J = 9.2 Hz, 1H), 8.31 - 8.29 (m, 2H), 7.97 (s, 1H), 7.77 (dd, J = 9.0, 2.9 Hz, 1H), 7.25 (d, J = 2.4 Hz, 1H), 6.73 (dd, J = 5.7, 2.4 Hz, 1H), 4.12 (q, J = 12 Hz, 8 Hz, 2H), 3.58 (s, 3H), 2.63 (s, 3H), 1.36 (t, J = 12 Hz, 3H).
39		446.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.85 (s, 1H), 8.74 (s, 1H), 8.38 (d, J = 5.7 Hz, 1H), 8.35 - 8.33 (m, 2H), 8.30 (d, J = 2.8 Hz, 1H), 7.97 (s, 1H), 7.76 (dd, J = 9.0, 2.9 Hz, 1H), 7.28 (d, J = 2.4 Hz, 1H), 6.72 (dd, J = 5.7, 2.4 Hz, 1H), 4.48 (dd, J = 13.3, 6.7 Hz, 1H), 3.58 (s, 3H), 2.63 (s, 3H), 1.42 (s, 3H), 1.40 (s, 3H).
40		434.0	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.56 (s, 1H), 8.78 (s, 1H), 8.38 - 8.36 (m, 1H), 8.33 - 8.28 (m, J = 2H), 8.25 (s, 1H), 7.96 (s, 1H), 7.78 - 7.74 (m, 1H), 7.24 (s, 1H), 6.73 - 6.71 (m, 1H), 3.84 (s, 3H), 3.49 (s, 3H), 3.26 (s, 3H).
41		415.0	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.87 (s, 1H), 8.74 (s, 1H), 8.67 - 8.66 (m, 2H), 8.61 (d, J = 5.6 Hz, 1H), 8.38 - 8.32 (m, 2H), 8.03 - 8.02 (m, 2H), 7.82 (dd, J = 8.9, 3.0 Hz, 1H), 7.76 (d, J = 2.3 Hz, 1H), 7.02 (dd, J = 5.6, 2.4 Hz, 1H), 3.58 (s, 3H), 2.63 (s, 3H).

Compound	Structural formula	MS (M+H) ⁺	¹ H NMR
42		433.0	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.84 (s, 1H), 9.19 (s, 1H), 8.75 (s, 1H), 8.34 (d, J = 9.0 Hz, 1H), 8.27 (d, J = 2.9 Hz, 1H), 8.01 (d, J = 5.8 Hz, 1H), 7.75 (dd, J = 9.0, 2.9 Hz, 1H), 7.45 (d, J = 2.2 Hz, 1H), 6.90 (d, J = 2.2 Hz, 1H), 6.33 (dd, J = 5.7, 2.3 Hz, 1H), 6.17 (d, J = 2.2 Hz, 1H), 3.65 (s, 3H), 3.59 (s, 3H), 2.64 (s, 3H).
43		433.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.85 (s, 1H), 8.74 (s, 1H), 8.73 (s, 1H), 8.34 (d, J = 9.0 Hz, 1H), 8.29 (d, J = 3.5 Hz, 1H), 8.01 (d, J = 5.8 Hz, 1H), 7.77 (dd, J = 6.7, 3.3 Hz, 1H), 7.26 (d, J = 1.9 Hz, 1H), 6.46 (dd, J = 5.8, 2.3 Hz, 1H), 6.19 - 6.18 (m, 2H), 3.60 (s, 3H), 3.58 (s, 3H), 2.63 (s, 3H).
44		445.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.79 (s, 1H), 8.82 (s, 1H), 8.37 - 8.35 (m, 1H), 8.32 (d, J = 2.9 Hz, 1H), 8.11 (s, 1H), 8.08 (d, J = 9.0 Hz, 1H), 7.81 (dd, J = 9.0, 2.9 Hz, 1H), 7.57 (s, 1H), 6.74 (s, 1H), 6.57 (s, 1H), 6.10 (d, J = 2.2 Hz, 1H), 4.15 (t, J = 6.6 Hz, 2H), 3.72 (s, 3H), 3.18 (t, J = 6.6 Hz, 2H), 2.25 - 2.19 (m, 2H).
45		445.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.78 (s, 1H), 8.84 (s, 1H), 8.76 (s, 1H), 8.35 (d, J = 9.0 Hz, 1H), 8.29 (d, J = 2.8 Hz, 1H), 8.03 (d, J = 5.8 Hz, 1H), 7.89 (s, 1H), 7.77 (dd, J = 9.0, 2.9 Hz, 1H), 7.33 (s, 1H), 6.34 (dd, J = 5.8, 2.2 Hz, 1H), 6.05 (d, J = 2.1 Hz, 1H), 4.18 (t, J = 8.0 Hz, 2H), 3.78 (s, 3H), 3.21 (t, J = 8.0 Hz, 2H), 2.29 - 2.20 (m, 2H).




Compound	Structural formula	MS (M+H) ⁺	¹ H NMR
46		418.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.64 (s, 1H), 9.21 (s, 1H), 8.50 (dd, J = 7.3, 2.1 Hz, 1H), 8.38 (d, J = 9.0 Hz, 1H), 8.28 (d, J = 2.8 Hz, 1H), 8.20 (dd, J = 6.5, 2.0 Hz, 1H), 8.02 (d, J = 5.8 Hz, 1H), 7.75 (dd, J = 9.0, 2.9 Hz, 1H), 7.47 (d, J = 2.1 Hz, 1H), 6.91 (d, J = 1.7 Hz, 1H), 6.64 - 6.61 (m, 1H), 6.35 (dd, J = 5.8, 2.3 Hz, 1H), 6.19 (d, J = 2.0 Hz, 1H), 3.66 (s, 3H), 3.64 (s, 3H).
47		445.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.79 (s, 1H), 8.83 (s, 1H), 8.76 (s, 1H), 8.36 (d, J = 9.0 Hz, 1H), 8.31 (d, J = 2.8 Hz, 1H), 8.03 (d, J = 5.8 Hz, 1H), 7.80 (dd, J = 9.0, 2.9 Hz, 1H), 7.28 (d, J = 1.8 Hz, 1H), 6.48 (dd, J = 5.8, 2.2 Hz, 1H), 6.22 - 6.20 (m, 2H), 4.17 (t, J = 8.0 Hz, 2H), 3.62 (s, 3H), 3.21 (t, J = 8.0 Hz, 2H), 2.28-2.20 (m, 2H).
48		418.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.65 (s, 1H), 8.75 (s, 1H), 8.50 (dd, J = 7.4, 2.1 Hz, 1H), 8.39 (d, J = 9.0 Hz, 1H), 8.30 (d, J = 2.8 Hz, 1H), 8.20 (dd, J = 6.5, 2.1 Hz, 1H), 8.03 (d, J = 5.8 Hz, 1H), 7.78 (dd, J = 9.0, 2.9 Hz, 1H), 7.28 (d, J = 1.8 Hz, 1H), 6.64 - 6.61 (m, 1H), 6.48 (dd, J = 5.8, 2.2 Hz, 1H), 6.21 - 6.20 (m, 2H), 3.64 (s, 3H), 3.62 (s, 3H).





Compound	Structural formula	MS (M+H) ⁺	¹ H NMR
49		454.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.88 (s, 1H), 8.85 (s, 1H), 8.76 (s, 1H), 8.47 (d, J = 5.7 Hz, 1H), 8.39 - 8.36 (m, 2H), 8.34 (d, J = 2.8 Hz, 1H), 7.99 (s, 0.25H), 7.83 (s, 0.5H), 7.81 (dd, J = 9.0, 2.9 Hz, 1H), 7.69 (s, 0.25H), 7.48 (d, J = 2.3 Hz, 1H), 6.87 (dd, J = 5.7, 2.4 Hz, 1H), 3.60 (s, 3H), 2.66 (s, 3H).
50		432.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.88 (s, 1H), 8.76 (s, 1H), 8.56 (d, J = 5.6 Hz, 1H), 8.39-8.35 (m, 2H), 8.14 - 8.10 (m, 2H), 7.83 (dd, J = 9.0, 2.9 Hz, 1H), 7.58 (d, J = 2.2 Hz, 1H), 7.32 - 7.27 (m, 2H), 6.92 (dd, J = 5.6, 2.3 Hz, 1H), 3.60 (s, 3H), 2.66 (s, 3H).
51		414.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.88 (s, 1H), 8.76 (s, 1H), 8.57 (d, J = 5.6 Hz, 1H), 8.39 - 8.36 (m, 2H), 8.07 - 8.04 (m, 2H), 7.83 (dd, J = 9.0, 2.9 Hz, 1H), 7.57 (d, J = 2.3 Hz, 1H), 7.50 - 7.43 (m, 3H), 6.93 (dd, J = 5.6, 2.4 Hz, 1H), 3.60 (s, 3H), 2.65 (s, 3H).
52		417.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.39 (s, 1H), 8.69 (s, 1H), 8.36 (d, J = 5.8 Hz, 1H), 8.25 (s, 1H), 7.96 (s, 1H), 7.81 - 7.78 (m, 2H), 7.23 (d, J = 2.1 Hz, 1H), 7.21 - 7.18 (m, 2H), 6.66 (dd, J = 5.7, 2.1 Hz, 1H), 3.84 (s, 3H), 3.58 (s, 3H), 2.63 (s, 3H).

Compound	Structural formula	MS (M+H) ⁺	¹ HNMR
53		447.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.64 (s, 1H), 8.70 (s, 1H), 8.51 (d, J = 8.8 Hz, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.24 (s, 1H), 7.94 (s, 1H), 7.21 (d, J = 2.4 Hz, 1H), 6.99 (d, J = 2.5 Hz, 1H), 6.77 (dd, J = 8.8, 2.5 Hz, 1H), 6.66 (dd, J = 5.5, 2.2 Hz, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 3.57 (s, 3H), 2.62 (s, 3H).
54		451.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.86 (s, 1H), 8.74 (s, 1H), 8.60 (d, J = 9.1 Hz, 1H), 8.37 (d, J = 5.7 Hz, 1H), 8.26 (s, 1H), 7.96 (s, 1H), 7.48 (d, J = 5.7 Hz, 1H), 7.25 - 7.22 (m, 2H), 6.70 (dd, J = 5.7, 2.1 Hz, 1H), 3.84 (s, 3H), 3.58 (s, 3H), 2.63 (s, 3H).
55		417.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.66 (s, 1H), 8.47 (dd, J = 7.3, 2.2 Hz, 1H), 8.37 (s, 1H), 8.36-8.34 (m, 1H), 8.28 (dd, J = 2.9, 0.6 Hz, 1H), 8.25 (s, 1H), 8.21-8.16 (m, 1H), 7.95 (d, J = 0.7 Hz, 1H), 7.74 (dd, J = 9.0, 3.0 Hz, 1H), 7.27-7.21 (m, 1H), 6.71 (dd, J = 5.7, 2.4 Hz, 1H), 6.62 (dd, J = 7.3, 6.5 Hz, 1H), 4.10 (q, J = 7.1 Hz, 2H), 3.82 (s, 3H), 1.29 (t, J = 7.1 Hz, 3H).
56		432.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.85 (s, 1H), 8.90 (s, 1H), 8.82 (s, 1H), 8.37 (d, J = 5.7 Hz, 1H), 8.33 (d, J = 9.0 Hz, 1H), 8.30 (d, J = 2.9 Hz, 1H), 8.25 (s, 1H), 7.95 (s, 1H), 7.77 (dd, J = 9.0, 2.9 Hz, 1H), 7.24 (d, J = 2.4 Hz, 1H), 6.71 (dd, J = 5.7, 2.3 Hz, 1H), 5.06-4.95 (m, 1H), 3.83 (s, 3H), 1.44 (d, J = 6.8 Hz, 6H).

Compound	Structural formula	MS (M+H) ⁺	¹ HNMR
57		465.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.52 (s, 1H), 8.44 (d, J = 2.9, 1H), 8.38-8.32 (m, 2H), 8.29 (d, J = 2.9 Hz, 1H), 8.24 (s, 1H), 8.11 (s, 1H), 7.95 (s, 1H), 7.75 (dd, J = 9.0, 2.9 Hz, 1H), 7.23 (d, J = 2.4 Hz, 1H), 6.70 (dd, J = 5.6, 2.3 Hz, 1H), 5.25-5.06 (m, 1H), 3.82 (s, 3H), 1.37 (d, J = 6.8 Hz, 6H).
58		401.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.18 (s, 1H), 8.38-8.33 (m, 2H), 8.31 (d, J = 2.7 Hz, 1H), 8.26 (s, 1H), 8.10 (d, J = 3.9 Hz, 1H), 7.96 (s, 1H), 7.77 (dd, J = 9.0, 2.9 Hz, 1H), 7.70 (d, J = 3.9 Hz, 1H), 7.24 (d, J = 2.4 Hz, 1H), 6.72 (dd, J = 5.7, 2.4 Hz, 1H), 3.83 (s, 3H), 3.59 (s, 3H).
59		432.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 10.91 (s, 1H), 8.38-8.34 (m, 2H), 8.33-8.26 (s, 2H), 8.26 (s, 1H), 8.24 (d, J = 2.6 Hz, 1H), 7.96 (s, 1H), 7.76 (dd, J = 9.0, 2.8 Hz, 1H), 7.26 (d, J = 2.3 Hz, 1H), 6.78-6.62 (m, 1H), 5.31 (m, 1H), 3.83 (s, 3H), 1.32 (d, J = 6.1 Hz, 6H).
60		432.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.33 (s, 1H), 8.37 (d, J = 5.7 Hz, 1H), 8.34 (d, J = 6.7 Hz, 1H), 8.33 (s, 1H), 8.31 (d, J = 4.2 Hz, 1H), 8.25 (s, 1H), 8.21 (d, J = 4.2 Hz, 1H), 7.96 (s, 1H), 7.79 (dd, J = 8.9, 3.0 Hz, 1H), 7.25 (d, J = 2.4 Hz, 1H), 6.72 (dd, J = 5.7, 2.4 Hz, 1H), 5.3-5.24 (m, 1H), 3.83 (s, 3H), 1.33 (d, J = 6.6 Hz, 6H).

Compound	Structural formula	MS (M+H) ⁺	¹ HNMR
61		439.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.03 (s, 1H), 8.40 -8.35 (m, 2H), 8.33-8.28 (m, 2H), 8.27 (s, 1H), 8.14 (dd, J = 7.5, 1.9 Hz, 1H), 7.97 (s, 1H), 7.89 (s, 0.25H), 7.77 (dd, J = 9.0, 3.0 Hz, 1H), 7.71 (s, 0.5H), 7.53 (s, 0.25H), 7.39 (dd, J = 7.4, 5.0 Hz, 1H), 7.27 (d, J = 2.4 Hz, 1H), 6.73 (dd, J = 5.7, 2.4 Hz, 1H), 3.84 (s, 3H).
62		435.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.88 (s, 1H), 8.76 (s, 1H), 8.43 (d, J = 5.8 Hz, 1H), 8.37 (d, J = 9.0 Hz, 1H), 8.34 (d, J = 2.9 Hz, 2H), 7.81 (dd, J = 9.0, 2.9 Hz, 1H), 7.64 (d, J = 2.4 Hz, 1H), 6.86 (dd, J = 5.8, 2.4 Hz, 1H), 3.60 (s, 3H), 2.67 (s, 3H), 2.65 (s, 3H).
63		433.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.86 (s, 1H), 8.76 (s, 1H), 8.74 (s, 1H), 8.35 (d, J = 8.9 Hz, 1H), 8.29 (d, J = 2.9 Hz, 1H), 8.02 (d, J = 5.8 Hz, 1H), 7.88 (s, 1H), 7.77 (dd, J = 9.0, 2.9 Hz, 1H), 7.32 (d, J = 0.6 Hz, 1H), 6.34 (dd, J = 5.8, 2.3 Hz, 1H), 6.04 (d, J = 2.2 Hz, 1H), 3.77 (s, 3H), 3.60 (s, 3H), 2.65 (s, 3H).
64		454.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.89 (s, 1H), 9.33 (s, 1H), 8.76 (s, 1H), 8.57 (d, J = 5.7 Hz, 1H), 8.44-8.33 (m, 2H), 8.03 (s, 1H), 7.93 (dd, J = 9.5, 1.6 Hz, 1H), 7.84 (dd, J = 9.0, 2.9 Hz, 1H), 7.63 (dd, J = 6.7, 4.5 Hz, 3H), 6.96 (dd, J = 5.6, 2.3 Hz, 1H), 3.60 (s, 3H), 2.66 (s, 3H).


Compound	Structural formula	MS (M+H) ⁺	¹ HNMR
69		481.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.78 (s, 1H), 9.68 (s, 1H), 8.84 (s, 1H), 8.35 (d, J = 9.0 Hz, 1H), 8.30 (d, J = 2.8 Hz, 1H), 8.09 (d, J = 5.8 Hz, 1H), 8.00 (d, J = 2.7 Hz, 1H), 7.78 (dd, J = 9.0, 2.9 Hz, 1H), 7.58 (t, J = 59.3 Hz, 1H), 6.98 (d, J = 2.1 Hz, 1H), 6.57 (d, J = 2.7 Hz, 1H), 6.44 (dd, J = 5.8, 2.3 Hz, 1H), 4.25-4.12 (m, 2H), 3.23-3.13 (m, 2H), 2.28-2.17 (m, 2H).
70		431.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.69 (s, 1H), 8.53 (d, J = 5.7 Hz, 1H), 8.46 (dd, J = 7.3, 2.1 Hz, 1H), 8.36 (d, J = 9.1 Hz, 1H), 8.31 (d, J = 2.8 Hz, 1H), 8.22 (dd, J = 6.7, 2.1 Hz, 1H), 7.77 (dd, J = 9.0, 2.9 Hz, 1H), 7.43 (d, J = 2.0 Hz, 1H), 7.39 (d, J = 2.4 Hz, 1H), 6.90 (dd, J = 5.7, 2.5 Hz, 1H), 6.76 (d, J = 2.0 Hz, 1H), 6.65 (m, 1H), 5.31-5.10 (m, 1H), 4.09 (s, 3H), 1.35 (d, J = 6.8 Hz, 6H).
71		431.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.71 (s, 1H), 8.48-8.45 (m, 1H), 8.44 (d, J = 5.8 Hz, 1H), 8.38 (d, J = 9.0 Hz, 1H), 8.32 (d, J = 2.9 Hz, 1H), 8.22 (dd, J = 6.7, 1.9 Hz, 1H), 7.78 (dd, J = 9.0, 2.9 Hz, 1H), 7.72 (d, J = 2.2 Hz, 1H), 7.26 (d, J = 2.6 Hz, 1H), 6.98-6.91 (m, 1H), 6.75 (dd, J = 2.2, 0.5 Hz, 1H), 6.66 (m, 1H), 5.21 (m, 1H), 3.82 (s, 3H), 1.36 (d, J = 6.8 Hz, 6H).

Compound	Structural formula	MS (M+H) ⁺	¹ H NMR
72		453.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.68 (s, 1H), 9.08 (s, 1H), 8.44 (d, J = 9.0 Hz, 1H), 8.40 (d, J = 5.7 Hz, 1H), 8.35 (d, J = 2.9 Hz, 1H), 8.29 (s, 1H), 8.12 (d, J = 7.9 Hz, 1H), 7.99 (s, J = 4.2 Hz, 1H), 7.88 - 7.79 (m, 2H), 7.74 (d, J = 8.6 Hz, 1H), 7.48 - 7.42 (m, 1H), 7.27 (d, J = 2.4 Hz, 1H), 6.76 (dd, J = 5.7, 2.4 Hz, 1H), 3.86 (s, 3H), 3.82 (s, 3H).
73		446.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.88 (s, 1H), 8.84 (s, 1H), 8.39 (d, J = 5.7 Hz, 1H), 8.37 (d, J = 9.0 Hz, 1H), 8.32 (d, J = 2.9 Hz, 1H), 8.28 (s, 1H), 7.98 (s, 1H), 7.79 (dd, J = 9.0, 2.9 Hz, 1H), 7.27 (d, J = 2.4 Hz, 1H), 6.75 (dd, J = 5.7, 2.4 Hz, 1H), 3.86 (s, 3H), 3.67 (s, 3H), 3.43 - 3.34 (m, 1H), 1.27 (d, J = 6.6 Hz, 6H).
74		444.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.86 (s, 1H), 8.72 (s, 1H), 8.39 (d, J = 5.7 Hz, 1H), 8.36 (d, J = 9.0 Hz, 1H), 8.31 (d, J = 2.9 Hz, 1H), 8.27 (s, 1H), 7.98 (s, 1H), 7.78 (dd, J = 9.0, 2.9 Hz, 1H), 7.26 (d, J = 2.4 Hz, 1H), 6.74 (dd, J = 5.7, 2.0 Hz, 1H), 3.85 (s, 3H), 3.77 (s, 3H), 2.41 - 2.33 (m, 1H), 1.25 - 1.20 (m, 4H).
75		450.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.67 (s, 1H), 8.75 (s, 1H), 8.45 - 8.33 (m, 2H), 8.29 (d, J = 2.8 Hz, 1H), 8.02 (d, J = 5.8 Hz, 1H), 7.88 (s, 1H), 7.76 (dd, J = 9.0, 2.9 Hz, 1H), 7.32 (s, 1H), 6.34 (dd, J = 5.8, 2.2 Hz, 1H), 6.04 (d, J = 2.1 Hz, 1H), 3.77 (s, 3H), 3.64 (s, 3H), 2.48 (s, 3H).

Compound	Structural formula	MS (M+H) ⁺	¹ H NMR
76		450.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.67 (s, 1H), 8.75 (s, 1H), 8.44 - 8.35 (m, 2H), 8.31 (d, J = 2.8 Hz, 1H), 8.03 (d, J = 5.8 Hz, 1H), 7.79 (dd, J = 9.0, 2.9 Hz, 1H), 7.28 (d, J = 1.8 Hz, 1H), 6.48 (dd, J = 5.8, 2.2 Hz, 1H), 6.26 - 6.17 (m, 2H), 3.63 (s, 3H), 3.62 (s, 3H), 2.48 (s, 3H).
77		436.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.66 (s, 1H), 8.75 (s, 1H), 8.56 - 8.50 (m, 1H), 8.49 - 8.42 (m, 1H), 8.38 (d, J = 9.0 Hz, 1H), 8.32 (d, J = 2.7 Hz, 1H), 8.03 (d, J = 5.8 Hz, 1H), 7.79 (dd, J = 9.0, 2.9 Hz, 1H), 7.28 (d, J = 1.8 Hz, 1H), 6.48 (dd, J = 5.8, 2.2 Hz, 1H), 6.29 - 6.12 (m, 2H), 3.62 (s, J = 1.4 Hz, 3H), 3.62 (s, 3H).
78		436.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.65 (s, 1H), 8.75 (s, 1H), 8.54 - 8.49 (m, 1H), 8.49 - 8.42 (m, 1H), 8.36 (d, J = 9.0 Hz, 1H), 8.29 (d, J = 2.8 Hz, 1H), 8.02 (d, J = 5.8 Hz, 1H), 7.88 (s, 1H), 7.77 (dd, J = 9.0, 2.9 Hz, 1H), 7.32 (s, 1H), 6.34 (dd, J = 5.8, 2.2 Hz, 1H), 6.04 (d, J = 2.1 Hz, 1H), 3.77 (s, 3H), 3.62 (s, 3H).

Compound 79

4-methoxy-1-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide



(A) 4-methoxy-*N*-(5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide

Under nitrogen, 5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine (100 mg, 0.37 mmol), 2-hydroxyl-4-methoxynicotinic acid (76 mg, 0.45 mmol),

- 5 HATU(213 mg, 0.56 mmol), DMF(5 ml) and TEA (155 μ l, 1.1 mmol) were successively added to a reaction flask, and the mixture was heated to 40°C and stirred overnight. The reaction solution was purified with flash column chromatography (water (0.5% formic acid): methanol =100 : 0 - 0 : 100, gradient elution), to obtain 80 mg of the title product as a white solid. MS (m/z): 419.2 [M+H]⁺.


10 **(B) 4-methoxy-1-methyl-*N*-(5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide**

Under nitrogen, 4-methoxy-*N*-(5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide (80 mg, 0.2 mmol), iodomethane (74 mg, 0.52 mmol), potassium carbonate (72 mg, 0.52 mmol) and DMF(5

- 15 ml) were successively added to a reaction flask, and the mixture was stirred at room temperature for 1 hour and completely reacted. The reaction solution was purified with flash column chromatography (water (0.5% formic acid): methanol =100 : 0 - 0 : 100, gradient elution) and p-TLC plate, to obtain 60 mg of the title product as a white solid. MS (m/z): 433.2 [M+H]⁺.


- 20 ¹H NMR (400 MHz, DMSO-d₆) δ 11.33 (s, 1H), 8.38 (d, J = 5.7 Hz, 1H), 8.31 (d, J = 9.0 Hz, 1H), 8.28 (s, 1H), 8.26 (d, J = 2.9 Hz, 1H), 7.98 (s, 1H), 7.93 (d, J = 7.7 Hz, 1H), 7.72 (dd, J = 9.0, 2.9 Hz, 1H), 7.25 (d, J = 2.4 Hz, 1H), 6.73 (dd, J = 5.7, 2.4 Hz, 1H), 6.42 (d, J = 7.8 Hz, 1H), 3.86 (s, 3H), 3.85 (s, 3H), 3.45 (s, 3H).

- The following compounds were prepared with corresponding intermediates and
25 reagents with reference to the preparation processes of compound 79 under suitable conditions recognized by the POSITA.

Compound	Structural formula	MS (M+H) ⁺	¹ H NMR
80		421.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.67 (s, 1H), 8.56 - 8.50 (m, 1H), 8.46 (dd, J = 8.1, 3.5 Hz, 1H), 8.42 - 8.36 (m, 2H), 8.33 (d, J = 2.8 Hz, 1H), 8.28 (s, 1H), 7.98 (d, J = 0.5 Hz, 1H), 7.79 (dd, J = 9.0, 2.9 Hz, 1H), 7.27 (d, J = 2.4 Hz, 1H), 6.74 (dd, J = 5.7, 2.4 Hz, 1H), 3.86 (s, 3H), 3.63 (s, 3H).

Compound 81

1-(2-(dimethylamino)ethyl)-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide










Under nitrogen, *N*-(5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide (80 mg, 0.21 mmol), 2-bromo-*N,N*-dimethylethyl-1-amine hydrochloride salt (144 mg, 0.63 mmol), cesium carbonate (267 mg, 0.82 mmol) and DMF (5 ml) were successively added to a reaction flask, and the mixture was heated to 80°C and stirred overnight. The reaction solution was cooled to room temperature, and then purified with flash column chromatography (water (0.5% ammonia): methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 50 mg of the title product as a white solid. MS (*m/z*): 460.2 [*M*+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ 12.66 (s, 1H), 8.50 (dd, J = 7.4, 2.2 Hz, 1H), 8.40 (s, 1H), 8.38 (d, J = 3.7 Hz, 1H), 8.31 (d, J = 2.8 Hz, 1H), 8.28 (s, 1H), 8.13 (dd, J = 6.5, 2.2 Hz, 1H), 7.98 (d, J = 0.5 Hz, 1H), 7.77 (dd, J = 9.0, 2.9 Hz, 1H), 7.26 (d, J = 2.4 Hz, 1H), 6.74 (dd, J = 5.7, 2.4 Hz, 1H), 6.66 - 6.59 (m, 1H), 4.19 (t, J = 6.1 Hz, 2H), 3.85 (s, 3H), 2.59 (t, J = 6.1 Hz, 2H), 2.20 (s, 6H).

The following compounds were prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 81 under suitable conditions recognized by the POSITA.

Compound	Structural formula	MS (M+H) ⁺	¹ H NMR
82		447.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.61 (s, 1H), 8.52 (dd, J = 7.4, 2.2 Hz, 1H), 8.40 (s, 1H), 8.38 (d, J = 3.1 Hz, 1H), 8.31 (d, J = 2.9 Hz, 1H), 8.28 (s, 1H), 8.10 (dd, J = 6.5, 2.2 Hz, 1H), 7.98 (d, J = 0.5 Hz, 1H), 7.78 (dd, J = 9.0, 2.9 Hz, 1H), 7.26 (d, J = 2.4 Hz, 1H), 6.74 (dd, J = 5.7, 2.4 Hz, 1H), 6.67 - 6.60 (m, 1H), 4.29 (t, J = 5.1 Hz, 2H), 3.86 (s, 3H), 3.68 (t, J = 5.2 Hz, 2H), 3.26 (s, 3H).
83		445.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.45 (s, 1H), 8.54 (dd, J = 7.4, 2.0 Hz, 1H), 8.43 - 8.35 (m, 2H), 8.30 (d, J = 2.9 Hz, 1H), 8.28 (s, 1H), 8.21 (dd, J = 6.7, 2.0 Hz, 1H), 7.98 (s, 1H), 7.78 (dd, J = 9.0, 2.9 Hz, 1H), 7.26 (d, J = 2.4 Hz, 1H), 6.77 - 6.69 (m, 2H), 5.68 - 5.54 (m, 1H), 4.94 (t, J = 7.5 Hz, 2H), 4.84 (t, J = 7.2 Hz, 2H), 3.85 (s, 3H).
84		433.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.66 (s, 1H), 8.52 (dd, J = 7.4, 2.2 Hz, 1H), 8.40 (d, J = 2.1 Hz, 1H), 8.39 (s, 1H), 8.31 (d, J = 2.9 Hz, 1H), 8.28 (s, 1H), 8.08 (dd, J = 6.5, 2.2 Hz, 1H), 7.98 (s, 1H), 7.77 (dd, J = 9.0, 2.9 Hz, 1H), 7.26 (d, J = 2.4 Hz, 1H), 6.74 (dd, J = 5.7, 2.4 Hz, 1H), 6.66 - 6.59 (m, 1H), 5.15 - 4.86 (m, 1H), 4.16 (t, J = 5.2 Hz, 2H), 3.86 (s, 3H), 3.73 (t, J = 5.2 Hz, 2H).


Compound	Structural formula	MS (M+H) ⁺	¹ H NMR
85		403.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.66 (s, 1H), 8.50 (dd, J = 7.4, 2.2 Hz, 1H), 8.40 (d, J = 2.6 Hz, 1H), 8.39 (s, 1H), 8.31 (d, J = 2.9 Hz, 1H), 8.28 (s, 1H), 8.21 (dd, J = 6.5, 2.2 Hz, 1H), 7.99 (d, J = 4.0 Hz, 1H), 7.77 (dd, J = 9.0, 2.9 Hz, 1H), 7.27 (d, J = 2.4 Hz, 1H), 6.74 (dd, J = 5.7, 2.4 Hz, 1H), 6.66 - 6.59 (m, 1H), 3.86 (s, 3H), 3.64 (s, 3H).
86		431.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.69 (s, 1H), 8.56 - 8.13 (m, 6H), 7.96 (s, 1H), 7.76 - 7.74 (m, 1H), 7.24 (s, 1H), 6.69 - 6.66 (m, 2H), 5.23 - 5.18 (m, 1H), 3.83 (s, 3H), 1.36 (s, 6H).
87		471.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.25 (s, 1H), 8.56 (dd, J = 7.2, 1.6 Hz, 1H), 8.37 - 8.33 (m, 2H), 8.28 (d, J = 2.8 Hz, 1H), 8.24 (s, 1H), 8.15 (d, J = 6.4 Hz, 1H), 7.95 (s, 1H), 7.74 (dd, J = 9.0, 2.8 Hz, 1H), 7.22 (d, J = 2.2 Hz, 1H), 6.79 - 6.65 (m, 2H), 5.08 (q, J = 8.9 Hz, 2H), 3.82 (s, 3H).
88		429.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.57 (s, 1H), 8.51 - 8.48 (m, 1H), 8.42 - 8.30 (m, 2H), 8.30 - 8.18 (m, 2H), 8.13 - 8.10 (m, 1H), 7.95 (s, 1H), 7.75 - 7.71 (m, 1H), 7.22 (s, 1H), 6.74 - 6.55 (m, 2H), 6.15 - 5.85 (m, 1H), 5.19 - 5.14 (m, 2H), 4.72 - 4.68 (m, 2H), 3.82 (s, 3H).

Compound	Structural formula	MS (M+H) ⁺	¹ HNMR
89		443.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.60 (s, 1H), 8.48 - 8.45 (m, 1H), 8.37 - 8.33 (m, 2H), 8.31 - 8.23 (m, 2H), 8.20 - 8.17 (m, 1H), 7.96 (s, 1H), 7.75 - 7.72 (m, 1H), 7.26 - 7.23 (m, 1H), 6.73 - 6.70 (m, 1H), 6.65 - 6.61 (m, 1H), 5.02 - 4.98 (m, 1H), 3.82 (s, 3H), 2.43 - 2.38 (m, 2H), 2.34 - 2.22 (m, 2H), 1.81 - 1.77 (m, 2H).
90		471.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.34 (s, 1H), 8.57 - 8.54 (m, 1H), 8.43 - 8.16 (m, 4H), 7.97 (s, 1H), 7.80 - 7.77 (m, 1H), 7.26 - 7.22 (m, 2H), 6.75 - 6.70 (m, 1H), 3.84 (s, 3H), 3.65 (s, 3H).
91		417.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.64 (s, 1H), 8.38 - 8.34 (m, 3H), 8.27 (d, J = 2.5 Hz, 1H), 8.25 (s, 1H), 7.95 (s, 1H), 7.73 (dd, J = 8.8, 2.6 Hz, 1H), 7.23 (s, 1H), 6.71 (d, J = 3.4 Hz, 1H), 6.55 (d, J = 7.6 Hz, 1H), 3.83 (s, 3H), 3.58 (s, 3H), 2.49 (s, 3H).

Compound 92

1-isopropyl-N-(3-methoxy-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide

-116-



(A) N-(5-bromo-3-methoxypyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide

The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 79(A). MS (m/z): 366.0 [M+H]⁺.

(B) (6-(1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamido)-5-methoxypyridin-3-yl)boronic acid

Under nitrogen, N-(5-bromo-3-methoxypyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide (360 mg, 1.0 mmol), pinacol borate (508 mg, 2 mmol), potassium acetate (294 mg, 3 mmol), dioxane (10 ml) and Pd(dppf)Cl₂ (73 mg, 0.1 mmol) were successively added to a reaction flask, and the mixture was refluxed and stirred overnight. The reaction solution was cooled to room temperature and then concentrated, the residue was purified with flash column chromatography (water (0.5% formic acid): methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 330 mg of the title product as a white solid. MS (m/z): 332.1 [M+H]⁺.

(C) N-(5-hydroxy-3-methoxypyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide

Under nitrogen, (6-(1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamido)-5-methoxypyridin-3-yl)boronic acid (330 mg, 1.0 mmol) and tetrahydrofuran (20 ml) were successively added to a reaction flask, and 1N sodium hydroxide aqueous solution (2 ml) and 30% hydrogen peroxide (567 mg, 5 mmol) were successively added dropwise, and

the mixture was stirred at room temperature for half an hour. After adjusting pH to 4 with 1N hydrochloric acid aqueous solution, saturated sodium thiosulfate aqueous solution (1 ml) was added dropwise, and the reaction solution was concentrated. The residue was purified with flash column chromatography (water (0.5% formic acid): methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 240 mg of the title product as a light yellow solid. MS (m/z): 304.1 [M+H]⁺.


(D) *N*-(5-((2-chloropyridin-4-yl)oxy)-3-methoxypyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide

Under nitrogen, *N*-(5-hydroxy-3-methoxypyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide (240 mg, 0.8 mmol), 2-chloro-4-fluoropyridine (126 mg, 0.96 mmol), potassium *t*-butoxide (135 mg, 1.2 mmol) and DMSO (6 ml) were successively added to a reaction flask, and the mixture was heated to 90°C and stirred for 6 hours. The reaction solution was cooled to room temperature, and then added water (40 ml), stirred for half an hour, and then filtered. The solid was washed with water and dried, to obtain 180 mg of the title product as a brown solid. MS (m/z): 415.1 [M+H]⁺.

(E) 1-isopropyl-*N*-(3-methoxy-5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide

Under nitrogen, *N*-(5-((2-chloropyridin-4-yl)oxy)-3-methoxypyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide (90 mg, 0.22 mmol), 1-methyl-4-pyrazole pinacol borate (69 mg, 0.33 mmol), potassium carbonate (59 mg, 0.43 mmol), dioxane/water (10 ml / 2 ml) and Pd(dppf)Cl₂ (15 mg, 0.02 mmol) were successively added to a reaction flask, and the mixture was refluxed and stirred overnight. The reaction solution was cooled to room temperature and then concentrated, the residue was purified with flash column chromatography (water (0.5% formic acid): methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 70 mg of the title product as a white solid. MS (m/z): 461.2 [M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ 12.38 (s, 1H), 8.43 (dd, *J* = 7.2, 1.9 Hz, 1H), 8.40 (d, *J* = 5.7 Hz, 1H), 8.29 (s, 1H), 8.22 (dd, *J* = 6.7, 2.0 Hz, 1H), 7.99 (s, 1H), 7.90 (d, *J* = 2.3 Hz, 1H), 7.48 (d, *J* = 2.2 Hz, 1H), 7.28 (d, *J* = 2.2 Hz, 1H), 6.76 (dd, *J* = 5.7, 2.3 Hz, 1H), 6.70 - 6.59 (m, 1H), 5.35 - 5.18 (m, 1H), 3.89 (s, 3H), 3.86 (s, 3H), 1.38 (d, *J* = 6.8 Hz, 6H).

Compound 93**1-isopropyl-N-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide****5 (A) 3-((2-bromopyridin-4-yl)oxy)-2-methyl-6-nitropyridine**

Under nitrogen, 2-methyl-6-nitropyridin-3-ol (616 mg, 4 mmol), 2-bromo-4-fluoropyridine (739 mg, 4.2 mmol), cesium carbonate (1.95 g, 6 mmol) and DMF (15 ml) were successively added to a reaction flask, and the mixture was heated to 90°C and stirred for 6 hours. The reaction solution was cooled to room temperature, and then added water (80 ml), stirred for half an hour, and then filtered. The solid was washed with water and dried, to obtain 460 mg of the title product as a brown solid. MS (m/z): 310.0 [M+H]⁺.

(B) 2-methyl-3-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)-6-nitropyridine

The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 92(E). MS (m/z): 312.1 [M+H]⁺.

(C) 6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine

2-methyl-3-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)-6-nitropyridine (250 mg, 0.8 mmol), methanol (20 ml) and palladium carbon (100 mg) were successively added to a reaction flask, after replacing hydrogen with hydrogen balloon, the reaction solution was stirred under normal pressure at room temperature overnight. The reaction solution was filtered, and the filtrate was concentrated, the residue was purified with flash column chromatography (water (0.5% formic acid): methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 180 mg of the title product as a brown solid. MS (m/z): 282.1 [M+H]⁺.

(D) 1-isopropyl-N-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide


The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 79(A). MS (m/z): 445.2 [M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ 12.65 (s, 1H), 8.49 (dd, J = 7.2, 2.0 Hz, 1H), 8.37 (d, J = 5.7 Hz, 1H), 8.32 - 8.17 (m, 3H), 7.98 (s, 1H), 7.66 (d, J = 8.8 Hz, 1H), 7.20 (d, J = 2.3 Hz, 1H), 6.74 - 6.58 (m, 2H), 5.30 - 5.14 (m, 1H), 3.85 (s, 3H), 2.30 (s, 3H), 1.40 (d, J = 6.8 Hz, 6H).

Compound 94

***N*-(5-((2-(1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide**

10



(A) *N*-(5-((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide

Under nitrogen, 5-((2-chloropyridin-4-yl)oxy)pyridin-2-amine (850 mg, 3.84 mmol), 2-hydroxynicotinic acid (640 mg, 4.6 mmol), HATU (2.2 g, 5.8 mmol), DMF (12 ml) and TEA (1.3 ml, 9.6 mmol) were successively added to a reaction flask, and the mixture was heated to 40°C and stirred overnight. The reaction solution was cooled to room temperature, and then added water (80 ml), stirred for two hours, and then filtered. The solid was washed with water and dried, to obtain 900 mg of the title product as a light yellow solid. MS (m/z): 343.0 [M+H]⁺.

(B) *N*-(5-((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide

Under nitrogen, *N*-(5-((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide (900 mg, 2.6 mmol), iodomethane (479 μl, 7.7 mmol), potassium carbonate (1.06 g, 7.7 mmol) and DMF (10 ml) were successively added to a reaction flask, and the mixture was stirred at room temperature for 1 hour and completely reacted. Water (80 ml) was added, the reaction solution was stirred for 1 hour, and then

25

filtered. The solid was washed with water and dried, to obtain 800 mg of the title product as a light yellow solid. MS (m/z): 357.0 [M+H]⁺.

(C) *N*-(5-((2-(1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide

5 Under nitrogen, *N*-(5-((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide (100 mg, 0.28 mmol), 4-pyrazole pinacol borate (82 mg, 0.42 mmol), potassium carbonate (77 mg, 0.56 mmol), dioxane/water (10 ml /2 ml) and Pd(dppf)Cl₂ (21 mg, 0.03 mmol) were successively added to a reaction flask, and the mixture was refluxed and stirred for 2 hours. The reaction solution was cooled to room
10 temperature and then concentrated, the residue was purified with flash column chromatography (water (0.5% formic acid): methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 80 mg of the title product as a light yellow solid. MS (m/z): 389.1 [M+H]⁺.

(D) *N*-(5-((2-(1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide

Under nitrogen, *N*-(5-((2-(1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide (80 mg, 0.21 mmol), 2-bromoethyl acetate (167 mg, 1 mmol), cesium carbonate (326 mg, 1 mmol) and DMF (5 ml) were successively added to a reaction flask, and the mixture was heated to 80°C and stirred
20 overnight. The reaction solution was cooled to room temperature, and then added dropwise 2N sodium hydroxide aqueous solution (2 ml), and stirred at room temperature for 2 hours. The reaction solution was purified with flash column chromatography (water (0.5% formic acid): methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 40 mg of the title product as a white solid. MS (m/z): 433.1 [M+H]⁺.


25 ¹H NMR (400 MHz, DMSO-d₆) δ 12.66 (s, 1H), 8.50 (dd, J = 7.3, 1.9 Hz, 1H), 8.43 - 8.35 (m, 2H), 8.35 - 8.25 (m, 2H), 8.20 (dd, J = 6.4, 1.9 Hz, 1H), 8.01 (s, 1H), 7.77 (dd, J = 9.0, 2.8 Hz, 1H), 7.29 (d, J = 2.1 Hz, 1H), 6.74 (dd, J = 5.6, 2.3 Hz, 1H), 6.67 - 6.57 (m, 1H), 4.94 (t, J = 5.2 Hz, 1H), 4.15 (t, J = 5.5 Hz, 2H), 3.80 - 3.69 (m, 2H), 3.64 (s, 3H).

30 The following compounds were prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 94 (steps A-C) under suitable conditions recognized by the POSITA.

Compound	Structural formula	MS (M+H) ⁺	¹ H NMR
127		444.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.41 (s, 1H), 8.51 (d, J = 7.2 Hz, 1H), 8.34 (d, J = 9.0 Hz, 1H), 8.30 (d, J = 5.7 Hz, 1H), 8.25 (d, J = 2.1 Hz, 1H), 8.17 (d, J = 6.5 Hz, 1H), 7.76-7.69 (m, 1H), 7.34 (s, 1H), 7.08 (s, 1H), 6.68 (d, J = 7.3 Hz, 2H), 6.60 (d, J = 5.5 Hz, 1H), 6.51 (s, 1H), 5.57 (p, J = 7.3 Hz, 1H), 4.90 (t, J = 7.3 Hz, 2H), 4.81 (t, J = 7.0 Hz, 2H), 3.60 (s, 3H).

Compound 95

***N*-(5-((2-(1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide**



(A) *N*-(5-((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide

The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 94(A). MS (m/z): 385.1 [M+H]⁺.

(B) *N*-(5-((2-(1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide

The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 94(C). MS (m/z): 417.1 [M+H]⁺.


(C) *N*-(5-((2-(1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide

The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 94(D). MS (m/z): 461.2[M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ 12.72 (s, 1H), 8.50 (dd, J = 7.3, 2.1 Hz, 1H), 8.40 (s, 1H), 8.39 (d, J = 2.5 Hz, 1H), 8.31 (d, J = 2.9 Hz, 1H), 8.29 (s, 1H), 8.26 (dd, J = 6.7, 2.1 Hz, 1H), 8.01 (s, 1H), 7.77 (dd, J = 9.0, 2.9 Hz, 1H), 7.29 (d, J = 2.3 Hz, 1H), 6.74 (dd, J = 5.7, 2.4 Hz, 1H), 6.72 - 6.66 (m, 1H), 5.30 - 5.18 (m, 1H), 4.93 (t, J = 5.3 Hz, 1H), 4.15 (t, J = 5.6 Hz, 2H), 3.79 - 3.70 (m, 2H), 1.39 (d, J = 6.8 Hz, 6H).

Compound 96


10 **1-isopropyl-N-(5-((2-((1-methyl-1H-pyrazol-4-yl)amino)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide**



Under nitrogen, *N*-(5-((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide (50 mg, 0.13 mmol), 1-methyl-1*H*-pyrazol-4-amine (38 mg, 0.39 mmol), BINAP (8 mg, 0.013 mmol), tert-butoxysodium (25 mg, 0.26 mmol), dioxane (10 ml) and Pd₂(dba)₃ (12 mg, 0.013 mmol) were successively added to a reaction flask, and the mixture was refluxed and stirred for 2 hours. The reaction solution was cooled to room temperature and then concentrated, the residue was purified with flash column chromatography (water (0.5% formic acid): methanol = 100 : 0 - 0 : 100, gradient elution) and p-TLC plate, to obtain 25 mg of the title product as a light yellow solid. MS (m/z): 446.2 [M+H]⁺.


¹H NMR (400 MHz, DMSO-d₆) δ 12.71 (s, 1H), 8.78 (s, 1H), 8.49 (dd, J = 7.3, 2.1 Hz, 1H), 8.38 (d, J = 9.0 Hz, 1H), 8.28 (d, J = 2.8 Hz, 1H), 8.25 (dd, J = 6.7, 2.1 Hz, 1H), 8.02 (d, J = 5.8 Hz, 1H), 7.89 (s, 1H), 7.76 (dd, J = 9.0, 2.9 Hz, 1H), 7.32 (s, 1H), 6.73 - 6.64 (m, 1H), 6.34 (dd, J = 5.8, 2.2 Hz, 1H), 6.04 (d, J = 2.2 Hz, 1H), 5.29 - 5.18 (m, 1H), 3.77 (s, 3H), 1.39 (d, J = 6.8 Hz, 6H).

The following compounds were prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 96 under suitable conditions recognized by the POSITA.

Compound	Structural formula	MS (M+H) ⁺	¹ H NMR
97		418.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.65 (s, 1H), 8.77 (s, 1H), 8.50 (dd, J = 7.3, 2.1 Hz, 1H), 8.38 (d, J = 9.0 Hz, 1H), 8.28 (d, J = 2.8 Hz, 1H), 8.20 (dd, J = 6.5, 2.1 Hz, 1H), 8.02 (d, J = 5.8 Hz, 1H), 7.89 (s, 1H), 7.76 (dd, J = 9.0, 2.9 Hz, 1H), 7.32 (s, 1H), 6.67 - 6.57 (m, 1H), 6.34 (dd, J = 5.8, 2.2 Hz, 1H), 6.03 (d, J = 2.1 Hz, 1H), 3.77 (s, 3H), 3.64 (s, 3H).

Compound 98


***N*-(5-((2-(4-ethylpiperazin-1-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide**



N-(5-((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide (50 mg, 0.13 mmol), 1-ethylpiperazine (74 mg, 0.65 mmol) and NMP (4.0 ml) were added to a microwave tube, and the mixture was reacted at 160°C under microwave for 1.5 hours, the reaction solution was purified with flash column chromatography (H₂O/MeOH = 100 : 0-0 : 100, gradient elution), to obtain 25 mg of the title product as a yellow solid. MS (m/z): 463.2 [M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ 12.64 (s, 1H), 8.44 (s, 1H), 8.39-8.26 (m, 1H), 8.26-8.11 (m, 2H), 7.97 (s, 1H), 7.78-7.56 (m, 1H), 6.75-6.54 (m, 1H), 6.31 (s, 1H), 6.17 (s, 1H), 5.19 (s, 1H), 3.36 - 3.30 (m, 4H), 2.41-2.20 (m, 6H), 1.35 (s, 6H), 0.97 (s, 3H).

Compound 99





1-methyl-*N*-(5-((2-(2-methyl-2*H*-1,2,3-triazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide


5 *N*-(5-((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide (120 mg, 0.336 mmol), (2-methyl-2*H*-1,2,3-triazol-4-yl)boronic acid (85 mg, 0.673 mmol), Na₂CO₃ (106 mg, 1.008 mmol), Pd(dppf)Cl₂·CH₂Cl₂ (27 mg, 0.0336 mmol), dioxane (23.0 ml) and water (3.0 ml) were added to a reaction flask, and the mixture was heated to 110°C and stirred overnight, after cooling, the reaction solution
10 was purified with flash column chromatography (H₂O/MeOH= 100 : 0-0 : 100, gradient elution), to obtain 65 mg of the title product as a white solid. MS (*m/z*): 404.2 [M+H]⁺.

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.67 (s, 1H), 8.51 (d, *J* = 5.7 Hz, 1H), 8.48 (dd, *J* = 7.4, 2.2 Hz, 1H), 8.39 (d, *J* = 9.0 Hz, 1H), 8.34 (d, *J* = 2.9 Hz, 1H), 8.20-8.15 (m, 2H), 7.81 (dd, *J* = 9.0, 2.9 Hz, 1H), 7.28 (d, *J* = 2.5 Hz, 1H), 7.02 (dd, *J* = 5.7, 2.5 Hz, 1H),
15 6.64-6.55 (m, 1H), 4.15 (s, 3H), 3.61 (s, 3H).

The following compounds were prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 99 under suitable conditions recognized by the POSITA.


Compound	Structural formula	MS (M+H) ⁺	¹ H NMR
100		431.2	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 12.70 (s, 1H), 8.46 (dd, <i>J</i> = 7.3, 2.1 Hz, 1H), 8.40-8.33 (m, 2H), 8.30 (d, <i>J</i> = 2.8 Hz, 1H), 8.22 (dd, <i>J</i> = 6.7, 2.1 Hz, 1H), 8.14 (s, 1H), 7.77 (dd, <i>J</i> = 9.0, 2.9 Hz, 1H), 7.66 (s, 1H), 7.58 (s, 1H), 7.24 (d, <i>J</i> = 2.6 Hz, 1H), 6.81 (dd, <i>J</i> = 5.7, 2.6 Hz, 1H), 6.73 - 6.59 (m, 1H), 5.21 (m, 1H), 3.65 (s, 3H), 1.36 (d, <i>J</i> = 6.8 Hz, 6H).

101		442.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.68 (s, 1H), 9.08 (s, 1H), 8.53 (d, J = 5.6 Hz, 1H), 8.45 (d, J = 5.7 Hz, 1H), 8.36 (d, J = 8.9 Hz, 1H), 8.33 - 8.16 (m, 3H), 7.77 (dd, J = 8.9, 2.6 Hz, 1H), 7.63 (s, 1H), 7.31 (d, J = 8.0 Hz, 1H), 6.95-6.83 (m, 1H), 6.65 (m, 1H), 5.30 - 5.08 (m, 1H), 2.47 (s, 3H), 1.35 (d, J = 6.7 Hz, 6H).
102		431.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.71 (s, 1H), 8.70-8.11 (m, 5H), 7.91-7.62 (m, 2H), 7.49 (s, 1H), 7.36 (s, 1H), 6.81 (s, 1H), 6.67 (s, 1H), 5.40-5.08 (m, 1H), 3.91 (s, 3H), 1.60-1.24 (br, 6H).
103		432.2	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.72 (s, 1H), 8.54 (s, 1H), 8.49-8.47 (m, 1H), 8.47 - 8.46 (m, 1H), 8.39 (d, J = 9.1 Hz, 1H), 8.34 (d, J = 2.5 Hz, 1H), 8.23 (dd, J = 6.7, 2.1 Hz, 1H), 7.81 (dd, J = 9.0, 2.9 Hz, 1H), 7.44 (d, J = 2.6 Hz, 1H), 6.95 (dd, J = 5.7, 2.6 Hz, 1H), 6.75 - 6.58 (m, 1H), 5.33 - 5.12 (m, 1H), 4.07 (s, 3H), 1.35 (s, 6H).
115		414.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.67 (s, 1H), 9.12 (d, J = 1.9 Hz, 1H), 8.57 (d, J = 5.7 Hz, 1H), 8.50 (dd, J = 7.3, 2.0 Hz, 1H), 8.40 (d, J = 9.0 Hz, 1H), 8.35 (d, J = 2.8 Hz, 1H), 8.31 (dd, J = 8.1, 2.3 Hz, 1H), 8.20 (dd, J = 6.5, 2.0 Hz, 1H), 7.81 (dd, J = 9.0, 2.9 Hz, 1H), 7.68 (d, J = 2.2 Hz, 1H), 7.35 (d, J = 8.1 Hz, 1H), 6.93 (dd, J = 5.6, 2.3 Hz, 1H), 6.65 - 6.58 (m, 1H), 3.64 (s, 3H), 2.51 (s, 3H).

125		430.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.64 (s, 1H), 8.46 (dd, J = 7.3, 2.1 Hz, 1H), 8.36 (d, J = 9.0 Hz, 1H), 8.30 (d, J = 5.7 Hz, 1H), 8.27 (d, J = 2.9 Hz, 1H), 8.22 (dd, J = 6.7, 2.1 Hz, 1H), 7.73 (dd, J = 9.0, 2.9 Hz, 1H), 7.36-7.32 (m, 1H), 7.08 (d, J = 2.4 Hz, 1H), 6.71-6.69 (m, 1H), 6.68-6.63 (m, 1H), 6.61 (dd, J = 5.7, 2.4 Hz, 1H), 6.51 (dd, J = 2.6, 1.8 Hz, 1H), 5.27 - 5.14 (m, 1H), 3.60 (s, 3H), 1.36 (d, J = 6.8 Hz, 6H).
-----	---	-------	---

Compound 104

1-cyclopropyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide




5

N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide (100 mg, 0.26 mmol), cyclopropyl boronic acid (66 mg, 0.78 mmol), 2,2'-bipyridine (8 mg, 0.05 mmol), copper acetate (55 mg, 0.30 mmol), triethylamine (53 mg, 0.52 mmol), molecular sieve (200 mg) and 1,2-dichloroethane (10 ml) were successively added to a reaction flask, and the mixture was reacted under oxygen at 70°C for 24 hours. The reaction solution was filtered, and the filtrate was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 10.1 mg of the title product as a yellow solid. MS (m/z): 429.2 [M+H]⁺.


¹H NMR (400 MHz, a mixed solution of CD₃OD and CDCl₃) δ 8.54 (dd, J = 7.3, 2.1 Hz, 1H), 8.40 (d, J = 9.0 Hz, 1H), 8.32 (d, J = 5.8 Hz, 1H), 8.19 (d, J = 2.9 Hz, 1H), 8.02 (s, 1H), 7.93 - 7.85 (m, 2H), 7.60 (dd, J = 9.0, 2.9 Hz, 1H), 7.13 (d, J = 2.4 Hz, 1H), 6.73 (dd, J = 5.8, 2.4 Hz, 1H), 6.55 (t, J = 7.0 Hz, 1H), 3.90 (s, 3H), 3.49 - 3.38 (m, 1H), 1.22 - 1.13 (m, 2H), 0.99 - 0.95 (m, 2H).

15

Compound 105**6-amino-1-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide**

5 6-chloro-1-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide (80 mg, 0.18 mmol), ammonium chloride (46 mg, 0.90 mmol), potassium carbonate (50 mg, 0.36 mmol) and DMSO (5 ml) were successively added to a reaction flask, and the mixture was reacted at room temperature for 15 hours. The reaction solution was filtered, and the filtrate was purified with flash
 10 column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 6.3 mg of the title product as a yellow solid. MS (m/z): 418.1[M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ 12.41 (s, 1H), 8.36 - 8.33 (m, 2H), 8.24 (s, 1H), 8.20 (d, J = 2.7 Hz, 1H), 8.05 (d, J = 8.8 Hz, 1H), 7.95 (s, 1H), 7.76 - 7.61 (m, 3H), 7.21 (d, J = 2.1 Hz, 1H), 6.68 (dd, J = 5.6, 2.3 Hz, 1H), 5.81 (d, J = 8.8 Hz, 1H), 3.82 (s, 3H),
 15 3.39 (s, 3H).

Compound 106**1-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-(methylamino)-2-oxo-1,2-dihydropyridine-3-carboxamide**


20 6-chloro-1-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide (80 mg, 0.18 mmol) and methylamine alcohol solution (5 ml) were successively added to a reaction flask, and the mixture was reacted at 80°C for 2 hours. The reaction solution was filtered, and the filtrate was
 25 purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 23.0 mg of the title product as a yellow solid. MS (m/z): 432.1[M+H]⁺.

^1H NMR (400 MHz, DMSO- d_6) δ 12.43 (s, 1H), 8.40 - 8.30 (m, 2H), 8.24 (s, 1H), 8.21 (d, J = 2.9 Hz, 1H), 8.17 (d, J = 8.9 Hz, 1H), 7.95 (s, 1H), 7.68 - 7.65 (m, 2H), 7.21 (d, J = 2.3 Hz, 1H), 6.68 (dd, J = 5.6, 2.2 Hz, 1H), 5.80 (d, J = 9.0 Hz, 1H), 3.82 (s, 3H), 3.41 (s, 3H), 2.85 (s, 3H).

5

Compound 107

1-methyl-*N*-(5-((2-(1-methyl-1*H*-imidazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide



10 (A) *N*-(5-((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide

The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 79(A). MS (m/z): 343.0 $[\text{M}+\text{H}]^+$.

15 (B) *N*-(5-((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide

Under nitrogen, *N*-(5-((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide (387 mg, 1.13 mmol), iodomethane (241 mg, 1.70 mmol), potassium carbonate (312 mg, 2.26 mmol) and DMSO (5 ml) were successively added to a reaction flask, and the mixture was reacted at 60°C for 1 hour. The reaction solution was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 203 mg of the title product as a yellow solid. MS (m/z): 356.7 $[\text{M}+\text{H}]^+$.



20 (C) 1-methyl-*N*-(5-((2-(1-methyl-1*H*-imidazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide

Under nitrogen, *N*-(5-((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide (130 mg, 0.37 mmol), 1-methyl-4-(tributylstannyl)-1*H*-imidazole (208 mg, 0.56 mmol), $\text{Pd}(\text{PPh}_3)_4$ (13 mg, 0.01 mmol) and DMF (5 ml) were successively added to a reaction flask, and the mixture was reacted at 100°C for 2 hours. The reaction solution was concentrated, and the residue was purified with flash column

chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 64.5 mg of the title product as a yellow solid. MS (m/z): 403.0 [M+H]⁺.


¹H NMR (400 MHz, DMSO-d₆) δ 12.65 (s, 1H), 8.47 (d, J = 6.9 Hz, 1H), 8.39 - 8.35 (m, 2H), 8.30 (s, 1H), 8.18 (d, J = 5.6 Hz, 1H), 7.78 (d, J = 7.7 Hz, 1H), 7.67 (s, 1H),
5 7.58 (s, 1H), 7.25 (s, 1H), 6.81 (s, 1H), 6.61 - 6.57 (m, 1H), 3.66 (s, 3H), 3.61 (s, 3H).

The following compounds were prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 107 under suitable conditions recognized by the POSITA.

Compound	Structural formula	MS (M+H) ⁺	¹ H NMR
108		449.0	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.29 (s, 1H), 8.45 - 8.37 (m, 2H), 8.27 (s, 1H), 8.25 - 8.21 (m, 2H), 7.98 (s, 1H), 7.93 (dd, J = 10.4, 1.9 Hz, 1H), 7.32 (d, J = 1.9 Hz, 1H), 6.80 (dd, J = 5.5, 2.1 Hz, 1H), 6.68 - 6.65 (m, 1H), 5.28 - 5.13 (m, 1H), 3.84 (s, 3H), 1.36 (d, J = 6.7 Hz, 6H).
114		420.1	¹ H NMR (400 MHz, CDCl ₃) δ 12.64 (s, 1H), 8.62 (dd, J = 7.3, 2.1 Hz, 1H), 8.48 (d, J = 9.0 Hz, 1H), 8.43 (d, J = 5.8 Hz, 1H), 8.24 (d, J = 2.8 Hz, 1H), 8.03 (s, 1H), 7.62 (dd, J = 6.6, 2.1 Hz, 1H), 7.50 (dd, J = 9.0, 2.9 Hz, 1H), 7.18 (d, J = 2.3 Hz, 1H), 6.73 (dd, J = 5.8, 2.3 Hz, 1H), 6.51 - 6.46 (m, 1H), 3.71 (s, 3H), 2.74 (s, 3H).

***N*-(5-((2-(1-(2-aminoethyl)-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide**

-130-



(A) tert-butyl (2-(4-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)-1H-pyrazol-1-yl)ethyl)carbamate

4-((6-nitropyridin-3-yl)oxy)-2-(1H-pyrazol-4-yl)pyridine (350 mg, 1.24 mmol), tert-butyl (2-bromoethyl)carbamate (415 mg, 1.85 mmol), cesium carbonate (601 mg, 1.85 mmol) and acetonitrile (20 ml) were successively added to a reaction flask, and the mixture was reacted at 80°C for 5 hours. The reaction solution was purified with flash column chromatography (dichloromethane/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 362 mg of the title product as a yellow solid. MS (m/z): 427.2[M+H]⁺.

(B) tert-butyl (2-(4-(4-((6-aminopyridin-3-yl)oxy)pyridin-2-yl)-1H-pyrazol-1-yl)ethyl)carbamate

Tert-butyl (2-(4-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)-1H-pyrazol-1-yl)ethyl)carbamate (110 mg, 0.26 mmol) and palladium carbon (11 mg) were dissolved in methanol (10 ml), and the mixture was stirred under hydrogen at room temperature for 5 hours. The reaction solution was filtered to remove palladium carbon, and the filtrate was concentrated, which was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 93 mg of the title product. MS (m/z): 397.2[M+H]⁺.

(C) tert-butyl (2-(4-(4-((6-(1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxamido)pyridin-3-yl)oxy)pyridin-2-yl)-1H-pyrazol-1-yl)ethyl)carbamate

Tert-butyl (2-(4-(4-((6-aminopyridin-3-yl)oxy)pyridin-2-yl)-1H-pyrazol-1-yl)ethyl)carbamate (93 mg, 0.23 mmol), 1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (35 mg, 0.23 mmol), HATU (86 mg, 0.23 mmol), triethylamine (70 mg, 0.69 mmol) and DMF (4 ml) were successively added to a reaction flask, and the mixture


was reacted at 45°C for 15 hours. The reaction solution was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 37 mg of the title product as a yellow solid. MS (m/z): 547.2[M+H]⁺.

(D) N-(5-((2-(1-(2-aminoethyl)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide

In a reaction flask, tert-butyl (2-(4-(4-((6-(1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxamido)pyridin-3-yl)oxy)pyridin-2-yl)-1H-pyrazol-1-yl)ethyl)carbamate (37 mg, 0.07 mmol) was dissolved in concentrated hydrochloric acid (1 ml) and methanol (5 ml), and the mixture was reacted at room temperature for half an hour, the reaction solution was concentrated at 50°C, which was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 7 mg of the title product as a yellow solid. MS (m/z): 447.1 [M+H]⁺.

¹H NMR (400 MHz, CD₃OD) δ 8.89 (s, 1H), 8.71 (s, 1H), 8.58 (d, J = 6.5 Hz, 1H), 8.49 - 8.45 (m, 2H), 8.35 (s, 1H), 7.97 (d, J = 8.5 Hz, 1H), 7.77 (s, 1H), 7.36 (d, J = 6.0 Hz, 1H), 4.62 - 4.57 (m, 2H), 3.77 (s, 3H), 3.53 - 3.48 (m, 2H), 2.90 - 2.67 (m, 3H).


The following compounds were prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 109 under suitable conditions recognized by the POSITA.

Compound	Structural formula	MS (M+H) ⁺	¹ H NMR
110		461.1	¹ H NMR (400 MHz, CD ₃ OD) δ 8.78 (s, 1H), 8.43 - 8.38 (m, 2H), 8.23 (d, J = 2.8 Hz, 1H), 8.22 (s, 1H), 8.08 (s, 1H), 7.69 (dd, J = 9.0, 2.8 Hz, 1H), 7.25 (d, J = 2.4 Hz, 1H), 6.82 (dd, J = 5.8, 2.4 Hz, 1H), 4.57 - 4.49 (m, 2H), 3.67 (s, 3H), 3.58 - 3.49 (m, 2H), 2.75 (s, 3H), 2.68 (s, 3H).

Compound 111

1,2-dimethyl-N-(5-((2-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide

-132-



(A) *N*-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-((6-nitropyridin-3-yl)oxy)pyridin-2-amine

2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (500 mg, 2.0 mmol), 5-methyl-1-
 5 (tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-amine (540 mg, 3.0 mmol), $\text{Pd}_2(\text{dba})_3$ (186 mg, 0.2 mmol), Xantphos (116 mg, 0.2 mmol), potassium carbonate (420 mg, 3.0 mmol) and dioxane (20 ml) were successively added to a reaction flask, and the mixture was reacted under nitrogen at 100°C for 15 hours. The reaction solution was purified with flash column chromatography (dichloromethane/methanol = 100 : 0 - 0 : 100, gradient elution),
 10 to obtain 320 mg of the title product as a yellow solid. MS (m/z): 397.0 [$\text{M}+\text{H}$] $^+$.

(B) 4-((6-aminopyridin-3-yl)oxy)-*N*-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyridin-2-amine

N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-((6-nitropyridin-3-yl)oxy)pyridin-2-amine (320 mg, 0.81 mmol), iron powder (168 mg, 3.24 mmol) and
 15 ammonium chloride (214 mg, 4.05 mmol) were dissolved in ethanol (8 ml) and water (2 ml), and the mixture was refluxed and reacted for 1 hour. The reaction solution was filtered to remove iron powder, and the filtrate was concentrated, which was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 227 mg of the title product. MS (m/z): 367.1 [$\text{M}+\text{H}$] $^+$.

(C) 1,2-dimethyl-*N*-(5-((2-((5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)amino)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide

The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 1(A). MS (m/z): 517.2 [$\text{M}+\text{H}$] $^+$.


(D) 1,2-dimethyl-N-(5-((2-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide

The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 109(D). MS (m/z): 433.1

5 [M+H]⁺.


¹H NMR (400 MHz, DMSO-d₆) δ 11.83 (s, 1H), 9.09 (s, 1H), 8.73 (s, 1H), 8.32 (d, J = 9.0 Hz, 1H), 8.26 (d, J = 2.8 Hz, 1H), 7.99 (d, J = 5.7 Hz, 1H), 7.73 (dd, J = 9.0, 2.9 Hz, 1H), 6.88 (s, 1H), 6.35 - 6.28 (m, 1H), 5.93 (s, 1H), 3.57 (s, 3H), 2.63 (s, 3H), 2.13 (s, 3H).

10 The following compounds were prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 111 under suitable conditions recognized by the POSITA.

Comp ound	Structural formula	MS (M+H) ⁺	¹ HNMR
112		418.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.61 (s, 1H), 9.16 (s, 1H), 8.53 - 8.41 (m, 1H), 8.35 (d, J = 9.0 Hz, 1H), 8.25 (d, J = 2.6 Hz, 1H), 8.17 (d, J = 4.7 Hz, 1H), 8.11 (s, 1H), 8.00 (d, J = 5.8 Hz, 1H), 7.71 (dd, J = 8.9, 2.6 Hz, 1H), 6.87 (s, 1H), 6.61 - 6.57 (m, 1H), 6.34 (d, J = 3.9 Hz, 1H), 5.93 (s, 1H), 3.62 (s, 3H), 2.13 (s, 3H).

Compound 113

15 **N-(5-((2-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide**



(A) 2-(1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-pyrazol-4-yl)-4-((6-nitropyridin-3-yl)oxy)pyridine

4-((6-nitropyridin-3-yl)oxy)-2-(1*H*-pyrazol-4-yl)pyridine (100 mg, 0.35 mmol), (2-bromoethoxy)(*tert*-butyl) dimethylsilane (101 mg, 0.42 mmol) and cesium carbonate (172 mg, 0.53 mmol) were dissolved in acetonitrile (10 ml), and the mixture was stirred at 80°C for 5 hours. The reaction solution was concentrated to obtain a crude product,

5 which was purified with flash column chromatography (dichloromethane/methanol = 100 : 0-90:10, gradient elution), to obtain 139 mg of the title product. MS (*m/z*): 442.2[M+H]⁺.

(B) 5-((2-(1-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine

The title compound was prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 111(B). MS (*m/z*): 412.2[M+H]⁺.


(C) *N*-((5-((2-(1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide

5-((2-(1-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine (83 mg, 0.20 mmol), 1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (34 mg, 0.20 mmol), HATU (76 mg, 0.20 mmol), triethylamine (60 mg, 0.60 mmol) and DMF (3 ml) were successively added to a reaction flask, and the mixture was reacted at 40°C for 15 hours. The reaction solution was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 23.3 mg of the title product as a yellow solid. MS (*m/z*): 448.2 [M+H]⁺.

20 ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.85 (s, 1H), 8.74 (s, 1H), 8.43 - 8.22 (m, 4H), 8.00 (s, 1H), 7.79 - 7.75 (m, 1H), 7.29 - 7.25 (m, 1H), 6.75 - 6.72 (m, 1H), 4.93 (s, 1H), 4.17 - 4.14 (m, 2H), 3.77 - 3.72 (m, 2H), 3.59 (s, 3H), 2.64 (s, 3H).

Compound 117

25 **1,2-dimethyl-*N*-((5-((2-(1-methyl-1*H*-pyrrol-3-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide**



(A) 2-bromo-4-((6-nitropyridin-3-yl)oxy)pyridine

2-bromo-4-hydroxypyridine (5.22 g, 30 mmol), 5-fluoro-2-nitropyridine (4.263 g, 30 mmol) and potassium carbonate (4.975 g, 36 mmol) were dissolved in DMF (40 ml), and the mixture was heated at 90°C for 4 hours. The reaction was cooled to room temperature, and quenched with water (200 ml). The reaction solution was filtered, and the solid was collected, to obtain 8.1 g of the title product. MS (m/z): 296.0, 298.0 [M+H]⁺.

(B) 5-((2-bromopyridin-4-yl)oxy)pyridin-2-amine

2-bromo-4-((6-nitropyridin-3-yl)oxy)pyridine (5 g, 16.89 mmol), iron powder (3.773 g, 67.56 mmol), ammonium chloride (4.517 g, 84.45 mmol), ethanol (60 ml) and water (15 ml) were successively added to a reaction flask, and the mixture was heated to reflux and reacted for 1 hour. The reaction solution was concentrated, and the residue was purified with flash column chromatography (petroleum ether/ethyl acetate = 100 : 0 - 0 : 100, gradient elution), to obtain 4.3 g of the title product. MS (m/z): 266.0, 268.0 [M+H]⁺.

(C) 5-((2-(1-methyl-1H-pyrrol-3-yl)pyridin-4-yl)oxy)pyridin-2-amine

5-((2-bromopyridin-4-yl)oxy)pyridin-2-amine (532 mg, 2.0 mmol), 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole (414 mg, 2.0 mmol), Pd(dppf)Cl₂ (73 mg, 0.1 mmol), K₂CO₃ (552 mg, 4.0 mmol), dioxane (20 ml) and water (4 ml) were successively added to a reaction flask, and the mixture was heated to 100°C under nitrogen and reacted for 15 hours. The reaction solution was concentrated, and then purified with flash column chromatography (petroleum ether/ethyl acetate = 100 : 0 - 0 : 100, gradient elution), to obtain 410 mg of the title product. MS (m/z): 267.1 [M+H]⁺.

(D) 1,2-dimethyl-N-(5-((2-(1-methyl-1H-pyrrol-3-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide



5 5-((2-(1-methyl-1*H*-pyrrol-3-yl)pyridin-4-yl)oxy)pyridin-2-amine (410 mg, 1.54 mmol), 1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (388 mg, 2.31 mmol), HATU (878 mg, 2.31 mmol), DMAP (282 mg, 2.31 mmol) and DMF (3 ml) were successively added to a reaction flask, and the mixture was heated to 40°C and reacted

10 for 15 hours. The reaction solution was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), and the resulting crude product was further purified with flash column chromatography (dichloromethane/methanol = 100 : 0 - 70 : 30, gradient elution), to obtain the title product (180 mg). MS (m/z): 417.1[M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ 11.84 (s, 1H), 8.73 (s, 1H), 8.35 - 8.25 (m, 3H), 7.74 (dd, J = 9.1, 2.9 Hz, 1H), 7.34 (s, 1H), 7.08 (d, J = 2.4 Hz, 1H), 6.72-6.67 (m, 1H), 6.61 (dd, J = 5.7, 2.4 Hz, 1H), 6.53-6.48 (m, 1H), 3.60 (s, 3H), 3.56 (s, 3H), 2.62 (s, 3H).

The following compounds were prepared with corresponding intermediates and reagents with reference to the preparation processes of compound 117(D) under suitable


15 conditions recognized by the POSITA.

Compound	Structural formula	MS (M+H) ⁺	¹ H NMR
120		435.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.86 (s, 1H), 8.72 (s, 1H), 8.48 (d, J = 5.6 Hz, 1H), 8.39-8.31 (m, 2H), 8.10 (s, 1H), 7.81 (dd, J = 8.9, 2.8 Hz, 1H), 7.45 (d, J = 2.4 Hz, 1H), 6.97 (dd, J = 5.6, 2.4 Hz, 1H), 3.57 (s, 3H), 2.65 (s, 3H), 2.62 (s, 3H).
121		418.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.84 (s, 1H), 8.72 (d, J = 3.0 Hz, 1H), 8.37 (d, J = 5.6 Hz, 1H), 8.32 (d, J = 9.0 Hz, 1H), 8.27 (d, J = 2.9 Hz, 1H), 7.74 (dd, J = 9.0, 2.9 Hz, 1H), 7.00 (d, J = 2.4 Hz, 1H), 6.77 (dd, J = 5.6, 2.3 Hz, 1H), 6.69-6.63 (m, 1H), 3.56 (s, 3H), 2.62 (s, 3H), 2.40-2.32 (m, 2H), 2.20 - 2.11 (m, 2H), 1.70 - 1.62 (m, 2H), 1.61 - 1.50 (m, 2H).

122		418.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.86 (s, 1H), 8.72 (s, 1H), 8.41 (d, J = 5.7 Hz, 1H), 8.34 (d, J = 9.0 Hz, 1H), 8.32 (d, J = 2.9 Hz, 1H), 7.79 (dd, J = 9.0, 2.9 Hz, 1H), 7.10 (d, J = 2.5 Hz, 1H), 6.99 (d, J = 3.3 Hz, 1H), 6.82 (dd, J = 5.6, 2.3 Hz, 1H), 6.25 - 6.20 (m, 1H), 3.56 (s, 3H), 2.62 (s, 3H), 2.30 (s, 3H).
126		431.1	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.35 (s, 1H), 8.40 - 8.30 (m, 4H), 8.23 (d, J = 4.2 Hz, 1H), 7.79 (dd, J = 9.0, 2.9 Hz, 1H), 7.40 - 7.35 (m, 1H), 7.13 (d, J = 2.4 Hz, 1H), 6.77 - 6.70 (m, 1H), 6.65 (dd, J = 5.7, 2.4 Hz, 1H), 6.57 - 6.51 (m, 1H), 5.42 - 5.27 (m, 1H), 3.63 (s, 3H), 1.36 (d, J = 6.6 Hz, 6H).

Compound 123

1,2-dimethyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)methyl)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide



(A) 2-(1-methyl-1H-pyrazol-4-yl)isonicotinaldehyde

Under nitrogen, 2-chloroisonicotinaldehyde (1 g, 7.1 mmol), 1-methyl pyrazol-4-boronic acid pinacol ester (1.8 g, 8.5 mmol), cesium carbonate (1.95 g, 14.2 mmol), dioxane/water (20 ml / 2 ml) and Pd(dppf)Cl₂ (512 mg, 0.7 mmol) were successively added to a reaction flask, and the mixture was heated to 90°C and stirred overnight. The reaction solution was cooled to room temperature and then concentrated, the residue was purified with flash column chromatography (water (0.5% formic acid): methanol = 100 :

0 - 0 : 100, gradient elution), to obtain 1 g of the title product as a brown solid. MS (m/z): 220.1 [M+MeOH+H]⁺.

(B) (2-(1-methyl-1*H*-pyrazol-4-yl)pyridin-4-yl)methanol

Under nitrogen, 2-(1-methyl-1*H*-pyrazol-4-yl)isonicotinaldehyde (1 g, 5.3 mmol)
5 and methanol (20 ml) were added to a reaction flask, and then sodium borohydride (1 g, 26.5 mmol) was slowly added batchwise, the mixture was stirred at room temperature for 1 hour and completely reacted. Water (2 ml) was slowly added dropwise, and the reaction was quenched and concentrated, the residue was purified with flash column chromatography (water : methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 800 mg
10 of the title product as a light yellow solid. MS (m/z): 190.1 [M+H]⁺.

(C) 4-(bromomethyl)-2-(1-methyl-1*H*-pyrazol-4-yl)pyridine

Under nitrogen, (2-(1-methyl-1*H*-pyrazol-4-yl)pyridin-4-yl)methanol (800 mg, 4.2 mmol), carbon tetrabromide (2.1 g, 6.3 mmol) and dichloromethane (30 ml) were successively added to a reaction flask, and then triphenylphosphine (1.7 g, 6.3 mmol) was
15 added batchwise, the mixture was stirred at room temperature for 1 hour and completely reacted. The reaction solution was concentrated, and then the residue was purified with flash column chromatography (dichloromethane : methanol = 100 : 0-90:10, gradient elution), to obtain 1.06 g of the title product as a light yellow solid. MS (m/z): 252.0 [M+H]⁺.

(D) 5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyridin-4-yl)methyl)pyridin-2-amine

Under nitrogen, 4-(bromomethyl)-2-(1-methyl-1*H*-pyrazol-4-yl)pyridine (200 mg, 0.79 mmol), 2-aminopyridin-5-boronic acid pinacol ester (262 mg, 1.2 mmol), tripotassium phosphate (503 mg, 2.4 mmol), dioxane/water (10 ml/2 ml) and Pd(dppf)Cl₂ (58 mg, 0.08 mmol) were successively added to a reaction flask, and the mixture was
25 heated to 90°C and stirred overnight. The reaction solution was cooled to room temperature and then concentrated, the residue was purified with flash column chromatography (water : methanol = 100 : 0 - 0 : 100, gradient elution) and flash column chromatography (dichloromethane : methanol = 100 : 0 - 90 : 10, gradient elution), to obtain 50 mg of the title product as a white solid. MS (m/z): 266.1 [M+H]⁺.


(E) 1,2-dimethyl-*N*-(5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyridin-4-yl)methyl)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide

Under nitrogen, 5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyridin-4-yl)methyl)pyridin-2-amine (50 mg, 0.19 mmol), 1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (64 mg, 0.38 mmol), HATU (144 mg, 0.38 mmol), DMF (5 ml) and DMAP (116 mg, 0.95 mmol) were successively added to a reaction flask, and the mixture was heated to 40°C and stirred for two days, water (2 ml) was added, and then the reaction solution was purified with flash column chromatography (water (0.5% formic acid): methanol = 100 : 0 - 0 : 100, gradient elution), to obtain 30 mg of the title product as a white solid. MS (m/z): 416.1 [M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ 11.73 (s, 1H), 8.72 (s, 1H), 8.38 (d, J = 5.0 Hz, 1H), 8.34 (d, J = 2.1 Hz, 1H), 8.24 (s, 1H), 8.19 (d, J = 8.5 Hz, 1H), 7.96 (s, 1H), 7.76 (dd, J = 8.4, 2.0 Hz, 1H), 7.57 (s, 1H), 7.04 (d, J = 4.9 Hz, 1H), 3.96 (s, 2H), 3.87 (s, 3H), 3.57 (s, 3H), 2.63 (s, 3H).

Compound 128

2-methyl-1-(methyl-d₃)-N-(5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide



(A) 2-methyl-1-(methyl-d₃)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile

In a reaction flask, 2-methyl-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (2702 mg, 20.0 mmol), deuterated iodomethane (3189 mg, 22.0 mmol) and potassium carbonate (4146 mg, 30.0 mmol) were dissolved in dimethyl sulfoxide (10 ml). The reaction solution was stirred at room temperature for 15 hours, and then purified with flash column chromatography (water : methanol = 100 : 0 - 0 : 100, gradient elution), to obtain the title product (2.05 g, yield 67.3%) as a white solid. MS (m/z): 153.0 [M+H]⁺

(B) 2-methyl-1-(methyl-d₃)-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid

In a reaction flask, 2-methyl-1-(methyl-d3)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (2.05 g, 13.47 mmol) was dissolved in concentrated hydrochloric acid (10 ml), and the reaction solution was heated and refluxed for 2 hours. The reaction solution was concentrated to dryness, and the residue was purified with flash column

- 5 chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain the title product (1.6 g, yield 69.4%) as a white solid. MS (m/z): 172.0 [M+H]⁺

(C) 2-methyl-1-(methyl-d3)-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide


- 5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine (1.92 g, 7.18 mmol), 2-methyl-1-(methyl-d3)-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (1.60 g, 9.34 mmol), HATU (3.55 g, 9.34 mmol), 4-dimethylaminopyridine (1.14 g, 9.34 mmol) and *N,N*-dimethylformamide (20 ml) were successively added to a reaction flask, and the mixture was reacted at room temperature and stirred for 15 hours. After the reaction was completed, water (2 ml) was added, and then the reaction solution was concentrated, the residue was purified with flash column chromatography (water (0.05% formic acid)/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain a white solid, the white solid was recrystallized with dichloromethane and methanol to obtain the title product (2.4g, yield 79.5%) as a white solid. MS (m/z): 421.0[M+H]⁺

- ¹ H NMR (400 MHz, DMSO-d₆) δ 11.85 (s, 1H), 8.73 (d, J = 0.7 Hz, 1H), 8.36 (d, J = 5.7 Hz, 1H), 8.33 (d, J = 9.0 Hz, 1H), 8.29 (d, J = 2.9 Hz, 1H), 8.25 (s, 1H), 7.96 (s, 1H), 7.76 (dd, J = 9.0, 2.9 Hz, 1H), 7.24 (d, J = 2.4 Hz, 1H), 6.76 - 6.67 (m, 1H), 3.83 (s, 3H), 2.62 (s, 3H).

Compound 129

- 25 **1,2-dimethyl-N-(5-((2-(1-(methyl-d3)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide**

-141-



(A) 1-(methyl-d3)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

In a reaction flask, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (582 mg, 3.0 mmol) was dissolved in *N,N*-dimethylformamide (5 ml), and sodium hydride (132 mg, 3.3 mmol) was added batchwise to a reaction solution at room temperature, after this, the reaction solution was stirred at room temperature for 10 minute, and then added deuterated iodomethane (522 mg, 3.6 mmol), the reaction solution was stirred at room temperature for another 4 hours. After the reaction was completed, the reaction solution was quenched with water, and extracted with ethyl

acetate, the organic phases were combined, and concentrated, and then purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain the title product (420 mg, yield 66%) as a white solid. MS (m/z): 212.1 [M+H]⁺

(B) 5-((2-(1-(methyl-d3)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine

1-(methyl-d3)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (441 mg, 1.99 mmol), 5-((2-bromopyridin-4-yl)oxy)pyridin-2-amine (447 mg, 1.66 mmol), Pd(dppf)Cl₂ (124 mg, 0.17 mmol) and potassium carbonate (458 mg, 3.32 mmol) were dissolved in the mixed solution of 1,4-dioxane (20 ml) and water (5 ml), and the mixture was heated to reflux and stirred for 15 hours. The reaction solution was cooled to room temperature, and concentrated to obtain a crude product, which was purified with flash column chromatography (water (0.05% formic acid)/ methanol = 100 : 0 - 0 : 100, gradient elution), to obtain the title product (370 mg, yield 82.5%) as a white solid. MS (m/z): 271.1 [M+H]⁺


(C) 1,2-dimethyl-N-(5-((2-(1-(methyl-d3)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide

5-((2-(1-(methyl-d3)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine (135 mg, 0.5 mmol), 1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (126 mg, 0.75 mmol), HATU (285 mg, 0.75 mmol), 4-dimethylaminopyridine (92 mg, 0.75 mmol) and *N,N*-dimethylformamide (3 ml) were successively added to a reaction flask, and the reaction solution was stirred at room temperature for 15 hours. After the reaction was completed, the reaction solution was quenched with 2 ml of water, and concentrated to obtain a crude product, which was purified with flash column chromatography (water (0.05% formic acid)/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain the title product (85 mg, yield 40.47%) as a white solid. MS (*m/z*): 421.0[M+H]⁺

¹H NMR (400 MHz, DMSO-d₆) δ 11.84 (s, 1H), 8.72 (s, 1H), 8.42 - 8.27 (m, 3H), 8.24 (s, 1H), 7.95 (s, 1H), 7.76 (d, *J* = 6.7 Hz, 1H), 7.23 (s, 1H), 6.71 (d, *J* = 3.6 Hz, 1H), 3.56 (s, 3H), 2.61 (s, 3H).

Compound 130

***N*-(5-((2-(1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide**



(A) 5-((2-(1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine

In a reaction flask, 5-((2-chloropyridin-4-yl)oxy)pyridin-2-amine (222 mg, 1.0 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (388 mg, 2.0 mmol), Pd(dppf)Cl₂ (73 mg, 0.1 mmol) and potassium carbonate (276 mg, 2.0 mmol) were dissolved in the mixed solution of 1,4-dioxane (20 ml) and water (5 ml), and the mixture was heated to reflux and stirred for 15 hours. The reaction was cooled to room temperature, and concentrated to obtain a crude product, which was purified with flash column chromatography (water (0.05% formic acid)/ methanol = 100 : 0 - 0 : 100, gradient elution), to obtain the title product (120 mg, yield 47.4%) as a white solid. MS (*m/z*): 254.0[M+H]⁺

(B) *N*-(5-((2-(1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide


5-((2-(1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine (120 mg, 0.47 mmol), 1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (128 mg, 0.76 mmol), HATU

(289 mg, 0.76 mmol), 4-dimethylaminopyridine (93 mg, 0.76 mmol) and *N,N*-dimethylformamide (3 ml) were successively added to a reaction flask, and the reaction solution was heated at 45°C for 15 hours. After the reaction was completed, the reaction solution was quenched with 2 ml of water, and concentrated to obtain a crude product, which was purified with flash column chromatography (water (0.05% formic acid)/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain the title product (18 mg, yield 9.5%) as a white solid. MS (m/z): 404.0[M+H]⁺

¹H NMR (400 MHz, DMSO-d₆) δ 12.99 (s, 1H), 11.85 (s, 1H), 8.73 (s, 1H), 8.37 (d, J = 5.7 Hz, 1H), 8.34 (d, J = 9.0 Hz, 1H), 8.30 (d, J = 2.9 Hz, 1H), 8.03 (s, 1H), 7.76 (dd, J = 9.0, 2.9 Hz, 1H), 7.34 (d, J = 2.4 Hz, 1H), 6.70 (dd, J = 5.7, 2.4 Hz, 1H), 3.57 (s, 3H), 2.63 (s, 3H).

Compound 131

2-methyl-*N*-(5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide



(A) 2-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid

In a reaction flask, 2-methyl-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (1.35 g, 10.0 mmol) was dissolved in concentrated hydrochloric acid (10 ml). The reaction solution was heated and refluxed for 2 hours. The reaction solution was concentrated to dryness, and the residue was purified with flash column chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain the title product (1.1 g, yield 71.4%) as a white solid. MS (m/z): 155.0 [M+H]⁺

(B) 2-methyl-*N*-(5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide

5-((2-(1-methyl-1*H*-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine (134 mg, 0.5 mmol), 2-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (123 mg, 0.8 mmol), HATU (304 mg, 0.8 mmol), 4-dimethylaminopyridine (98 mg, 0.8 mmol) and *N,N*-dimethylformamide (3 ml) were successively added to a reaction flask. The reaction solution was heated at 45°C for 15 hours. After the reaction was completed, the reaction


solution was quenched with 2 ml of water, and concentrated to obtain a crude product, which was purified with flash column chromatography (water (0.05% formic acid)/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain the title product (130 mg, yield 64%) as a white solid. MS (m/z): 404.0 [M+H]⁺

- 5 ¹H NMR (400 MHz, DMSO-d₆) δ 12.02 (s, 1H), 8.71 (s, 1H), 8.36 (d, J = 5.7 Hz, 1H), 8.33 (d, J = 9.0 Hz, 1H), 8.28 (d, J = 2.8 Hz, 1H), 8.24 (s, 1H), 7.95 (s, 1H), 7.75 (dd, J = 9.0, 2.9 Hz, 1H), 7.23 (d, J = 2.3 Hz, 1H), 6.71 (dd, J = 5.7, 2.4 Hz, 1H), 3.83 (s, 3H), 2.40 (s, 3H).

10

Compound 132


2-(2-hydroxyethyl)-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide



2-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-

- 15 1,6-dihydropyrimidine-5-carboxamide (100 mg, 0.248 mmol), formaldehyde aqueous solution (1 ml) and ethanol (3 ml) were successively added to a microwave tube, the microwave tube was sealed, and the reaction solution was reacted in a microwave reactor at 140°C for 1 hour. After the reaction was completed, the reaction solution was concentrated to dryness, and the residue was purified with flash column chromatography (water (0.05% formic acid)/methanol = 100 : 0 - 0 : 100, gradient elution), and further purified with preparative thin layer chromatography, to obtain the title product (9 mg, yield 8.4%) as a white solid. MS (m/z): 434.0 [M+H]⁺

- 20 ¹H NMR (400 MHz, DMSO-d₆) δ 12.13 (s, 1H), 8.74 (s, 1H), 8.36 (dd, J = 9.9, 7.4 Hz, 2H), 8.28 (d, J = 2.9 Hz, 1H), 8.25 (s, 1H), 8.15 (s, 1H), 7.96 (s, 1H), 7.75 (dd, J = 9.0, 2.9 Hz, 1H), 7.23 (d, J = 2.4 Hz, 1H), 6.72 (dd, J = 5.7, 2.4 Hz, 1H), 3.83 (s, 3H), 2.5
- 25 3.78 (t, J = 6.2 Hz, 2H), 2.80 (t, J = 6.2 Hz, 2H).

Compound 133**2-(hydroxymethyl)-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide****5 (A) 2-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid**

In a reaction flask, 2-methyl-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (6.0 g, 44.4 mmol) was dissolved in concentrated hydrochloric acid (15 ml). The reaction solution was heated and refluxed for 2 hours. The reaction solution was concentrated to dryness, and the crude product was directly used in the next step without purification
 10 (6.84 g, yield 100%). MS (m/z): 155.2 [M+H]⁺

(B) Ethyl 2-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate

In a reaction flask, the acid intermediate 2-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (6.84 g, 44.4 mmol) prepared in the previous step was dissolved in ethanol (100 ml). Thionyl chloride (5 ml) was added dropwise to the mixture in an ice
 15 bath, after the dropwise addition was completed, the reaction solution was heated and refluxed for 15 hours. After the reaction was completed, the reaction solution was concentrated, and the residue was purified with flash column chromatography (water (0.05% formic acid)/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain the title product (4.5 g, two-step reaction yield 55.6%) as a white solid. MS (m/z): 183.2 [M+H]⁺

20 (C) Ethyl 2-(chloromethyl)-6-oxo-1,6-dihydropyrimidine-5-carboxylate

Ethyl 2-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate (4500 mg, 24.7 mmol), N-chlorosuccinimide (3298 mg, 24.7 mmol) and dichloromethane (100 ml) were successively added to a reaction flask, and the mixture was heated and refluxed for 2.5 hours. After the reaction was completed, the reaction solution was cooled to room

temperature and quenched with water, the reaction solution was concentrated to dryness, and the residue was purified with flash column chromatography (water (0.05% formic acid)/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain the title product (1.7 g, yield 37.7%) as a white solid. MS (m/z): 217.0[M+H]⁺

5 **(D) 2-(chloromethyl)-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid**

In a reaction flask, ethyl 2-(chloromethyl)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (1.7 g, 7.85 mmol) was dissolved in concentrated hydrochloric acid (15 ml), and the reaction solution was heated and refluxed for 2 hours. The reaction solution was concentrated to dryness, and the residue was purified with flash column chromatography
10 (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain the title product (1.2 g, yield 81%) as a white solid. MS (m/z): 189.0[M+H]⁺

(E) 2-(chloromethyl)-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide

5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine (1742 mg, 6.52
15 mmol), 2-(chloromethyl)-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (1.23 g, 6.52 mmol), HATU (2.73 g, 7.17 mmol), 4-dimethylaminopyridine (876 mg, 7.17 mmol) and *N,N*-dimethylformamide (15 ml) were successively added to a reaction flask, and the reaction solution was stirred at room temperature for 15 hours. After the reaction was completed, the reaction solution was quenched with 2 ml of water, and concentrated, the
20 crude product was purified with flash column chromatography (water (0.05% formic acid)/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain the title product (1.8 g, yield 63%) as a white solid. MS (m/z): 438.1[M+H]⁺

(F) (5-((5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)carbamoyl)-6-oxo-1,6-dihydropyrimidin-2-yl)methyl acetate

25 2-(chloromethyl)-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide (500 mg, 1.14 mmol), potassium acetate (500 mg, 5.1 mmol) and *N,N*-dimethylformamide (4 ml) were successively added to a reaction flask. The reaction solution was heated at 80°C for 15 hours. After the reaction was completed, the reaction solution was cooled to room temperature, and quenched with
30 water (1 ml). The reaction solution was concentrated, and the crude product was purified with flash column chromatography (water (0.05% formic acid)/methanol = 100 : 0 - 0 :

100, gradient elution), to obtain the title product (290 mg, yield 55.1%) as a white solid.

MS (m/z): 462.2 [M+H]⁺


(G) 2-(hydroxymethyl)-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide

- 5 (5-((5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)carbamoyl)-6-oxo-1,6-dihydropyrimidin-2-yl)methyl acetate (30 mg, 0.065 mmol), methanol (3 ml) and sodium methoxide (14 mg, 0.26 mmol) were successively added to a reaction flask, and the reaction solution was stirred at room temperature for 1 hour. After the reaction was completed, the PH of the reaction solution is adjusted to about 5 with dilute hydrochloric acid (2M). The reaction solution was concentrated, and the crude product was purified with flash column chromatography (water (0.05% formic acid)/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain the title product (15 mg, yield 55.5%) as a white solid. MS (m/z): 420.1[M+H]⁺

- 15 ¹H NMR (400 MHz, DMSO-d₆) δ 12.19 (s, 1H), 8.65 (s, 1H), 8.36 (d, J = 5.7 Hz, 1H), 8.33 (d, J = 9.0 Hz, 1H), 8.28 (d, J = 2.8 Hz, 1H), 8.24 (s, 1H), 7.95 (s, 1H), 7.74 (dd, J = 9.0, 2.9 Hz, 1H), 7.22 (d, J = 2.3 Hz, 1H), 6.71 (dd, J = 5.7, 2.4 Hz, 1H), 5.86 (s, 1H), 4.44 (s, 2H), 3.82 (s, 3H).

Compound 134

- 20 **2-hydroxy-1-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide**



(A) (1-methyl-5-((5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)carbamoyl)-6-oxo-1,6-dihydropyrimidin-2-yl)methyl acetate

- 25 (5-((5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)carbamoyl)-6-oxo-1,6-dihydropyrimidin-2-yl)methyl acetate (200 mg, 0.433 mmol), potassium carbonate (72 mg, 0.519 mmol), *N,N*-dimethylformamide (3 ml) and iodomethane (62 mg, 0.433 mmol) were successively added to a reaction flask. The reaction solution was stirred continuously at room temperature for 4 hours. After the reaction was completed, the reaction solution was quenched with water, and extracted with ethyl acetate, the organic phases were combined, and concentrated, and then purified with flash column

chromatography (water/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain the title product (140 mg, yield 67.96%) as a white solid. MS (m/z): 476.1 [M+H]⁺


(B) 2-hydroxy-1-methyl-N-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide

(1-methyl-5-((5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)carbamoyl)-6-oxo-1,6-dihydropyrimidin-2-yl)methyl acetate (48 mg, 0.1 mmol), methanol (3 ml) and sodium methoxide (216 mg, 0.4 mmol) were successively added to a reaction flask, and the reaction solution was stirred at room temperature for 1 hour. After the reaction was completed, the PH of the reaction solution is adjusted to about 5 with dilute hydrochloric acid (2M). The reaction solution was concentrated, and the crude product was purified with flash column chromatography (water (0.05% formic acid)/methanol = 100 : 0 - 0 : 100, gradient elution), to obtain the title product (10 mg, yield 23.8%) as a white solid. MS (m/z): 420.1 [M+H]⁺

¹H NMR (400 MHz, DMSO-d₆) δ 11.69 (s, 1H), 8.45 (s, 1H), 8.35 (d, J = 5.6 Hz, 1H), 8.31 (d, J = 8.9 Hz, 1H), 8.24 (s, 2H), 7.95 (s, 1H), 7.70 (d, J = 9.0 Hz, 1H), 7.22 (d, J = 2.0 Hz, 1H), 6.70 (dd, J = 5.5, 2.0 Hz, 1H), 3.82 (s, 3H), 3.21 (s, 3H).

Compound 135

N-((5-((2-(3-hydroxy-1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide



(A) 3-(benzyloxy)-1-methyl-1H-pyrazole

Under nitrogen, 1-methyl-1H-pyrazol-3-ol (4 g, 41 mmol), potassium carbonate (6.8 g, 49 mmol) and DMF (50 ml) were successively added to a reaction flask, and benzyl bromide (8.4 g, 49 mmol) was added dropwise in an ice bath, the mixture was warmed to

room temperature and stirred for 1.5 hours, and then heated to 50°C and stirred for another 4 hours. The reaction solution was cooled to room temperature, and then water (100 ml) and ethyl acetate (150 ml) were added, after layering, the organic phase was washed with saturated brine (100 ml) two times, dried with anhydrous sodium sulfate and
5 filtered, concentrated. The residue was purified with flash column chromatography (petroleum ether : ethyl acetate = 100 : 0 - 0 : 100, gradient elution), to obtain 4.7 g of the title product as a colorless oil. MS (m/z): 189.1 [M+H]⁺

(B) 3-(benzyloxy)-4-iodo-1-methyl-1H-pyrazole

Under nitrogen, 3-(benzyloxy)-1-methyl-1H-pyrazole (4.7 g, 25 mmol), acetonitrile
10 (60 ml), cerium ammonium nitrate (8.22 g, 15 mmol) and elemental iodine (3.8 g, 15 mmol) were successively added to a reaction flask, and the mixture was stirred at room temperature for 2 hours. The reaction solution was cooled in an ice bath, and then 5% sodium bisulfite (100 ml) was added dropwise, and the mixture was extracted with ethyl acetate (100 ml). The organic phase was washed with saturated brine (100 ml), dried with
15 anhydrous sodium sulfate and filtered, concentrated. The residue was purified with flash column chromatography (petroleum ether : ethyl acetate = 100 : 0 - 0 : 100, gradient elution), to obtain 5.1 g of the title product as a brown oil. MS (m/z): 315.0 [M+H]⁺

(C) 3-(benzyloxy)-1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

Under nitrogen, 3-(benzyloxy)-4-iodo-1-methyl-1H-pyrazole (5.1 g, 16 mmol) and anhydrous tetrahydrofuran (80 ml) were successively added to a reaction flask, and the mixture was cooled to -10°C in an ice salt bath, and then isopropyl magnesium chloride (12 ml, 24 mmol) was added dropwise, the reaction solution was warmed to 0°C and stirred for 1.5 hours, and then cooled to -10°C again in an ice salt bath, 2-isopropoxy -
25 4,4,5,5-tetramethyl-1,3,2-dioxaborolan (5.95 g, 32 mmol) was added dropwise, and then the reaction solution was slowly warmed to room temperature and stirred for 4 hours. Saturated ammonium chloride (100 ml) was added, and the reaction solution was extracted with ethyl acetate (100 ml), and the organic phase was washed with saturated brine (100 ml), dried with anhydrous sodium sulfate and filtered, and concentrated. The
30 residue was purified with flash column chromatography (petroleum ether : ethyl acetate = 100 : 0 - 0 : 100, gradient elution), to obtain 4.6 g of the title product as a colorless oil. MS (m/z): 315.2 [M+H]⁺

(D) 5-((2-(3-(benzyloxy)-1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine

Under nitrogen, 3-(benzyloxy)-1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.57 g, 5 mmol), 5-((2-chloropyridin-4-yl)oxy)pyridin-2-amine (742 mg, 3.33 mmol), cesium carbonate (2.7 g, 8.3 mmol), tetra(triphenylphosphine)palladium (380 mg, 0.33 mmol) and DMF/H₂O (18 ml /6 ml) were successively added to a reaction flask, and the mixture was heated to 90°C and then stirred overnight. The reaction solution was cooled to room temperature and then concentrated, the residue was purified with flash column chromatography (water (0.1% formic acid): acetonitrile = 100 : 0 : 100, gradient elution), to obtain 1.2 g of the title product as a light yellow solid. MS (m/z): 374.2 [M+H]⁺

(E) 4-(4-((6-aminopyridin-3-yl)oxy)pyridin-2-yl)-1-methyl-1H-pyrazol-3-ol

5-((2-(3-(benzyloxy)-1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine (1.2 g, 3.33 mmol), methanol (60 ml), dichloromethane (6 ml) and palladium hydroxide (600 mg) were successively added to a reaction flask, under hydrogen, the mixture was stirred at room temperature overnight. The reaction solution was filtered, and the filter cake was washed with methanol, the filtrate was combined and then concentrated, and the residue was purified with flash column chromatography (dichloromethane : methanol = 100 : 0-90:10, gradient elution), to obtain 590 mg of the title product as a white solid. MS (m/z): 284.1 [M+H]⁺

(F) N-(5-((2-(3-hydroxy-1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide

Under nitrogen, 4-(4-((6-aminopyridin-3-yl)oxy)pyridin-2-yl)-1-methyl-1H-pyrazol-3-ol (283 mg, 1 mmol), 1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (202 mg, 1.2 mmol), HATU (570 mg, 1.5 mmol), DMF (10 ml) and DMAP (183 mg, 1.5 mmol) were successively added to a reaction flask, and the mixture was heated to 40°C and then stirred overnight. Water (2 ml) was added, and the reaction solution was purified with flash column chromatography (water (0.1% formic acid): acetonitrile = 100 : 0 - 0 : 100, gradient elution) and preparative thin layer chromatography, to obtain 75 mg of the title product as a white solid. MS (m/z): 434.2 [M+H]⁺

¹H NMR (400 MHz, DMSO-d₆) δ 11.89 (s, 1H), 10.96 (s, 1H), 8.76 (s, 1H), 8.45 - 8.28 (m, 3H), 8.07 (s, 1H), 7.81 (dd, J = 9.0, 2.9 Hz, 1H), 7.24 (d, J = 2.4 Hz, 1H), 6.76 (dd, J = 5.8, 2.5 Hz, 1H), 3.65 (s, 3H), 3.59 (s, 3H), 2.65 (s, 3H).

Example 3

Measurement of CSF1R kinase activity at molecular level

1. Reagents and materials:

- 5 Z-LYTE™ Tyr 1 peptide substrate: Invitrogen, PV3190;
5X kinase buffer: Invitrogen, PV3189;
10 mM ATP: Invitrogen, PV3227;
Development reagent B: Invitrogen, PV3295;
Development buffer: Invitrogen, P3127;
10 Stopping solution: Invitrogen, P3094;
Recombinant human CSF1R kinase: Invitrogen, PR4598A;
384 well plate, black: Corning, 3575;
Envision: Perkin Elmer.

2. Preparation of reaction solutions

- 15 1) 1.33X kinase buffer: 5X kinase buffer was diluted to a 1.33X kinase buffer with ddH₂O.
- 2) Dilution of a 4X test compound: The test compound was diluted in gradient to 4-fold the reaction concentration and the concentration of DMSO was kept at 8%. The final concentration of the compound in reaction was: 1, 0.33, 0.11, 0.037, 0.012, 0.004, 20 0.0014, 0.00046 μ M, and the final concentration of DMSO was 2%.
- 3) A mixture of kinase/peptide substrate: In 1.33X kinase buffer, the kinase and Z-LYTE™ Tyr 1 peptide substrate were diluted to 0.12 μ g/mL and 4 μ M, respectively, to prepare a mixture of kinase/peptide substrate. The mixture was mixed gently with a pipette.
- 25 4) A phosphorylated peptide substrate solution (PP solution): 0.4 μ L of Z-LYTE™ Tyr1 phosphorylated peptide substrate was added to 99.6 μ L of 1.33X kinase buffer.
- 5) ATP solution: 10 mM of ATP was diluted to 760 μ M with 1.33X kinase buffer to prepare ATP solution.
- 30 6) Development solution: Development reagent B was diluted with Development buffer at a ratio of 1 : 200.

3. Methods

1) Kinase reaction (10 μ L system)

2.5 μ L of 4X test compound was added to each reaction well of the 384 plate, and the corresponding volume of 8% DMSO was added to the control well. The plate was placed on ice. 5 μ L of a mixture of kinase/peptide substrate, 2.5 μ L of kinase buffer and ATP solution were successively added to each well. Three control groups were set up: Group C1 contains only kinase buffer, group C2 contains the mixture of kinase/peptide substrate, kinase buffer and ATP, and group C3 contains 5 μ L of PP solution. After adding the reaction components, the 384-well plate was sealed and incubated at 25-30 $^{\circ}$ C for 1 h in dark.

2) Development reaction

5 μ L of Development solution was added to each well, sealed and incubated at 25-30 $^{\circ}$ C for another 1 h in dark.

3) Reaction stopping and plate reading

5 μ L of stopping solution was added to each well. The Coumarin value (excitation at 400 nm, emission at 445 nm) and Fluorescein value (excitation at 400 nm, emission at 520 nm) were measured, respectively.

4. Data Analysis

% phosphorylation rate = $100\% - 100\% \times [\text{ER} \times \text{C3 520 nm} - \text{C3 445 nm}] / [(\text{C1 445 nm} - \text{C3 445 nm}) + \text{ER} \times (\text{C3 520 nm} - \text{C1 520 nm})]$

wherein

ER (emission ratio): Coumarin emission read-out (445 nm)/Fluorescein emission read-out (520 nm);

C3 445nm: 100% phosphorylated Coumarin emission read-out;

C3 520nm: 100% phosphorylated Fluorescein emission read-out;

C1 445nm: 0% phosphorylated Coumarin emission read-out;

C1 520nm: 0% phosphorylated Fluorescein emission read-out.

Inhibition rate %(IR) = $[1 - \% \text{ phosphorylation rate}_{\text{test sample}} / 100\% \text{ phosphorylation rate}_{\text{control}}] \times 100\%$

wherein

% phosphorylation rate_{test sample}: phosphorylation rate of the test compound;

100% phosphorylation rate_{control}: phosphorylation rate of C3 control group.

5. IC₅₀ values: calculated by using software XL-Fit™ (version 5.3) supplied by ID Business Solutions (Guildford, UK), which is an additional software to Microsoft Excel.

6. Test results

Compound No.	IC ₅₀ (μM)	Compound No.	IC ₅₀ (μM)	Compound No.	IC ₅₀ (μM)
1	0.217	38	0.012	77	0.006
2	0.008	39	0.033	78	0.015
3	0.005	40	0.016	79	0.307
4	0.066	41	0.027	80	0.004
5	0.022	42	0.005	81	0.034
6	0.007	43	0.006	82	0.006
7	0.067	44	0.007	83	0.009
8	0.004	45	0.009	84	0.006
9	0.012	46	0.012	85	0.005
10	0.015	47	0.005	86	0.005
11	0.005	48	0.005	87	0.008
12	0.009	49	0.023	88	0.003
13	0.091	50	0.078	89	0.008
14	0.063	51	0.056	90	0.006
15	0.034	53	0.135	91	0.003
16	0.088	55	0.003	92	0.029
17	0.019	56	0.004	93	0.017
18	0.013	57	0.024	94	0.025
19	0.274	58	0.069	95	0.008
20	0.008	59	0.121	96	0.008
21	0.028	60	0.008	97	0.018
22	0.011	61	0.045	98	0.484
23	0.022	62	0.020	99	0.070
24	0.030	63	0.009	100	0.008
25	0.016	64	0.016	101	0.007

26	0.005	65	0.005	102	0.036
27	0.008	66	0.054	103	0.006
28	0.015	67	0.033	104	0.005
29	0.173	68	0.007	105	0.009
30	0.035	69	0.003	106	0.007
31	0.689	70	0.032	107	0.009
32	0.059	71	0.010	108	0.011
33	0.062	72	0.014	109	0.177
34	0.079	73	0.011	110	0.111
35	0.113	74	0.009	111	0.019
36	0.028	75	0.008	112	0.019
37	0.169	76	0.005	113	0.034
114	0.042	119	0.467	124	0.016
115	0.046	120	0.052	125	0.007
116	0.105	121	0.413	126	0.025
117	0.007	122	0.055	127	0.017
118	0.019	123	0.019	128	0.005
129	0.004	130	0.021	131	0.076
132	0.198	133	0.548	134	0.078
135	0.012				

Example 4

Detection of CSF1R phosphorylation activity at cell level

1. Cell line

5 THP-1 (ATCC), human acute monocytic leukemia cells. The cells were cultured in an RPMI 1640 medium containing 10% FBS.

2. Reagents and instruments

- Human phosphorylation-CSF1R ELISA kit: R&D, #DYC3268-2;
- RPMI 1640 culture solution: GIBCO, #10491;
- 10 • Human M-CSF recombinant cytokine: R&D, #216-MC-500;
- Cell lysis buffer: Cell Signal, #9803S;

- 1XPBS buffer (1L): 8.0 g of NaCl, 0.2 g of KCl, 3.58 g of $\text{Na}_2\text{HPO}_4 \cdot 12\text{H}_2\text{O}$, 0.24 g of KH_2PO_4 were dissolved in 1L of dd H_2O , and the pH was adjusted to 7.4;
- Blocking solution: PBS buffer containing 1% BSA;
- PBST washing liquid: PBS buffer containing 0.05% Tween-20;
- 5 • Chromogenic substrate: R&D, #DY999;
- 2N H_2SO_4 ;
- Microwell plate reader: Labsystems Multiskan K3; Thermo; Envision: Perkin Elmer;
- ELISA plate: Corning, #9018;
- 10 • Cell culture plate: Facol, #353027.

3. Treatment of cells and preparation of lysis buffer

THP-1 cells were resuspended in RPMI-1640 culture solution containing 2% FBS, and the culture was added to a 96-well plate at a density of 5×10^4 /well, 50 μL /well, and cultured in a cell incubator at 5% CO_2 and 37°C overnight; The test compound was
15 diluted with a serum-free RPMI-1640 medium to 3, 1.1, 0.37, 0.12, 0.04, 0.014, 0.005 and 0.002 μM , and the concentration of DMSO was 5%. 5 μL of the diluted compound was added to the 50 μL cell culture system, the culture was cultured in a 5% CO_2 , 37°C cell incubator for 60 min, 300 ng/mL of M-CSF was added to the cells, and the mixture was stimulated in the 37°C cell incubator for 1 min, added 50 μL of cell lysis buffer, and
20 stored in a refrigerator at -80°C.

4. ELISA detection steps

100 μL /well of the p-CSF1R capture antibody diluted to 0.8 $\mu\text{g/mL}$ with PBS was added to the ELISA plate, and the plate was coated on a shaker at room temperature overnight. The culture was washed with PBST, and then added blocking solution and
25 incubated at room temperature for 2 h. The culture was washed with PBST, added 90 μL of cell lysis buffer, and incubated on a shaker at 25°C for 2 h. The plate was washed with PBST three times, added 100 μL of anti-p-tyrosine-HRP detection antibody diluted with 0.1% PBS-BSA diluent, and incubated on a shaker at 25°C for 2 h. The plate was washed with PBST washing liquid, added 100 μL of chromogenic substrate and incubated at
30 room temperature for 10-20 min. The reaction was stopped by adding 50 μL of 2N H_2SO_4 . The optical density signal (450/570 nm) of each well was detected in Labsystems Multiskan K3 or Envision.

5. Data Analysis

$$\text{Inhibition rate (\%)} = 100 \% - \frac{\text{Drug-treated well read-out} - \text{background read-out}}{\text{Cell well read-out} - \text{background read-out}} \times 100\%$$

wherein

- Drug-treated well read-out: indicating the optical density signal of a cell well with the test compound treatment.
- 5 • Background read-out: indicating the optical density signal of a well without cells but with cell lysis buffer.
- Cell well read-out: indicating the optical density signal of a cell well not treated with the compound.

6. Calculation of IC₅₀: obtained by using XL-Fit 5.3 software.

10 7. Test results

Compound No.	IC ₅₀ (μM)	Compound No.	IC ₅₀ (μM)	Compound No.	IC ₅₀ (μM)
2	0.022	40	0.296	77	0.010
3	0.063	41	0.019	78	0.011
4	0.028	42	0.006	80	0.003
5	0.011	43	0.006	81	0.145
6	0.021	44	0.003	82	0.011
7	0.025	45	0.003	83	0.013
8	0.004	46	0.009	84	0.01
9	0.105	47	0.003	85	0.005
10	0.062	48	0.005	86	0.007
11	0.006	49	0.014	87	0.017
12	0.143	50	0.054	88	0.01
13	0.042	51	0.067	89	0.016
14	0.021	55	0.007	90	0.01
15	0.215	56	0.021	91	0.009
16	0.020	57	0.043	92	0.307
17	0.256	58	0.126	93	0.061
18	0.060	60	0.014	94	0.033

20	0.109	61	0.075	95	0.016
21	0.043	62	0.009	96	0.008
22	0.01	63	0.005	97	0.007
23	0.038	64	0.021	99	0.748
24	0.059	65	0.010	100	0.015
25	0.038	66	0.023	101	0.022
26	0.003	67	0.009	102	0.132
27	0.018	68	0.006	103	0.007
28	0.012	69	0.003	104	0.014
30	0.014	70	0.203	105	0.069
32	0.015	71	0.036	106	0.010
33	0.015	72	0.016	107	0.017
34	0.024	73	0.031	108	0.024
36	0.008	74	0.015	111	0.010
38	0.007	75	0.014	112	0.010
39	0.012	76	0.018	113	0.017
114	0.035	118	0.021	125	0.024
115	0.022	120	0.021	126	0.030
116	0.021	123	0.016	127	0.026
117	0.008	124	0.019	128	0.006
129	0.007	130	0.007	131	0.056
132	2.115	133	> 3	134	0.295

Example 5

Cell proliferation experiment

1. Cell line

- 5 Ba/F3^{BCR-FMS-11}, mouse primary B lymphocytes stably expressing the BCR-FMS fusion gene. The cells were cultured in an RPMI 1640 medium containing 10% FBS.

2. Reagents and instruments

- cckit-8 kit: Dojindo, # CK04;
- Envision: Perkin Elmer;
- 10 • Cell culture plate: Facol, #353027.

3. Experimental steps

The BCR-FMS fusion gene was transfected into Ba/F3 cells, and the cell line Ba/F3^{BCR-FMS-11} that stably expresses BCR-FMS and grows depending on CSF-1R was screened. Ba/F3^{BCR-FMS-11} cell proliferation experiments is completed by using the Cell Counting kit cckit-8 in a 96-well plate. In a 96-well plate, 5000/well of Ba/F3^{BCR-FMS-11} cells were inoculated at 100 μ L/well. After 24 hours, the test compound was diluted to 10, 3.33, 1.11, 0.37, 0.12, 0.037, 0.012, and 0.004 μ M, the concentration of DMSO was kept at 5%. 10 μ L of the compound dilutions with the above 8 concentrations were added to the culture cell wells. The culture was incubated in a 37°C and 5% CO₂ cell incubator for 72 hours. 10 μ L of Cell Counting kit cckit-8 detection reagent was added to each well, and incubated at 37°C and 5% CO₂ in a cell incubator for another 1 h. The optical density absorption value at 450 nm of each well was detected by using Perkin Elmer Envision instrument.

4. Data Analysis

$$\text{Inhibition rate (\%)} = 100\% - \frac{\text{Drug-treated well read-out} - \text{background read-out}}{\text{Cell well read-out} - \text{background read-out}} \times 100\%$$

wherein

- Drug-treated well read-out: indicating the optical density signal of a cell well with the test compound treatment.
- Cell well read-out: indicating the optical density signal of a cell well not treated with the test compound (only 0.5% DMSO).
- Background read-out: indicating the optical density signal of a well with the cell medium.

5. Calculation of IC₅₀: obtained by using XL-Fit 5.3 software.

6. Test results


Compound No.	IC ₅₀ (μ M)	Compound No.	IC ₅₀ (μ M)	Compound No.	IC ₅₀ (μ M)
2	0.011	40	0.046	77	0.005
3	0.012	41	0.052	78	0.011
4	0.060	42	0.006	80	0.005
5	0.047	43	0.005	81	0.143
6	0.015	44	0.006	82	0.009

7	0.039	45	0.009	83	0.007
8	0.007	46	0.02	84	0.008
9	0.107	47	0.006	85	0.007
10	0.088	48	0.005	86	0.007
11	0.006	49	0.024	87	0.006
12	0.066	50	0.112	88	0.008
13	0.231	51	0.097	89	0.008
14	0.044	55	0.005	90	0.002
15	0.493	56	0.008	91	0.003
16	0.045	57	0.012	92	0.567
17	0.072	58	0.179	93	0.013
18	0.057	60	0.015	94	0.142
20	0.044	61	0.087	95	0.014
21	0.073	62	0.032	96	0.010
22	0.014	63	0.008	97	0.015
23	0.045	64	0.040	99	0.534
24	0.037	65	0.008	100	0.015
25	0.066	66	0.055	101	0.031
26	0.01	67	0.025	102	0.151
27	0.008	68	0.012	103	0.009
28	0.014	69	0.004	104	0.006
30	0.024	70	0.225	105	0.084
32	0.099	71	0.051	106	0.007
33	0.058	72	0.007	107	0.035
34	0.125	73	0.017	108	0.012
36	0.023	74	0.012	111	0.008
38	0.017	75	0.007	112	0.022
39	0.063	76	0.004	113	0.048
114	0.079	118	0.006	125	0.017
115	0.038	120	0.039	126	0.028
116	0.201	123	0.025	127	0.011

117	0.009	124	0.011	128	0.002
129	0.002	130	0.015	131	0.396
132	1.189	133	> 3.3	134	0.526
135	0.007				

CLAIMS

1. A compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof, and/or a deuterate, a solvate, a racemic mixture, an enantiomer, a diastereomer and a tautomer thereof, wherein

X is N or CR₅;

Z₁ and Z₂ are each independently N or CR₆;

Y₁ is N or CR₇; Y₂ is N or CR₈; Y₃ is N or CR₉;

L is O or CH₂;

W is absent or NH;

R₁ is phenyl, 5-12 membered heteroaryl, 4-6 membered heterocyclyl or C₃₋₈ cycloalkyl, each of which is optionally substituted with one or more groups chosen from: halogen, -CN, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, -(C₁₋₆ alkylene)_n-NH₂, -(C₁₋₆ alkylene)_n-NH(C₁₋₆ alkyl), -(C₁₋₆ alkylene)_n-N(C₁₋₆ alkyl)₂, -(C₁₋₆ alkylene)_n-OH, -(C₁₋₆ alkylene)_n-O-(C₁₋₆ alkyl) or -(C₁₋₆ alkylene)_n-O-(C₁₋₆ haloalkyl);

R₂ is hydrogen, -CN, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, -(C₁₋₆ alkylene)-NH₂, -(C₁₋₆ alkylene)-NH(C₁₋₆ alkyl), -(C₁₋₆ alkylene)-N(C₁₋₆ alkyl)₂, -(C₁₋₆ alkylene)-O-(C₁₋₆ alkyl), -(C₁₋₆ alkylene)-O-(C₁₋₆ haloalkyl), -(C₁₋₆ alkylene)-OH, C₃₋₈ cycloalkyl or 4-6 membered heterocyclyl;


R₃, R₄, R₅, R₆, R₇ and R₈ are each independently chosen from: hydrogen, halogen, -CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -O(C₁₋₆ alkyl), -O(C₁₋₆ haloalkyl) or -OH;

R₉ is hydrogen, halogen, -CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -O(C₁₋₆ alkyl), -O(C₁₋₆ haloalkyl), -OH, -(C₁₋₆ alkylene)-OH, -NH₂, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂ or C₃₋₈ cycloalkyl;

n is 0 or 1;

or when Y_3 is CR_9 , R_2 and R_9 together with the N atoms and C atoms to which they are attached form a 5-6 membered heteroaromatic ring or 5-6 membered heterocycle;

or when Y_2 is CR_8 and Y_3 is CR_9 , R_8 and R_9 together with the C atoms to which they are attached form a benzene ring;



provided that when X is CH, Z_1 is not N;

wherein the term "cycloalkyl" refers to a saturated or partially unsaturated cyclic hydrocarbon radical.

10 2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, and/or a deuterate, a solvate, a racemic mixture, an enantiomer, a diastereomer and a tautomer thereof, wherein X is N.

15 3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, and/or a deuterate, a solvate, a racemic mixture, an enantiomer, a diastereomer and a tautomer thereof, wherein X is CR_5 ; R_5 is hydrogen, halogen, C_{1-6} alkyl or $-O(C_{1-6}$ alkyl).

20 4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, and/or a deuterate, a solvate, a racemic mixture, an enantiomer, a diastereomer and a tautomer thereof, wherein Z_1 and Z_2 are each independently CR_6 .

25 5. The compound of claim 4, or a pharmaceutically acceptable salt thereof, and/or a deuterate, a solvate, a racemic mixture, an enantiomer, a diastereomer and a tautomer thereof, wherein both Z_1 and Z_2 are CH.

30 6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, and/or a deuterate, a solvate, a racemic mixture, an enantiomer, a diastereomer and a tautomer thereof, wherein Y_1 is CR_7 , Y_2 is CR_8 , and Y_3 is CR_9 ; R_7 and R_8 are each independently chosen from: hydrogen, halogen, C_{1-6} alkyl or $-O(C_{1-6}$ alkyl), R_9 is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, $-O(C_{1-6}$ alkyl), $-NH_2$, $-NH(C_{1-6}$ alkyl) or $-N(C_{1-6}$ alkyl)₂; preferably, R_7 is

hydrogen or -O(C₁₋₆ alkyl), R₈ is hydrogen, halogen or C₁₋₆ alkyl, R₉ is hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -O(C₁₋₆ alkyl), -NH₂, -NH(C₁₋₆ alkyl) or -N(C₁₋₆ alkyl)₂; and more preferably, R₇ is hydrogen, R₈ is chosen from hydrogen or fluoro, and R₉ is hydrogen or methyl.

5

7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, and/or a deuterate, a solvate, a racemic mixture, an enantiomer, a diastereomer and a tautomer thereof, wherein Y₁ is CR₇, Y₂ is N, and Y₃ is CR₉; R₇ is hydrogen, C₁₋₆ alkyl or -O(C₁₋₆ alkyl); R₉ is hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl or C₃₋₆ cycloalkyl; preferably, R₇ is
10 hydrogen; R₉ is hydrogen, C₁₋₆ alkyl or C₃₋₆ cycloalkyl; and more preferably, R₇ is hydrogen; R₉ is hydrogen or methyl.

8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, and/or a deuterate, a solvate, a racemic mixture, an enantiomer, a diastereomer and a tautomer
15 thereof, wherein L is O.

9. The compound of claim 1, or a pharmaceutically acceptable salt thereof, and/or a deuterate, a solvate, a racemic mixture, an enantiomer, a diastereomer and a tautomer thereof, wherein W is absent.

20

10. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, and/or a deuterate, a solvate, a racemic mixture, an enantiomer, a diastereomer and a tautomer thereof, wherein R₁ is phenyl, 5-12 membered heteroaryl, 4-6 membered heterocyclyl or C₃₋₈ cycloalkyl, each of which is optionally substituted with one or more
25 groups chosen from: halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -(C₁₋₆ alkylene)_n-NH₂, -(C₁₋₆ alkylene)_n-NH(C₁₋₆ alkyl), -(C₁₋₆ alkylene)_n-N(C₁₋₆ alkyl)₂ or -(C₁₋₆ alkylene)_n-OH; preferably R₁ is phenyl, pyrazolyl, pyrrolyl, furanyl, thienyl, pyridyl, thiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, imidazolyl, imidazo[1,2-a]pyridyl, piperazinyl or cyclohexenyl, each of which is optionally substituted with one or more groups chosen from: halogen,
30 C₁₋₆ alkyl, C₁₋₆ haloalkyl, -(C₁₋₆ alkylene)_n-NH₂, -(C₁₋₆ alkylene)_n-NH(C₁₋₆ alkyl), -(C₁₋₆ alkylene)_n-N(C₁₋₆ alkyl)₂ or -(C₁₋₆ alkylene)_n-OH; more preferably R₁ is pyrazolyl or

pyrrolyl, each of which is optionally substituted with one or more groups chosen from: C₁₋₆ alkyl, C₁₋₆ haloalkyl, -(C₁₋₆ alkylene)-NH₂, -(C₁₋₆ alkylene)-NH(C₁₋₆ alkyl), -(C₁₋₆ alkylene)-N(C₁₋₆ alkyl)₂ or -(C₁₋₆ alkylene)-OH; and still more preferably R₁ is pyrazolyl or pyrrolyl, each of which is optionally substituted with one or more C₁₋₆ alkyl, preferably methyl.

11. The compound of claim 10, or a pharmaceutically acceptable salt thereof, and/or a deuterate, a solvate, a racemic mixture, an enantiomer, a diastereomer and a tautomer thereof, wherein R₁ is phenyl optionally substituted with one or more halogen.

12. The compound of claim 10, or a pharmaceutically acceptable salt thereof, and/or a deuterate, a solvate, a racemic mixture, an enantiomer, a diastereomer and a tautomer thereof, wherein R₁ is furanyl, thienyl, pyridyl, thiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, imidazolyl, imidazo[1,2-a]pyridyl, piperazinyl or cyclohexenyl, each of which is optionally substituted with one or more C₁₋₆ alkyl.

13. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, and/or a deuterate, a solvate, a racemic mixture, an enantiomer, a diastereomer and a tautomer thereof, wherein W is NH; R₁ is pyrazolyl, pyridyl or thiazolyl, each of which is optionally substituted with one or more groups chosen from: halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -(C₁₋₆ alkylene)-NH₂, -(C₁₋₆ alkylene)-NH(C₁₋₆ alkyl), -(C₁₋₆ alkylene)-N(C₁₋₆ alkyl)₂ or -(C₁₋₆ alkylene)-OH; preferably R₁ is pyrazolyl, pyridyl or thiazolyl, each of which is optionally substituted with one or more groups chosen from: C₁₋₆ alkyl or C₁₋₆ haloalkyl.



14. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, and/or a deuterate, a solvate, a racemic mixture, an enantiomer, a diastereomer and a tautomer thereof, wherein R₂ is hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ haloalkyl, -(C₁₋₆ alkylene)-N(C₁₋₆ alkyl)₂, -(C₁₋₆ alkylene)-O-(C₁₋₆ alkyl), -(C₁₋₆ alkylene)-OH, C₃₋₆ cycloalkyl or 4-6 membered heterocyclyl, preferably R₂ is C₁₋₆ alkyl, C₂₋₆ alkenyl, -

(CH₂CH₂)-O-(C₁₋₆ alkyl), -(CH₂CH₂)-OH, C₃₋₆ cycloalkyl or oxetanyl, and more preferably R₂ is C₁₋₆ alkyl, preferably methyl, ethyl or i-propyl.

15. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt thereof, and/or a deuterate, a solvate, a racemic mixture, an enantiomer, a diastereomer and a tautomer thereof, wherein R₃ and R₄ are each independently chosen from: hydrogen, halogen, -CN, C₁₋₆ alkyl or -O(C₁₋₆ alkyl); and when X is CH, at least one of R₃ and R₄ is hydrogen; preferably wherein R₃ is hydrogen, halogen, -CN, C₁₋₆ alkyl or -O(C₁₋₆ alkyl); R₄ is hydrogen or C₁₋₆ alkyl.

16. The compound of claim 1, or a pharmaceutically acceptable salt thereof, and/or a deuterate, a solvate, a racemic mixture, an enantiomer, a diastereomer and a tautomer thereof, wherein when Y₃ is CR₉, R₂ and R₉ together with the N atoms and C atoms to which they are attached form pyridine or pyrrolidine.

17. The compound of claim 1, or a pharmaceutically acceptable salt thereof, and/or a deuterate, a solvate, a racemic mixture, an enantiomer, a diastereomer and a tautomer













thereof, wherein  is ; R₁₀ is C₁₋₆ alkyl.















18. The compound of claim 1, or a pharmaceutically acceptable salt thereof, and/or a deuterate, a solvate, a racemic mixture, an enantiomer, a diastereomer and a tautomer thereof, wherein X is CR₅; Z₁ and Z₂ are each independently CR₆; Y₁ is CR₇; Y₂ is N or CR₈; Y₃ is CR₉; W is absent; R₁ is 5-6 membered heteroaryl optionally substituted with one or more C₁₋₆ alkyl; R₂ is C₁₋₆ alkyl; R₃, R₄, R₅, R₆, R₇ and R₈ are each independently chosen from: hydrogen, halogen, C₁₋₆ alkyl or -O(C₁₋₆ alkyl), and at least one of R₃ and R₄ is hydrogen; R₉ is hydrogen or C₁₋₆ alkyl.

















19. The compound of claim 18, or a pharmaceutically acceptable salt thereof, and/or a deuterate, a solvate, a racemic mixture, an enantiomer, a diastereomer and a tautomer thereof, wherein X is CH; both Z₁ and Z₂ are CH; Y₁ is CH; Y₂ is N or CH; Y₃















is CR₉; W is absent; R₁ is pyrazolyl optionally substituted with one or more C₁₋₆ alkyl; R₂ is C₁₋₆ alkyl; R₃ is hydrogen, halogen, C₁₋₆ alkyl or -O(C₁₋₆ alkyl); R₄ is hydrogen; R₉ is hydrogen or C₁₋₆ alkyl.















- 5 20. The compound of formula (I) of claim 1, or a pharmaceutically acceptable salt thereof, which is chosen from:















No.	Structural formula	No.	Structural formula
1		69	
2		70	
3		71	
4		72	
5		73	
6		74	















7		75	
8		76	
9		77	
10		78	
11		79	
12		80	
13		81	

















14		82	
15		83	
16		84	
17		85	
18		86	
19		87	
20		88	
21		89	

















22		90	
23		91	
24		92	
25		93	
26		94	
27		95	
28		96	






29		97	
30		98	
31		99	
32		100	
33		101	
34		102	
35		103	

36		104	
37		105	
38		106	
39		107	
40		108	
41		109	
42		110	

43		111	
44		112	
45		113	
46		114	
47		115	
48		116	
49		117	

50		118	
51		119	
52		120	
53		121	
54		122	
55		123	
56		124	
57		125	

58		126	
59		127	
60		128	
61		129	
62		130	
63		131	
64		132	
65		133	

66		134	
67		135	
68			

21. A pharmaceutical composition, comprising the compound of any one of claims 1-20 or a pharmaceutically acceptable salt thereof, and optionally comprising a pharmaceutically acceptable excipient.

22. Use of the compound of any one of claims 1-20 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease in a subject, wherein the disease is cancer, an autoimmune disease, an inflammatory disease, a metabolic disease, a neurodegenerative disease, obesity or an obesity-related disease; preferably, wherein the cancer is chosen from solid tumor or hematologic malignancy; the autoimmune disease or inflammatory disease is chosen from arthritis (including rheumatoid arthritis and collagen-induced arthritis), osteoarthritis, pigmented villonodular synovitis (PVNS), systemic lupus erythematosus, multiple sclerosis, autoimmune nephritis, Crohn's disease, asthma or chronic obstructive pulmonary disease; and more preferably, wherein the cancer is chosen from ovarian cancer, lung cancer (including non-small cell lung cancer), brain tumor (including glioblastoma (GBM)), tenosynovial giant cell tumor, gastrointestinal stromal tumor (GIST), gastric cancer, esophageal cancer, colon cancer, colorectal cancer, pancreatic cancer, prostate cancer,

breast cancer, cervical cancer, melanoma, mesothelioma, mesothelial carcinoma, renal cancer, liver cancer, thyroid carcinoma, head and neck cancer, urothelial carcinoma, bladder cancer, endometrial cancer, choriocarcinoma, adrenal carcinoma, sarcoma, leukemia, lymphoma or myeloma.

5

23. A combination, comprising the compound of any one of claims 1-20 or a pharmaceutically acceptable salt thereof, and at least one additional therapeutic agent, for example, an anti-neoplastic agent, including a chemotherapeutic agent, an immune checkpoint inhibitor or agonist, and a targeted therapeutic agent.

10